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Abstract
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New drug discoveries and new approaches towards diagnosis and treatment have improved
cancer therapeutics remarkably. One of the most influential and effective discoveries in the field
of cancer therapeutics was antimetabolites, such as the antifolates. The interest in antifolates
increased as some of the antifolates showed responses in cancers, such as mesothelioma,
leukemia, and breast cancers. When pemetrexed (PTX) was discovered, our laboratory had
established that the primary mechanism of action of pemetrexed is to inhibit thymidylate
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synthase (TS) (E. Taylor et al., 1992). Preclinical studies have shown that PTX has a broad
range of antitumor activity in human and murine models of cancer (Adjei, 2000; Adjei, 2004; S.
Chattopadhyay, Moran, & Goldman, 2007; Miller et al., 2000). Accordingly, in February 2004,
the FDA issued first-line treatment approval for pemetrexed in malignant pleural mesothelioma
and in 2008 for first line treatment for locally advanced or metastatic NSCLC (reviewed in
(Rollins & Lindley, 2005). As an antifolate this level of therapeutic activity of PTX against lung
cancers was surprising and atypical (Hazarika, White, Johnson, & Pazdur, 2004). This led us to
the question whether the effects of pemetrexed on other folate-dependent targets could explain
the clinical activity of the drug. Our lab showed that, in addition to inhibiting thymidylate
synthase, PTX also inhibits aminoimidazolecarboxamide ribonucleotide formyltransferase
(AICART), the second folate-dependent enzyme of de novo purine synthesis. Inhibition of
AICART leads to massive accumulation of its substrate 5-amino-4-imidazolecarboxamide
ribonucleotide (ZMP), causing activation of AMP-dependent kinase (AMPK), which ultimately
leads to suppression of mTORC1 signaling, a central regulator of cell growth and proliferation.
This secondary mechanism could explain the unusual activity of PTX against mesothelioma and
lung cancers.
The large proportion of lung cancers are either null or mutant for p53 function.
Therefore, this thesis focused on defining what the role of p53 is in the PTX-mediated AMPK
activation and mTORC1 inhibition and how the loss of p53 affects mTORC1 signaling. These
two questions proved to be interlinked. Chapter 2 investigates this relationship in detail. We
found that, upon loss of p53, mTORC1 signaling is enhanced to a significant degree in colon
carcinoma and lung cancer cell lines. Clearly, this observation required explanation. We found
that the major factors responsible for these differences in mTORC1 activity upon loss of p53
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were lower levels of two p53 target genes Tuberin (TSC2) and sestrin2. Immunoprecipitation
studies of mTORC1 complexes from p53 wt and p53 null cells revealed quite interesting
differences in the components of the mTORC1 complex. Immunoprecipitates from p53 null cells
had higher levels of mTOR and lower levels of TSC2 and PRAS40 bound to raptor. This
suggested that, in comparision to p53 competent cells, p53 null cells have more mTORC1
complex with enhanced activity due to decreased interaction of TSC2 and PRAS40, both of
which are inhibitors of mTORC1. These observations explained the higher mTORC1 in p53 null
cells and laid the foundation for determining the role of p53 in PTX-activated AMPK and
mTORC1 inhibition.
In the experiments described in Chapter 3, we found that PTX-mediated AMPK
activation inhibited mTORC1 regardless of the p53 status in colon carcinoma cells. This
suggested that mTORC1 inhibition by PTX was either independent of p53 mediated negative
regulation of mTORC1 or was somewhere bypassing it. Therefore, we compared the effects of
PTX with the classic AMPK activator aminoimidazolecarboxamide ribonucleoside (AICAR). In
spite of a common mechanism of AMPK activation, namely, expansion of cellular ZMP levels,
signaling from AMPK activated by PTX or AICAR were quite different. PTX-activated AMPK
phosphorylated the mTORC1 component Raptor but not tuberin (TSC2), whereas AICARactivated AMPK phosphorylated both the targets. This differential behavior of two AMPK
activators was due to differential behavior of p53 under these two treatments. Both, AICAR and
PTX treatment led to increase in p53 levels but the p53 that accumulated after AICAR treatment
was transcriptionally active while the p53 that accumulated after PTX treatment was not.
Transcription of p53 targets, including TSC2 and sestrin2, was activated in AICAR- but not in
PTX-treated cells. In the absence of p53 function, TSC2 was deficient and mTORC1 activity
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enhanced, but Raptor phosphorylation by AMPK following PTX was robust and independent of
both p53 and TSC2. Therefore we concluded that p53 deficiency suppresses TSC2 and
upregulates mTORC1, but AMPK-phosphorylation of Raptor after pemetrexed treatment was
sufficient to suppress mTORC1, even in TSC2 deficiency. This suggested pemetrexed as a drug
for treatment of Tuberous Sclerosis, a genetic disease caused by functional inactivity of TSC1 or
TSC2 due to point mutations in these genes.
Mutation of p53 is one of the most common genetic alterations in human cancers and
tumors. Cancers that express mutant p53 tend to be more aggressive, resistant to chemotherapy
and show worse prognosis then p53-null tumors (Elledge et al., 1993; Olivier et al., 2006). This
tumor-promoting activity of mutant p53 has been correlated with acquired and novel
transcriptional activities of mutant p53.

It has been shown that mutp53 can activate the

transcription of cell growth promoting genes, such as, NFκB2, PCNA, MDR1, Axl, EGFR,
hTERT, and HSP70, which are not usually transcriptional targets of wt p53. Interestingly, we
found that whereas DNA damaging drugs enhance the acquired oncogenic transcriptional
activities of mutp53, PTX interferes with this transcription activation. We also found in Chapter
4 that PTX can limit or block the DNA damaging drug-mediated increment of transcriptional
activation of mutp53. This suggests that blockade of transcriptional activation of mutp53 by
pemetrexed may provide an additional therapeutic benefit in mutp53 bearing cancers.
As discussed in Chapter Three, although pemetrexed (with TdR) increases the levels of
p53 and its binding to the promoter of its target gene, p21, this p53 is transcriptionally inactive.
In order to understand the mechanism of the pemetrexed-mediated transcriptional defect of wt
p53, we studied the PTX-mediated signaling towards ATM and ATR and their effects on their
substrates Chk2 and Chk1, respectively. These studies suggested that the difference between
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signaling under AICAR treatment and PTX treatment was that, unlike PTX, AICAR treatment
was leading to DNA damage, followed by Chk2 phosphorylation at Thr68.
We found there were three major differences between AICAR and pemetrexed (+ TdR)
mediated signaling: AICAR caused DNA damage, followed by ATM mediated phosphorylation
of Chk2 at Thr68 and phosphorylation of p53 at Ser15 all of which lead to activation of p53
transcriptional activity, events which do not take place under PTX treatment. Studies aimed at
understanding the effects of PTX on wt and mutp53 transcriptional activities are discussed in
detail in Chapters Three and Four of this dissertation.
Overall, we concluded that PTX interferes with the transcription activity of wild type as
well as gain-of-function mutant p53. The blockade of DNA damaging agent-mediated
enhancement of mutp53 transcription activity by PTX, suggests the clinical relevance of PTX in
carcinomas with mutp53. We suggest that this could be one of the contributing factors in the
effects of PTX against human lung cancers.
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Chapter 1

1
1.1

Overview and Introduction

STRUCTURAL, ABSORBTIVE AND TRANSPORT CHARACTERISTICS OF
NATURALLY OCCURRING FOLATES

Folic acid (also known as folate, vitamin M, vitamin B9, vitamin Bc (or folacin), and pteroyl-Lglutamic acid) is a water soluble vitamin. Folates were first discovered in the early 1940's from
yeast and liver extracts as a responsible factor for reversing macrocytic anemia in pregnant
women (Hoffbrand & Weir, 2001). Folic acid was isolated and crystallized from spinach and its
structure was determined (C. Baugh & Krumdieck, 1971). Folic acid is the most oxidized and
stable form of the folates that can be utilized for cellular metabolism. Our current understanding
of folates, their absorption at the cellular levels, metabolism and utilization at the molecular level
is a result of a combined effort of basic and clinical research. Antifolates have been very useful
tools in understanding these pathways. Three distinct moieties of folic acid are; (A) 2-amino-4
hydroxy-pteridine ring which is conjugated through a methylene group to (B) para-aminobenzoic
acid (PABA), which forms a peptide linkage to (C) glutamic acid (Fig1-1). Tissue folates are
commonly reduced forms of folic acid, which are formed due to its reduction to tetrahydro forms
at the 5,6, 7,8 positions of pteridine ring.
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The N5 or N10 nitrogen atoms of 5,6,7,8- tetrahydrofolate (H4PteGlu) can be linked to methyl
(CH3), formyl (CHO), methenyl (=CH+), or methylene (=CH2) groups. Additional glutamate
residues are processively added to the γ−carboxyl tail by the enzyme folylpoly-γ-glutamate
synthetase (FPGS), forming H4PteGlun (Fig 1-1) (C. Baugh & Krumdieck, 1971; Tomsho,
Moran, & Coward, 2008).
Humans obtain folates from dietary sources, including vegetables (particularly dark green leafy
vegetables), fruits, fruit juices, nuts, beans, peas, dairy products, poultry, meat, eggs, seafood,
grains and supplemental sources. Spinach, liver, yeast, asparagus, and brussels sprouts are
among the foods with the highest levels of folates. Although the human body can synthesize all
the components of a folate molecule individually, but it cannot produce two enzymes associated
with folate de novo synthesis, present in microorganism. Microorganisms have dihydropteroate
synthase, which conjugates the pteridine and a PABA ring to make dihydropteroic acid, and
dihydrofolate synthetase, an activity of bacterial FPGS. A lack of dietary folates can lead to
folate deficiency. A normal individual can store up to 500- 20,000µg of folate; therefore, even
with a complete lack of folates in the diet, it can take months before the signs of folate deficiency
appear. This deficiency can result in many health problems, such as megaloblastic anemia and
neural birth defect in developing embryos. Other folate deficiency related health problems
include pregnancy complications, mental confusion, forgetfulness or other cognitive deficits,
mental depression, sore or swollen tongue, peptic or mouth ulcers, headaches, heart palpitations,
irritability, and behavioral disorders. The human body needs folate to synthesize DNA, repair
DNA, and methylate DNA (C. Baugh & Krumdieck, 1971). It is especially important in aiding
rapid cell division and growth such as in infancy and pregnancy, to produce healthy red blood
and prevent anemia (Tomsho et al., 2008). In the US, grains, such as wheat flour, all purpose
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flour, bread, juice, breakfast cereals etc., are fortified with folic acid to complete the daily
requirement of the folic acid in human body; the concept of fortifying food with folic acid is now
being accepted all around the world, including developing countries like China and India.
1.1.1 Intracellular uptake and compartmentalization of folate
The most abundant natural forms of folate found in the diet are polyglutamated derivatives of 5CH3-H4PteGlu and 10-CHO-H4PteGlu (Fig1-1). As polyglutamation limits the transport of
folates across membranes; nature has provided a group of enzymes called γ−glutamyl
carboxypeptidases, which are located in the brush-border of the proximal jejunum. These
enzymes hydrolyze 5-CH3-H4PteGlu polyglutamates to monoglutamates, that are substrate for
transport (Halsted, 0321). Due to the hydrophilic nature of the charged folate molecule, its
passive diffusion across cell membrane is minimal. The efficient transport of folates across
membranes, its intestinal absorption and transport to systemic tissue involves four classes of
transporters:
•

The Reduced folate carrier (RFC)

•

Folate receptors FRα and FRβ

•

The proton-coupled folate transporter (PCFT)

•

Folate transport mediated by ATP-binding cassette transport proteins and members
of the SLC21 and SLC22 families of solute carrier

Reduced folate carrier (RFC)-The RFC (SLC19A1) was the first folate transporter studied at
the kinetic, thermodynamic and molecular levels. The human RFC (hRFC) encoding gene is
located on chromosome 21q22.3 (I. D. Goldman, Lichtenstein, & Oliverio, 1968; I. Goldman &
Matherly, 1985; Matherly & Goldman, 2003; Sirotnak & Tolner, 1999). At neutral pH, the
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reduced folate carrier (RFC) facilitates the transport of systemic 5- CH3-H4PteGlu, the principal
folate found in mammalian serum, into cells. (G. I. & Oliverio, 1122; I. D. Goldman et al., 1968;
Matherly, Seither, & Goldman, 1987; Matherly et al., 2007; Matherly, Hou, & Deng, 2007)
(Fig1-2). Folates are negatively charged due to the two carboxyl groups in the glutamate side
chain that are fully ionized at physiological pH. In order to facilitate transport via the RFC, there
must be a substantial electrochemical potential difference for folates across the cell membranes
(G. I. FAU et al., 1122). RFC mediated transport is highly sensitive to the transmembrane anion
gradient, especially the organic phosphate gradient. This provides a driving force for RFCmediated uphill transport to folates into cell (I. D. Goldman, 1971; Henderson & Zevely, 1983)
(Fig. 1-3). The low affinity of the RFC for folic acid and its neutral pH optimum clearly
distinguishes it from the PCFT. However, both RFC (Liu et al., 2005) and PCFT (Qiu et al.,
2007) expression are markedly increased in the small intestine of mice when they are fed a folate
deficient diet. The regulatory mechanism lying under this response is not well understood.
Folate receptors, FRα,β and γ)- FRs, are encoded by three distinct genes designated α, β, and
γ, all located on chromosome 11, are very high affinity folate binding proteins (Lu & Low, 2002;
Salazar & Ratnam, 2007). These three FRs are homologous proteins (68– 79% identical amino
acid sequences) but show differential expression in different tissues.

FRα is expressed in

epithelial cells of the kidney, choroid plexus, retina, uterus, and placenta (Parker et al., 2005;
Salazar & Ratnam, 2007) . FRβ is expressed during normal myelopoiesis and is present in
placenta, spleen, thymus, and in CD34+ monocytes (Ratnam, Marquardt, Duhring, & Freisheim,
1998; Reddy et al., 1999; Ross et al., 1989; H. Wang, Zheng, Behm, & Ratnam, 2000). The FRs
have high affinity for folic acid (Kd 1–10 nM). FR-mediated folate internalization involves
receptor mediated endocytosis (B. G. FAU, FAU, FAU, & Moran, 0207; Kamen, Wang,
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Streckfuss, Peryea, & Anderson, 1998; Lu & Low, 1217; Ross et al., 1989).

Folic Acid

Tetrahydrofolate

Figure 1-1 Chemical structure of Folic acid and Tetrahydrofolate.
Figure 1-1. Chemical structures of folic acid and tetrahydrofolate.
(Adapted from PhD. Dissertaion of Scott Rothbart, 2010)
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Figure 1-2. Schema of folate metabolism and folate-dependent reactions that occur in the
cytosolic subcellular compartment of cells.
Enzyme abbreviations are AICART – aminoimidazole carboxamide ribonucleotide
formyltransferase ; cSHMT – cytosolic serine hydroxymethyltransferase isoform ; DHFR –
dihydrofolate reductase ; GART – glycinamide ribonucleotide formyltransferase ; TS –
thymidylate synthase. Single arrows representing the direction of the reaction show irreversible
reactions and reversible reactions are represented by double arrow.
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When folate molecules bind to the FR on the cell surface, in causes invagination of the plasma
membrane surface at that site, leading to formation of a vesicle (endosome). This endosome
migrates to the cytoplasm, where it is acidified to a pH of ~ 6.5, resulting in dissociation of the
folate from the FR complex (Yang, Chen, Vlahov, Cheng, & Low, 2007). The folate ligand is
exported into the cytoplasm (Kamen, Peryea & Anderson, 1998; Rothberg, Ying, Kolhouse,
Kamen, & Anderson, 1990) (Fig. 1-3). While FRs α and β can transport folate into cells, this is
inefficient compared to transporters such as RFC (Sierra, Brigle, Spinella, & Goldman, 1995;
Spinella, Brigle, Sierra, & Goldman, 1995).
ii) Proton-coupled folate transporter (PCFT)- The proton- coupled folate transporter (PCFT)
is used to transport folate monoglutamates (including folic acid) across the apical surface of the
proximal jejunum. PCFT symports folates optimally at pH 5.5 against its concentration gradient
with protons along their concentration gradient into the enterocytes, explaining why the acidic
microenvironment of the small intestine is favorable for PCFT- mediated folate transport (Qiu et
al., 2006; Zhao & Goldman, 2007) (Fig. 1-3).
Folate transport mediated by ATP-binding cassette transport proteins and members of the
SLC21 and SLC22 families of solute carrier- It has been suggested that there are other folate
transport routes other than these highly specific transporters. The multidrug resistance-associated
proteins MRP1-5 (ABCC1-ABCC5) and the breast cancer resistant proteins BCRP, (ABCG2)
are relevant ATP-binding cassette exporters (Assaraf, 2006; Kruh & Belinsky, 2003; Wielinga et
al., 2005)(Fig. 1-3). These are low affinity, high capacity transporters (Kms ~0.2 – 2 mM for
folates/antifolates). Members of this family are widely expressed in mammalian cells and
suppress the level of free folates or antifolates that accumulate in most cells grown in vitro (Fry,
Yalowich, & Goldman, 1982).
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Figure 1-3. Schema of the known folate transporters.
Abbriviation of various transporters are as follows; PCFT= Proton-coupled
folate transporters, RFC= Reduced folate carrier, FR= Folate receptors,
MRPs and BCRP= multidrug resistance proteins and breast cancer resistant
protein
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Some of the shorter chain-length polyglutamate folates may be weak substrates for MRPs (Fry et
al., 1982). The physiological importance of MRP2 in folate export is demonstrated by impaired
biliary secretion of MTX in MRP2 (-/-) mice (Masuda et al., 1997).
In summary, it is during intestinal uptake that folic acid from fortified foods is reduced to 5CH3-H4PteGlu. 5-CH3-H4PteGlu, which is absorbed in small intestine enters the portal
circulatory system and is first delivered to the liver, where it can be passed through to the
systemic circulation, can be secreted into the bile for reabsorption, or can be polyglutamated for
storage. Systemic 5-CH3-H4PteGlu can be transported into cells by folate receptor-mediated
endocytosis, a high affinity and low capacity process. The detailed discussion of this process is
as follows.
1.1.2 Folate absorption in intestine
During intestinal absorbtion, polyglutamated folates are converted into monoglutamates and are
transported across the apical brush border membrane of the proximal jejunum mediated by the
PCFT. As PCFT transport is very efficient, concentrative and driven by a transmembrane proton
gradient, the amount of folate transported to enterocytes is high enough to facilitate folate efflux
across the basolateral membrane into the periserosal space and then enter the vascular system.
The mechanism of folate export from enterocyte is unclear as neither PCFT not RFC are
expressed at the basolateral membrane. However, MRPs, particularly MRP3 (Kruh & Belinsky,
2003) are expressed at this site and may be involved in the export of folates through this route.
After intestinal absorption, folates enter the hepatic portal system and are delivered to hepatic
sinusoids. Once folates are in the liver, they have three potential destinations. i) Folate can be
converted to polyglutamate storage forms mediated by FPGS ; ii) they can be secreted in the bile
at the hepatic canalicuar membrane, by MRP2 mediated process (Masuda et al., 1997), return to
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the deudenum and jejunum for reabsorption and thus completing the cycle of enterohepatic
circulation or iii) they can stay as monoglutamates or get converted into monoglutamates from
stored polyglutamates in hepatocytes, and delivered directly from the hepatic portal vein ,
ultimately reaching the systemic circulation where they accumulate and participate in the
processes of the one-carbon requirement of peripheral tissue.
1.1.3 Transport into systemic tissues
At neutral pH 7.4, RFC mediate the membrane transport of folate into systemic tissue. Although
PCFT is co-expressed with the RFCin many tissues at the plasma membrane, due to the neutral
pH at these sites, the function of the PCFT is minimal at these sites.
1.1.4 Polyglutamation and storage of folate
Polyglutamation of folates is attributed to the enzyme folylpoly-γ-glutamate synthetase (FPGS)
(Moran, Werkheiser, & Zakrzewski, 1976). Polyglutamation is not only essential to increase the
stability and retention of folates within the cell, but also to increase the affinity of folates for
their target enzymes. Humans have two isoform of FPGS, cytosolic and mitochondrial, coded
from same gene. These two isoforms help in maintaining the equal distribution of folate
polyglutamate between the cytosol and the mitochondria (Cook & Blair, 1979; Freemantle,
Taylor, Krystal, & Moran, 1995; S. M. Taylor, Freemantle, & Moran, 1995). Folates are
transported into the mitochondria by the mitochondrial folate transporter (MFT), a family
member of the inner mitochondrial membrane transport carriers that was cloned and
characterized by our lab (McCarthy, Titus, Taylor, Jackson-Cook, & Moran, 2004; Perchiniak et
al., 2007; Titus & Moran, 2000). Folate monoglutamates are the substrates for mitochondrial
transport, suggesting substrate competition between cytosolic FPGS and the MFT (Freemantle et
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al., 1995; Perchiniak et al., 2007). Chinese hamster ovary (CHO) cells that lack functional FPGS,
known as AuxB1 cells, are unable to accumulate any cellular folates and therefore require an
exogenous supply of purines, thymidine and glycine to the growth culture medium (T. R. FAU &
Hanna, 0812; McBurney & Whitmore, 1974). These studies suggested that the purpose of
mammalian folate metabolism is to produce purines, thymidine and glycine.
1.1.5 Intracellular folate metabolism
Folate metabolism takes place in both cytosolic and mitochondrial compartments and allow the
recycling of folate molecules. Although, in the mammalian cells all the enzymes required to
synthesize purines, thymidine, methionine and glycine are present in the cytosol. Cytosolic folate
metabolism contributes to and is limited to purine, thymidine, and methionine synthesis. A study
showed that the cytosolic isoform of FPGS when transfected into AUXB1 cells, relived the
exogenous requirement of the purine and thymidine but not of glycin (Garrow et al., 1993; Lin,
Huang, & Shane, 1993). It was found that mitochondrial folate metabolism fulfills the
requirement of glycine supply to the cells (McCarthy et al., 2004) and cytosolic folate
metabolism is essential for purine and pyrimidine synthesis. Synthesis of purines, thymidine and
methionine is done in the cytosol using folate molecules as cofactors (Fig. 1-3). First, 5-methyltetrahydrofolate and homocysteine are converted into tetrahydrofolate and methionine. The
tetrahydrofolate then can be converted to either 10-formyl-tetrahydrofolate or 5,10-methylenetetrahydrofolate. The conversion of tetrahydrofolate (H4PteGlun) to 10-formyl tetrahydrofolate
consumes a formate molecule. Conversion of tetrahydrofolate to 5,10-methylene-tetrahydrofolate
is done by the cytosolic serine hydroxymethyltransferase isoform (cSHMT). The two folatedependent enzymes of purine synthesis, glycinamide ribonucleotide formyltransferase (GART)
and aminoimidazole carboxamide ribonucleotide formyltransferase (AICARFT), use the formyl
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carbon of 10-formyl-tetrahydrofolate. 5,10-methylene-tetrahydrofolate can be converted either to
5-methyl-tetrahydrofolate or to dihydrofolate (H2PteGlun). Thymidylate synthase (TS) uses 5,10methylene-tetrahydrofolate and deoxyuridylate to produce thymidylate and dihydrofolate. The
dihydrofolate produced during thymidylate synthesis is then converted to tetrahydrofolate by
dihydrofolate reductase (DHFR) (Fig. 1-3).
Mitochondrial folate metabolism is also important for glycine synthesis (Fig. 1-4). Cells keep
separate pools for cytosolic and mitochondrial folate reactions (Appling, 1991). All the
molecules required for folate metabolism such as glycine, serine and formate appears to get
exchanged between the mitochondrial and cytosolic compartments (Pasternack, Laude, &
Appling, 1994). In mitochondria, folates are utilized as cofactors to metabolize glycine.
Conversion of serine and tetrahydrofolate into glycine and 5,10-methylene-tetrahydrofolate is
mainly done by mitochondrial isoform of serine hydroxymethyltransferase. CHO-derived GlyA
cells, that lack activity of the mSHMT isoform, but have an active cytosolic isoform, are
auxotrophic for glycine (Kao, Chasin, & Puck, 1969). Later it was shown that GlyA cells have
increased amounts of intracellular serine and decreased amounts of glycine when compared to
wild-type CHO cells (Narkewicz, Sauls, Tjoa, Teng, & Fennessey, 1996). For a better regulation
of glycine metabolism, mitochondria also contain a unique system known as glycine cleavage
system (GCS). The GCS catabolizes glycine into formate, ammonia, and 5,10-methylenetetrahydrofolate and NADH+ by using tetrahydrofolate and NAD (Kikuchi, Motokawa, Yoshida,
& Hiraga, 1114).
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Figure 1-4. Schematic of folate metabolism and folate-dependent reactions that occur in the
mitochondrial subcellular compartment.
Enzyme abbreviations are GCS – glycine cleavage system; mSHMT – mitochondrial serine
hydroxymethyltransferase isoform. Single arrows represent the direction of irreversible reactions and
double arrows represent reversible reactions. The two reversible reactions catalyzed by mSHMT and
GCS, converting tetrahydrofolate to 5,10-methylene-tetrahydrofolate, do not occur simultaneously;
they are separate reactions that use the same molecules in different reactions with different enzymes.
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In an in-silico study, mathematical models were generated to stimulate hepatic folate metabolism
and suggested that both the mSHMT and GCS reactions are reversible, but are predicted to run in
the direction of tetrahydrofolate to 5,10-methylene-tetrahydrofolate which ultimately is to
generate 10-formyl- tetrahydrofolate (Nijhout et al., 2006). Although, both the reactions, by
mSHMT and GCS, generate formate, they oppose each other in glycine regulation. While
catabolizing glycine, the GCS directly generates formate. The 5,10-methylene-tetrahydrofolate
converts into 10-formyl-tetrahydrofolate in two steps, and 10-formyl-tetrahydrofolate can be
metabolized into formate and tetrahydrofolate. Later, it was shown that the mitochondrial folate
metabolism is very important in yeast, especially in term of formate generation, as ~25% of the
carbon units used in purine synthesis were from mitochondrially-derived formate (Pasternack et
al., 1994). In-silico studies done by Pastenack et. al showed that in the absence of mitochondrial
folate metabolism in in-silico mathematical models, thymidine and purine synthesis were
reduced by ~40% and 60% respectively, and that other cytosolic folate-dependent processes were
relatively unaffected (Pasternack et al., 1994). Thus, the role of mitochondrial folate metabolism
is to produce glycine that can be metabolized into formate for the use in cytosolic synthesis of
purines and thymidine.
1.1.6 Development of Cancer chemotherapy
The origin of effective cancer chemotherapy goes back to World War I. It began in the 1940's
with the use of mustard gas by the German army as the first introduction of chemical warfare.
Soldiers exposed to mustard gas showed dramatic symptoms like atrophy of lymphoid and
testicular tissue and died within 2-3 weeks due to hypoplasia of the bone marrow (Krumbhaar &
Krumbhaar, 1919). Later, Berendulum et. al showed the anticancer properties of mustard gas
(BERENBLUM & SCHOENTAL, 1947). Studies on the effects of mustard gas on biological
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systems led to an understanding of its selective toxicity towards proliferating cells
(Gilman & Philips, 1946). On animal models, the most striking benefit of mustard gas was noted
in chronic myelogenous leukemia, although quite significant responses was observed in
Hodgkin's disease (cross ref. (GILMAN, 1963; Papac, 2001). Studies done by Gilman and other
groups using mustard gas suggested that systemic administration of cytotoxic drugs could be a
possible therapeutics for cancer.
1.1.6.1 Discovery and development of antifolates as cancer therapeutics
The origin of effective cancer chemotherapy goes back to World War I. It began in the 1940's
with the use of mustard gas by the German army as the first introduction of chemical warfare.
Soldiers exposed to mustard gas showed dramatic symptoms like atrophy of lymphoid and
testicular tissue and died within 2-3 weeks due to hypoplasia of the bone marrow (Krumbhaar &
Krumbhaar, 1919). Later, Berendulum et. al showed the anticancer properties of mustard gas
(BERENBLUM & SCHOENTAL, 1947). Studies on the effects of mustard gas on biological
systems led to an understanding of its selective toxicity towards proliferating cells
(Gilman & Philips, 1946). On animal models, the most striking benefit of mustard gas was noted
in chronic myelogenous leukemia, although quite significant responses was observed in
Hodgkin's disease (cross ref. (GILMAN, 1963; Papac, 2001). Studies done by Gilman and other
groups using mustard gas suggested that systemic administration of cytotoxic drugs could be a
possible therapeutics for cancer.
1.1.6.2 Discovery and development of antifolates as cancer therapeutics
The discovery of antifolates led to a great advancement in the cancer chemotherapy. Syndey
Farber showed that administration of folic acid to children suffering from acute lymphocytic
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leukemia (ALL) stimulated the proliferation of cancer cells and exacerbated the disease
(FARBER & DIAMOND, 1948). Further, Farber and colleagues demonstrated that the antifolate
aminopterin (Fig.1-5) could induce remission of pediatric acute leukemia (FARBER &
DIAMOND, 1948). Initially, it was thought that the mechanism of action of antifolate
specifically targeted the fast dividing cells and thus supported the concept of targeting therapy to
inhibit cell division.

These effects of antifolates on cancer led to the modern era of

antimetabolite cancer drugs starting in the late 1940's.
Antimetabolites such as aminopterin, methotrexate, pemetrexed, hydroxyurea, or N(phosphonacetyl)-L-aspartic acid (PALA) interfer with DNA and RNA production and therefore
cell division and the growth of tumors. Thus, antimetabolite therapy is very effective for some
cancer cells. Aminopterin, an antifolate (Fig. 1-4), was first synthesized by Dr. Yellapragada
Subbarow et al, and was subsequently was first used by Sidney Farber in 1947 to induce
remission among children (FARBER & DIAMOND, 1948). Aminopterin was used in the United
States from 1953 to 1964 for the indication of pediatric leukemia. Later, aminopterin was
replaced by methotrexate due to manufacturing difficulties and to a better therapeutic index of
methotrexate in a rodent tumor model (GOLDIN et al., 1955). In a study in 2005, Cole et. al
suggested that aminopterin has greater cellular accumulation, metabolism and more reliable
bioavailability than methotrexate. They concluded that considering the tolerable toxicity at the
recommended dose and schedule, aminopterin deserves further study as an alternative to
methotrexate. (Cole et al., 2005). In the 1950’s, several more antimetabolites were discovered
such as the purine analog 6- mercaptopurine (Hitchings and Elion, 1954), which was shown to
have anti-cancer activity in mice with acute leukemia (Hitchings and Elion, 1954; Skipper,
Thomson, Elion and Hitchings,1954).
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5-Florouracil (5-FU), a pyrimidine analog, is a suicide inhibitor (mechanism based irreversible
inhibitor) for thymidylate synthase. It is one of the oldest chemotherapeutic drugs which is still
being used in the treatment of several human cancers including colorectal, breast, stomach and
pancreatic cancers, suggesting that “cytotoxic” chemotherapy is still one of the most useful and
prevalent method of cancer treatment.
Due to dramatic results against various cancers, the efforts toward making new and better
antifolates continued. Several of these agents have been rationally designed to target specific
folate dependent enzymes or circumvent known mechanisms of resistance to classical antifolates.
One of the most extensively studied and widely used antifolate is methotrexate (Fig. 1-5).
Shortly after the discovery of methotrexate and its analogs, the primary folate-dependent
therapeutic target of this drug was identified to be DHFR (Werkheiser, 1963) (Fig. 1-3, 1-6).
Methotrexate is a tight-binding inhibitor of DHFR (Ki ~ 0.004 nM) (C. Shih, Habeck,
Mendelsohn, Chen, & Schultz, 1998). DHFR inhibition by methotrexate prevents DNA and
RNA synthesis by preventing the reduction of H2PteGlun to H4PteGlun, the vital precursor for
thymidylate and purine biosynthesis cofactors (Fig. 1-3 and 1-7). Additional H4PteGlundependent reactions, such as serine-glycine interconversions and methionine synthesis, are also
hindered. It is now known that, like natural folates, methotrexate is polyglutamated in cells (C.
M. Baugh, Krumdieck, & Nair, 1973). This is important, as polyglutamation of methotrexate
enhances intracellular retention of the drug and permits methotrexate to inhibit DHFR for longer
periods of time, expanding the H2PteGlun pool (Rosenblatt et al., 1978). Polyglutamation also
broadens the spectrum of target inhibition. Significant to cancer therapy, polyglutamation adds a
layer of selectivity to methotrexate, as metabolites accumulate in tumor cells to a much greater
extent than in bone marrow and intestinal tissues (Poser, Sirotnak, & Chello, 1981). Various

42

analogs of methotrexate were synthesized and tested as cancer therapeutics with the goal of
maintaining the potency against DHFR while enhancing the substrate specificity of transport and
polyglutamation, and limiting the uptake in normal tissues. Most attempts failed, as methotrexate
was indeed a superior drug in this sense. However, the analog pralatrexate (10-propargyl-10deazaaminopterin, Folotyn®) has been shown to meet these criteria and showed remarkable
responses in some T-cell lymphomas. That study (Thompson, 2009) ultimately led to the U.S.
Food and Drug Administration (FDA) approval of pralatrexate for relapsed peripheral T-cell
lymphoma, a rare form of non-Hodgkins lymphoma, in 2009 (Thompson, 2009).

Other

rigorously studied antifolate that has proven itself to be promising, is Pemetrexed. The most
sensitive cellular target of pemetrexed is thymidylate synthase.
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A

B

Figure 1-5. Chemical structures of; A) aminopterin, the first antifolate. B)
methotrexate
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1.1.6.3 Second- generation antifolates targeting thymidylate synthase and purine synthesis
pathway
In 1980s and 1990s, the efforts towards antifolate drug discovery has been shifted away from
targeting DHFR, focusing on pharmacophores targeting the folate-dependent enzymes of
thymidylate and purine biosynthesis. The first potent antifolate thymidylate synthase inhibitor
(Ki ~ 3 nM) to come from this effort was CB3717 (Jones et al., 1981). CB3717 (Fig. 1-8) had
antitumor activity in breast, ovarian, and liver cancers, but was ultimately withdrawn from the
clinic due to life-threatening renal toxicity caused by poor solubility at the low pH of urine in the
collecting ducts (Calvert et al., 1986; Jackman et al., 1991). Keeping this same 5,8-dideazafolate
pharmacophore, analogs of CB3717 were synthesized in an attempt to increase solubility while
maintaining specificity for thymdylate synthase. Ultimately, Raltitrexed (Tomudex®, ZD1694)
was identified from this effort. Raltitrexed is a 2-desamino-2-methyl-N10-substituted-5,8dideazafolate analog with a thiophene substitution for the PABA ring (Fig. 1-8) (Jackman et al.,
1991). Compared to CB3717, these characteristics not only increased solubility, they made
raltitrexed a superior substrate for both RFC-mediated transport and polyglutamation by FPGS
(Jackman et al., 1991).
In addition to intracellular trapping of raltitrexed metabolites, polyglutamation increases the
potency of raltitrexed as a TS inhibitor by more than 100-fold. Raltitrexed showed significant
clinical response rates in colorectal and breast cancer patients. It is currently in widespread use
outside the United States for the treatment of colorectal cancer, but never gained U.S. FDA
approval, as it was not determined to be superior to the current standard of care for colorectal
cancer, 5-fluorouracil (5-FU, also a TS inhibitor) with leucovorin, a reduced folic acid (Maughan
et al., 2002; Popov et al., 2008).

45

The discovery of the first antifolate inhibitor of de novo purine biosynthesis, 5,10- dideazaH4PteGlu (DDATHF, lometrexol) was serendipitous (Figure 1-8). The structure was originally
proposed by G. Peter Beardsley as a potential TS inhibitor, but cell culture end-product reversal
experiments performed in our lab showed it was targeting purine synthesis (Moran, Baldwin,
Taylor, & Shih, 1989). Subsequently, enzyme kinetic studies demonstrated that DDATHF was a
potent inhibitor of GART, the first folate-dependent enzyme of de novo purine synthesis
(Baldwin et al., 1991; Moran et al., 1989; Sanghani & Moran, 1997) (Fig. 1-3 and 1-7).
DDATHF is transported into cells via the RFC as well as the PCFT (Beardsley et al., 1989).
DDATHF showed potent antitumor activity against a broad spectrum of carcinomas, but the
development of DDATHF was halted in Phase I clinical testing due to induction of severe
thrombocytopenia (Ray et al., 1993). Oral supplementation with folic acid ablated the
unfavorable toxicity of lometrexol (DDATHF) (Alati et al., 1996; Roberts et al., 2000). These
findings set a precedent for future clinical regimens to include folic acid and vitamin B12,
although the protective mechanism is still not fully understood. Lometrexol posed a problem; it
was made by a very complex 23 step process, and the product was mixture of diastereomers
about carbon 6. The diastereomers needed to be separated before clinical trails, to meet FDA
administration requirements. The fractional crystallization approach was not efficent and proved
to have low yield. This led to the evaluation of alternative approaches to avoiding the preparation
of diastereomeric mixtures. One strategy was to replace the 5-deazapteridine ring of lometrexol
with the pyrrolopyrimidine ring, which removed the chiral center of lometrexol and resulted in
the compound LY231514, which became known as pemetrexed (E. Taylor et al., 1992).
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Figure 1-6. Human DHFR with bound dihydrofolate and NADPH.
Adapted from http://en.wikipedia.org/wiki/dihydrofolate_reductase
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Figure 1-7. Folate metabolism and its key targets of chemotherapy.
In the beginning of the concept of the antimetabolite for cancer therapy started
with targeting DHFR and later it shifted towards TS. Multitargeted antifolate
Pemtrexed also targets AICART. Adapted from Muhsin M et al., 2004. Nat. Rev.
Drug Disc. 3(10):825-826 {{ Muhsin,M. et al, 2004;}}
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1.1.6.4 Pemetrexed: a multi-targeted antifolate
Pemetrexed (L-glutamic acid, N-(4-(2-(2amino-4,7- dihydro-4-oxo-1H-pyrrolo(2,3-d) pyrimidin5-yl)ethyl)benzoyl)) is arguably the most interesting of the new generation antifolates (Fig.1-8,
1-9). Although an analogue of folic acid, structurally and chemically it can be differentiated
from MTX and DDATHF, as it has a 6-5 fused pyrrolo (2,3-d) pyrimidine nucleus (E. Taylor et
al., 1992). Pemetrexed (LY231514, Alimta) was discovered from synthetic approaches aimed at
eliminating the chirality of carbon 6 of DDATHF, in which a pyrrolopyrimidine ring replaced
the 5-deazapteridine (E. Taylor et al., 1992) Surprisingly, this modification also changed the
target profile. Pemetrexed polyglutamates were potent inhibitors of thymidylate synthase both in
vitro (Ki ~ 1.3 nM) and in cell culture {{; 234 Taylor 1228;}}. Pemetrexed was reported to have
effects on multiple enzymes involved in the folate metabolism, but the importance of some of
these steps is questionable. End-product cell culture reversal experiments suggested that higher
doses of pemetrexed had a significant secondary target, reversible with the addition of preformed
purine (C. Shih et al., 1997; E. Taylor et al., 1992) This suggested that, like its predecessor
DDATHF, pemetrexed was also targeting de novo purine synthesis. As structural analogues of
folic acid, antimetabolites also use the same transporters (Westerhof et al., 1995). Pemetrexed
enters the cells using the reduced folate carrier (RFC), a bidirectional transporter and major
cellular transport system for folates (Zhao, Babani, Gao, Liu, & Goldman, 2000). Pemetrexed
also uses folate receptor- α, a cellular membrane receptor. A low pH transporter, the PCFT, is
also involved in pemetrexed internalization (S. Chattopadhyay, Wang, Zhao, & Goldman, 2004;
Sierra & Goldman, 1998; Y. Wang et al., 2004; Y. Wang, Zhao, & Goldman, 2004; Zhao et al.,
2000). As the microenvironment surrounding carcinoma cells is acidic due to secretion of lactic
acid as a byproduct of anaerobic respiration, it has been suggested that the PCFT is, in fact, the
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primary transporter of pemetrexed in solid tumors. Pemetrexed is one of the most efficient
substrate of FPGS ever tested. Pemetrexed is polyglutamated 90 to 195 times more efficiently
than methotrexate and 6 to 13 times more efficiently than lometrexol (Habeck et al., 1995). As
pharmacological activity is achieved by polyglutamation, higher levels of glutamation not only
increase retention of the pemetrexed inside the cell but also increase its specificity for its targets
enzymes. Pentaglutamated pemetrexed has a Ki of 1.3 nm for its primary target TS in
comparison to monoglutamated pemetrexed, which has Ki of 109 nM (I. D. Goldman & Zhao,
2002; Schultz, Patel, Worzalla, & Shih, 1999; C. Shih et al., 1997). Pentaglutamated pemetrexed
is a potent inhibitor of TS, which catalyzes the transformation of deoxyuridine monophosphate to
deoxythymidine monophosphate (dTMP). Inhibition of TS decreases formation of dTMP, a
progenitor of the nucleoside deoxythymidine triphosphate (dTTP) needed for the DNA synthesis.
The enzyme deoxycytidine deaminase is negatively regulated by dTTP. (I. D. Goldman & Zhao,
2002; Rustum et al., 1997; Schultz et al., 1999; Westerhof et al., 1995). As polyglutamated
pemetrexed is also an inhibitor of GART and AICART, inhibition of these enzymes leads to
inhibition of de novo purine synthesis. The DHFR-binding of pemetrexed is 1000 times less avid
than methotrexate, and inhibition of DHFR by pemetrexed is reportedly minimal (I. D. Goldman
& Zhao, 2002; C. Shih et al., 1997; Zhao & Goldman, 2007; Zhao et al., 2008)
1.1.6.4.1 De novo purine synthesis
Actively dividing cells require continuous availability of purine nucleotides due to active
replication and transcription. This demand is mainly fulfilled by synthesis of purines in a de novo
process known as de novo purine synthesis. The two parent nucleotides of purines in nucleic
acids are adenosine monophosphate (AMP) and guanosine monophosphate (GMP). The de novo
purine synthesis is an energy-consuming process consisting of 10 sequential enzymatic reactions

50

(Fig. 1-10).
The whole purpose of this biosynthetic pathway is to build an end product, inosine
monophosphate (IMP) from a 5-carbon molecule PRPP. Cells can also make IMP from the
breakdown of nucleic acid using salvage pathways. Addition of preformed purines like
hypoxanthine or inosine, can rescue cells from de novo purine synthesis inhibition or deficiency.
Hypoxanthine can be converted into IMP by hypoxanthine-guanine phosphoribosyl transferase
(HGPRT). De novo purine synthesis is subjected to feedback inhibition by the end products of
the pathway. The first and committed step of de novo purine synthesis is catalyzed by
phosphoribosylpyrophosphate amidotransferase (PPAT). In this step, an amino group is donated
by glutamine is attached at C-1 of PRPP, resulting into 5-phosphoribosylamine, a highly unstable
intermediate with a half-life of 30 sec at pH 7.5. The activity of PPAT is inhibited by purine
nucleotides IMP, AMP, GMP, and ATP (WYNGAARDEN & ASHTON, 1959). Out of ten
reactions, two reactions of this pathway are dependent on the folate cofactor 10-CHO-H4PteGlu
(HARTMAN & BUCHANAN, 1959). The third step of de novo purine synthesis and the first
folate dependent step of this pathway, is catalyzed by Glycinamide ribonucleotide Pemetrexed
has been tested in and showed dramatic effects against various carcinomas including bladder,
breast, cervix, colon, gastrointestinal tract, and pancreas (Adjei, 2000; Adjei, 2004; Britten et al.,
1999). In the past, typical antifolates, especially TS inhibitors, have been ineffective against
NSCLC but pemetrexed has been proven to have strong therapeutic effects against these
diseases.
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Figure 1-8. Chemical structure of inhibitors representing various classes of inhibitors of folate
metabolism
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Figure 1-9. Mechanism of action of pemetrexed.
THF= tetrahydrofolate; DHF= dihydrofolate; DHFR= DHF reductase; PRPP=
phosphoribosyl pyrpphosphate; GAR= glycinamide ribonucleotode; fGAR= Nformylglycinamide
ribonucleotide;
AICAR
=
5-aminoimidazole-4carboxamine
ribonucleotide;
fAICAR=
5-formylaminoimidazole-4carboxamide ribonucleotide; IMP = inosine monophosphate
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Figure 1-10. Folate dependent steps of de novo purine synthesis pathway.
De novo purine biosynthesis consists of ten sequential enzymatic reactions in which
phosphoribosyl-1-pyrophosphate (PRPP) is converted to inosine monophosphate (IMP).
IMP is converted to AMP and GMP thorough additional enzymatic steps (not shown).
The two folate- dependent formyl transfer reactions of this pathway are catalyzed by
GART and AICART. AICAR, after entering mammalian cells, gets converted into
ZMP, leading reaction in forward direction thus feeds into the reaction. PTX inhibits
AICART, causing its substrate ZMP to accumulate. Additionally, IMP can be produced
by salvage of the preformed purine, hypoxanthine, by hypoxanthine-guanine
phosphoribosyltransferase (HGPRT) and the cofactor PRPP. Adapted from the
Racanelli AC. et al., Cancer Res. 2009 Jul 1;69(13):5467-74.

!
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Also pemetrexed is very effective against malignant pleural mesothelioma (MPM), a highly
aggressive malignancy of the pleural cavities lining the lungs and chest usually associated with
the exposure of asbestos fibers (Craighead et al., 1982). The median survival following diagnosis
of MPM is approximately 11 months. This disease is resistant to most of the chemotherapeutic
regimens including methotrexate and 5-FU with leucovorin (Harvey, Slevin, Ponder, Blackshaw,
& Wrigley, 1984; Hazarika et al., 2004; Price, 1997; Solheim, Saeter, Finnanger, Finnanger, &
Stenwig, 1992). A rigorous clinical study conducted in an area of northern Germany where
exposure of asbestos was abnormally high, hence enriched in MPM patients, showed very
effective results of pemetrexed on MPM (Hughes et al., 2002; Thodtmann et al., 1999). Also,
cell-based combination studies of pemetrexed with cisplatin on MPM cells showed synergism
and its extension to clinical study showed a survival benefit in this disease (Britten et al., 1999;
Vogelzang et al., 2003). This led to the approval of pemetrexed and cisplatin as a first line
treatment for MPM (Hazarika et al., 2004). Due to high retention of pemetrexed in the target
tissue following plasma clearance, a dosage of 500 mg /m2 pemetrexed infused every 21 days
was chosen as a very effective treatment modality for various cancers (S. Chattopadhyay et al.,
2007). Folic acid and B12 supplementation with pemetrexed help in limiting toxicity (Hazarika
et al., 2004).
Pemetrexed was also approved as a second line, single- agent treatment of locally advanced and
metastatic NSCLC in 2004. The majority (90-95%) of lung cancers are of non-small cell origin
and over a million of people are diagnosed with lung cancer each year worldwide (Parkin, Bray,
Ferlay, & Pisani, 2001; Parkin, Bray, Ferlay, & Pisani, 2005). NSCLC is a highly progressive
disease with a survival of 6 months following diagnosis if left untreated (Chemotherapy in
addition to supportive care improves survival in advanced non-small-cell lung cancer: A
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systematic review and meta-analysis of individual patient data from 16 randomized controlled
trials.2008). This unusual success of pemetrexed against MPM suggested that it might be helpful
in treatment of NSCLC. The effect of pemetrexed on NSCLC was initially tested in comparison
to docetaxel (Taxotere), which was the standard treatment of the care for NSCLC at that time
(Hanna et al., 2004). Although the median survival time of patients treated with pemetrexed and
docetaxel were not significantly different (8.3 vs. 7.9 months median survival respectively),
pemetrexed was significantly less toxic. This study played a favorable role in convincing FDA to
approve pemetrexed for second-line treatment of NSCLC.
Various kind of tumors which have grown resistance against other antifolates have been shown
to preserve sensitivity for pemetrexed (Jackman et al., 1995; Schultz et al., 1996; Zhao,
Chattopadhyay, Hanscom, & Goldman, 2004; Zhao, Hanscom, Chattopadhyay, & Goldman,
2004). Pemetrexed retained activity in MCF-7 breast carcinoma and H630 colon carcinoma cells
resistant to 5-FU and other TS inhibitors due to TS amplification (Schultz et al., 1996). The
retention of pemetrexed antitumor activity in these cell lines was attributed to GART inhibition
and other secondary targets of metabolites.

Methotrexate resistance in patents with acute

leukemia has been associated with low RFC expression (Gorlick et al., 1997) and these patient
preserve sensitivity for pemetrexed. This presumably was because of the uptake of pemetrexed
by the PCFT (Zhao et al., 2004).
Various studies were done with pemetrexed in combination with cisplatin chemotherapy in early
stage NSCLC. Most of the evidence supporting this combination therapy, are based on the results
of the trial on refinement of early stage lung cancer adjuvant therapy (TREAT), which included
132 patients with completely resected stage pIB-T3N1 NSCLC (Kreuter et al., 2013). The study
showed a statistically significant improved feasibility rate of 95.5% for the pemetrexed- cisplatin
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compared with 75.4% for the vinorelbine cisplatin treatment. Overall, the incidence of Grade 3/4
hematologic toxicities was significantly higher in vinorelbine cisplatin treatment.
In 2009, due to its favorable toxicity profile, results and convenient route of drug administration,
FDA approved pemetrexed for maintenance therapy of NSCLC (Ciuleanu et al., 2009). This
treatment strategy entails administering pemetrexed prior to disease progression following a
platinum-based treatment cycle. Although this limits the treatment-free period following therapy,
the low overt toxicity of pemetrexed combined with best supportive care has shown significance
in survival benefit (Ciuleanu et al., 2009).
1.1.6.5 AICAR
AICAR (5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide), enters the cells and is
converted into ZMP, an analog of AMP that is capable of stimulating AMPK-dependent protein
kinase activity (AMPK).
AICAR is being clinically used to treat and protect against cardiac ischemic injuries which, if left
untreated, may lead to a myocardial infarction. Cardiac Ischemia is caused by insufficient blood
flow to the myocardium (J. Corton , Gillespie, Hawley, & Hardie, 1999). The drug was first used
in the 1980s as a method to preserve blood flow to the heart during surgery (Galinanes, Bullough
D FAU - Mullane,,K.M., FAU, & Hearse, 0903). Currently, the drug has also been shown as a
potential treatment for diabetes by increasing the metabolic activity of tissues by changing the
physical composition of muscle [Zarembo, Alan. An article in the Los Angeles Times claimed
AICAR to be an “Exercise pill' could take the work out of workouts." Los Angeles Times].
Activation of AMPK by AICAR can inhibit basal or insulin stimulated glucose uptake,
lipogenesis, glucose oxidation and lactate production on rat adipocytes (Gaidhu, Fediuc, &
Ceddia, 2006).
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1.1.6.5.1 Mechanism of action of AICAR
AICAR (commonly under the name Acadesine) is an analog of adenosine that enters cardiac
cells to inhibit adenosine kinase and adenosine deaminase. In cardiac myocytes, AICA-riboside
is phosphorylated to AICA-ribotide (ZMP) to activate AMPK without changing the levels of the
nucleotides (Zhang, Frederich, He, & Balschi, 2006). Corton et al. showed similar results, where
incubation of rat hepatocytes with AICAR, results in accumulation of the monophosphorylated
derivative, ZMP, within the cell (J. M. Corton, Gillespie, Hawley, & Hardie, 1995). ZMP, an
AMP mimetic, mimics both activating effects of AMP on AMPK, i.e. direct allosteric activation
and promotion of phosphorylation by AMPK kinase. Due to activation of AMPK, AICAR
affects several catabolic pathways (glycolysis, fatty acid oxidation), anabolic pathways
(lipogenesis, glycogen synthesis, gluconeogenesis) and cell growth and survival pathways
(mTORC1 and autophagy). In this dissertation, AICAR is used as an AMPK activator and its
effects on the mTORC1 pathway were compared to those of PTX which were also shown to
activate AMPK and inhibit mTORC1 (Racanelli, Rothbart, Heyer, & Moran, 2009; Rothbart,
Racanelli, & Moran, 2010).
1.1.6.5.2 Clinical evaluation of AICAR against cardiac ischemic injuries
A brief period of coronary arterial occlusion followed by reperfusion prior to prolonged ischemia
is known as preconditioning and has been shown to be protective of the effects of the prolonged
ischemic peroid. Preconditioning preceding myocardial infarction may delay cell death and
allow for greater salvage of myocardium through reperfusion therapy (Murry, Jennings, &
Reimer, 1986). AICAR has been shown to precondition the heart shortly before or during
ischemia (Burckhartt B, 1995). AICAR triggers a preconditioning anti-inflammatory state by
increasing NO production via endothelial nitric oxide synthase. When AICAR is given 24 hours
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prior to reperfusion, it prevents post ischemic leukocyte-endothelial cell adhesive interactions
with increased NO production (Gaskin et al., 2009). AICAR also increases AMPK-dependent
glucose uptake through translocation of GLUT-4, which is beneficial for the heart during postischemic reperfusion (3rd, Bergeron R, Shulman,,G.I. & Young, 1999). The increase in glucose
levels during AICAR preconditioning lengthens the period for preconditioning up to 2 hours in
rabbits and 40 minutes in humans undergoing coronary ligation (Burckhartt et al., 1995; Murry et
al., 1986). As a result, AICAR reduces the frequency and size of myocardial infarcts up to 25%
in humans allowing improved blood flow to the heart. As well, the treatment has been shown to
decrease the risk of an early death and improve recovery after surgery from an ischemic injury
(Murry et al., 1986). This clearly suggests the importance of AICAR as a pharmacological agent
in clinical therapeutics of heart diseases and cardiac surgeries. However, due to activation of
AMPK, AICAR has been shown to act by inhibit mTORC1, a central pathway for cell growth
and proliferation. Therefore, AICAR has attracted the attention of researchers for its anti-cancer
properties.
1.1.6.5.3 Clinical Evaluation of AICAR as a cancer therapeutic agent
With the gradual inclination of chemotherapeutics towards targeted therapy, emerging evidence
suggests that targeting cancer cell metabolism can be a promising and future therapeutic
approach against human cancers. AMP-activated protein kinase (AMPK) is a known cellular
metabolic sensor and plays an important role in the control of energy homeostasis in response to
external stresses (Carling, 2005; Hardie, 2008; Kuhajda, 2008; Witczak, Sharoff, & Goodyear,
2008). The activation of AMPK is a signal of energy stress and the cell responds to AMPK
activation by inhibiting or slowing down cell growth process and biosynthetic process and
activating catabolic processes (Fogarty & Hardie, 2010). Therefore, the AMPK activators
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AICAR and metformin has been intensively studied to determine their potential as cancer
therapeutic agents (Fogarty & Hardie, 2010).
It has been shown that activation of AMP-activated protein kinase (AMPK) by AICAR,
Metformin or the direct AMPK activator A23187 hampers cervical cancer cell growth through
blocking the Wnt/β-catenin signaling activity (Kwan et al., 2013). This same group later reported
that activated AMPK (p-AMPK) also inhibits cervical cancer cell growth by counteracting
Forkhead box M1 (FOXM1) function (Yung, Chan, Liu, Yao, & Ngan, 2004). FOXM1 regulates
a number of key cell cycle regulators that control the G1 to S and the G2 to M transitions (I. C.
Wang et al., 2005). Some studies have shown that over-expression of FOXM1 might stem from
the constitutively active ERK which confers metastatic activity to ovarian cancer cells and
inhibition of ERK/FOXM1 has also been shown to repress the growth of ovarian cancer (Chan et
al., 2012; Lok et al., 2011). Therefore activation of AMPK by AICAR followed by inhibition of
ERK/FOXM1 and/ or Wnt/β-catenin signaling has been suggested to be an effective therapeutic
approach against ovarian and cervical cancers. Despite significant progress and success in the
treatment of ALL, a significant number of children continue to relapse and for them, overall
outcome remains poor. Some studies have studied the response of AICAR against ALL cells in
culture. AICAR-mediated AMPK activation was found to be an antiproliferative agent in ALL.
The mechanism of its anti-proliferative and apoptotic effects appear to be mediated via activation
of p38-MAPK pathway, increased expression of cell cycle inhibitory proteins p27 and p53, and
downstream effects on the mTOR pathway. Therefore, AICAR exhibits therapeutic potential as a
targeted drug for the treatment of childhood ALL (Sengupta et al., 2007). The proliferation of
various cancer cell lines was significantly inhibited by AICAR due to arrest in S- phase (Rattan,
Giri, Singh, & Singh, 2005). Signaling pathway analysis suggested that this S-phase arrest was
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accompanied by increased levels of p21, p27 and p53 proteins and attenuation of PI3K/AKT
pathway. This inhibition of in vitro cell growth was also mimicked in vivo with a similar pattern
of modulation of signaling pathways. AICAR mediated inhibition of cell proliferation due to Sphase blockade, occurs to a similar extent in both LKB1 wild-type and LKB1 knockout mouse
embryonic fibroblasts. This suggests that AICAR mediated activation of AMPK can be LKB1
independent, a surprising outcome. (Rattan et al., 2005).
A considerable level of research has been performed with AICAR to understand the AMPK
mediated mTORC1 inhibition. AICAR activated AMPK phosphorylates the Raptor subunit of
the mTORC1 complex and inhibits mTORC1 signaling, causing cell cycle arrest at G1/S phase
(Gwinn et al., 2008). As mTOR is a central regulator of cell growth and proliferation, its
inhibition blocks cancer cells proliferation and cancer progression.
1.2

FOCUS OF THIS DISSERTATION

Whereas the evolution of cancer chemotherapy is continuing, the understanding of molecular and
genetic mechanisms involved in the development and progression of cancer has been undergoing
revolutionary growth, continually changing the landscape for chemotherapy. This also
encouraged the molecular approach for cancer diagnosis and treatment. FDA approvals of the
antifolate pemetrexed for NSCLC and MPM boosted the enthusiasm for antifolates as cancer
therapeutics. As other TS inhibiting antifolates (5-FU/ leucoverin and raltitrexed) have shown
minimal response against MPM and NSCLC, the approval of pemetrexed as a first line therapy
drug for these diseases suggested that the mechanism of action which is effective in NSCLC, is
other then inhibition of TS. (Cunningham et al., 1996; Porta et al., 2005). Our lab recently
showed that this TS- independent mechanism of action is due to inhibition of the enzyme
AICART in the de novo purine synthesis pathway, which causes accumulation of the substrate of
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this enzyme ZMP, leading to activation of the AMP-dependent protein kinase and to subsequent
inhibition of mTORC1 (Racanelli et al., 2009; Rothbart et al., 2010). The studies of this
dissertation are focusing on understanding the role of p53 in mTORC1 regulation, which is
discussed in detail in Chapter 2. Understanding of the p53 mediated regulation on mTORC1
allowed us to address the question of how PTX effects are modulated by the p53 regulation on
this pathway. In order to address this question, the differences in the downstream signaling of
two AMPK activators, AICAR and pemetrexed were studied and directly compared during this
dissertation. Although both of these agents cause activation of AMPK by increasing the amount
of ZMP, the signaling downstream from AMPK was significantly different. Chapter 3 of this
thesis is focused on understanding the causes for these differences, which seems to be due to
differential behavior of p53 under these two drug treatments. Chapter 4 is mainly focused on
determining the effects of pemetrexed on transcriptional activity of gain-of-function mutant p53.
The overall finding of this thesis work indicates that the atypical response of pemetrexed against
several cancers including lung cancers may involve its effects on the transcriptional activity of
wild type and mutant p53.
1.3

MATERIALS AND METHODS

1.3.1 Chemicals and reagents
Pemetrexed (LY231514, PTX) was obtained from Eli Lilly and Company (Indianapolis, IN). In
some experiments, pemetrexed was purchased from LC Laboratories (#P-7177 Woburn, MA).
AICAR (#A611700) was purchased from Toronto Research Biochemicals. PTX and AICAR
were dissolved in PBS. Etoposide was purchased from Sigma Aldrich (#E1383) and was
dissolved in DMSO. TRIzol Reagent (#15596026), DNAse 1 (Invitrogen, # AM2222)
SuperScript III First-strand Synthesis System (#18080), primers were from Invitrogen (Carlsbad,
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CA) or Eurofin. Bradford Reagent (#5000006) was from Bio-Rad Laboratories. All other
reagents were from Fisher Scientific (Waltham, MA) or Sigma Aldrich (St. Louis, MO) and were
of the highest available purity.
Stock solutions of thymidine (560 µM) were routinely made by dissolving 0.00678 g of
thymidine powder in 48 ml of 1x PBS. The concentration was determined by measuring
absorbance at 267 nm from a 1:10 dilution of the stock solution in 1x PBS using an extinction
coefficient of 9.7 mM-1 cm-1. The volume was adjusted accordingly with 1x PBS for a final
concentration of 560 µM. This solution was filter-sterilized and was stored in single-use aliquots
at -20°C. Thymidine was typically used at a final concentration of 5.6 µM in rescue experiments.
DharmaFECT transfection reagent no. 2, siGENOME SMARTpool siRNAs targeting human p53
and scrambled siRNA pool no. 1 were purchased from Dharmacon (GE Healthcare, Lafayette,
CO, USA).

Four TSC2 siRNAs were purchased from Qiagen (Catalog # SI0001718,

SI03027339, SI00011697, SI00011711) and mixed in equal amounts to make a pool. Complete
EDTA-free Protease Inhibitor Cocktail tablets (#11873580001) were from Roche Applied
Science (Indianapolis, IN). Thirty % Acrylamide/BIS solution 37.5:1 (#1610158), Laemmli
Sample Buffer (#1610737), and Dual Color Precision Plus Protein Standard (#1610374) were
from

Bio-Rad

Laboratories.

Immobilon

polyvinylidene

fluoride

(PVDF)

membrane

(#IPVH00010) was from Millipore (Billerica, MA). StartingBlock Blocking Buffer (#37542),
Goat anti-rabbit IgG (#31462), and Goat anti-mouse IgG (#31348) secondary antibodies were
from Thermo Scientific. Blotting Grade Blocker Non-fat Dry Milk (#1706404) was from BioRad Laboratories. A list of antibodies and their sources can be found in Table 1 -1
1.3.2 Cell culture and reagents
HCT116 cell lines were a gift from Dr Bert Vogelstein. H460, A549, H441 and H661 cell lines
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were purchased from ATCC (Manassas, VA, USA.) and grown in RPMI 1640 with 10%
dialyzed fetal bovine serum (dFBS). H1299 cells expressing a ponasterone A-inducible p53
gene were made in Jennifer A. Pietenpol’s laboratory and were given to us by Dr. Sumitra Deb.
Mutant p53 containing H1437 and H1048 NSCLC cells were generous gift form Dr. sumitra
Deb. Mutant p53 conatining H661 and H441 NSCLC cells were purchased from ATCC. All
these cell lines were grown and maintained in RPMI 1640 with 10% dFBS and at 37°C with 5%
CO2 with fresh media replacement after every 2-3 days. Immortalized p53-/-TSC2-/- MEFs and
Sestrin 2 -/- MEFs were generous gifts from Dr. Andrei Budanov and were grown in DMEM
(#11995 Gibco/Invitrogen Carlsbad, CA) supplemented with 10% dFBS and maintained at 37°C
with 10% CO2 and given fresh media every 2-3 days. All cell lines were passaged by seeding in
T-75 flasks at a density of 106 cells/ flask every 2-3 days. Passaging of adherent cell lines
included washing with 1x phosphate buffered saline (#10010 Gibco/Invitrogen) and trypsinizing
for 5 minutes at 37°C with 1x trypsin-EDTA (#15400 Gibco/Invitrogen).
1.3.3 Generating p53 mutant stable cell lines
HCT116 p53-/- or H1299 cells were plated in 6 well plates at a density of 2x105 cells per well
and transfection was performed 24 hrs later with 2 µg of various mutant p53 plasmids containing
different mutant form of p53. Forty-eight hrs later transfection media was replaced with RPMI +
10% dFBS. Cells were allowed to grow for 24hrs. 24 hrs later cells were trypsinized and replated
in 10 cm dishes. These plasmids have selection marker for Zeocin. Thus, the cells which receive
the plasmid and express it will be resistant to the Zeocin. Therefore, in parallel, cell survival
assays were performed using the range of zeocin concentration from 20 µg/ml to 200 µg/ml on
untransfected HCT116 and H1299 cells. Cells were plated in 24 well plate and 24 hrs later each
well was supplied with a certain concentration of Zeocin containing media. Cellswere left in the
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zeocin containing media for 2 weeks with replacing zeocin contatining media at the interval of 23 days. The lowest concentrations of Zeocin which were able to kill 100% of cells were choosen
for each cell line to use it for selection of cells expessing mut p53. The lowest concentration
with 100% cell kill was found to be at 100 µg/ml for HCT116 and 40 µg/ml for H1299 cells.
Therefore to select the transfected cells, cells were exposed to 100 µg/ml (HCT116) or 40 µg/ml
(H1299) zeocin for 2 weeks, with selection media change after every 2-3 days. Cells were
trypsinized and replated in 10cm dishes with Zeocin contining media. After two generations cells
were plated to perform a western blot analysis to check the expression of mutant p53. As we
found that the each plamid was being expressed to the similar levels, we froze a batch of the cells
in FBS with 10% DMSO. One batch was carried on for further experimental analysis.
1.3.4 Immunoblotting
Total Protein Isolation: Protein was typically harvested from 2-5 x 106 cells grown on 100 mm
dishes. Prior to total protein harvest, one protease inhibitor cocktail tablet (manufacturer, catalog
#) was dissolved in 50 ml 1x PBS and placed on ice. Tissue culture plates were kept cold
throughout the harvesting procedure. Cells were washed once with cold 10 ml PBS (containing
protease inhibitor), scraped, and pelleted at 1,000 rpm for 5 minutes at 4°C. Cells were lysed in
cold buffer containing 62.5 mM Tris-HCl pH 6.5, 2% SDS, 5% glycerol, 5% 2-mercaptoethanol,
50 mM NaF, and a 1x concentration of Complete EDTA-free Protease Inhibitor Cocktail
(manufacturer). Lysates were sheared through a 21-gauge needle for 30 times before being
centrifuged at 14,000 rpm for 2 minutes. This shearing procedure was repeated, and lysates were
spun at 14,000 rpm for 5 minutes. The protein concentration was determined using the Bradford
Reagent according to the manufacturers protocol with BSA as a standard. Typical protein
concentrations in lysates were 2-5 µg/µl. Protein was placed in single-use aliquots and stored at -
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80°C.
SDS-PAGE and Protein Transfer: Gel electrophoresis and wet membrane transfers were
performed using the Mini PROTEAN-3 Cell system (#1653301) from Bio-Rad Laboratories.
Total protein was mixed with an equal volume of Laemmli Sample Buffer, boiled for 5 minutes,
and 20 µg of protein was loaded onto 1.5 mm SDS-polyacrylamide gels, poured according to the
recipe provided with 30% Acrylamide/Bis 37:5:1 (#1610158) from Bio-Rad Laboratories. An
aliquot (5-10 µl) of Dual Color Precision Plus Protein Standard was also loaded onto every gel
for mass determination. Typically, protein was resolved on 7.5% or 12% gels in running buffer
(25 mM Tris base, 250 mM glycine, 0.1% SDS) at 50 volts for 30 minutes (or until protein
migrated out of the stacking gel) followed by 120 volts for 1-1.5 hours to optimally separate the
protein of interest.
Polyvinylidene fluoride (PVDF) membrane that had been pre-soaked in methanol was rinsed in
water along with the gels and PVDF, gels, and sponges for the transfer were equilibrated for at
least 20 minutes in cold transfer buffer (25 mM Tris, pH 8.3, 192 mM glycine, 10% methanol).
Six pieces of Whatman paper per gel were cut to the approximate size of an electrophoresis
plate, and the transfer sandwich was assembled as follows: Layering on the black face of a
transfer cassette, 3 pieces of Whatman paper (dipped in transfer buffer) were placed on top of 1
sponge. Air bubbles were removed by rolling with a 5 ml plastic pipette. The gel was centered
on the Whatman paper, and a PVDF membrane was placed on top of the gel. Again, it was
important to remove all air bubbles from the transfer sandwich by rolling. It also helped to keep
the sandwich as wet as possible with transfer buffer during assembly. Whatman papers (dipped
in transfer buffer) were placed on top of the membrane, followed by another sponge. The
transfer cassette was closed, placed in its holder in the gel box along with a plastic ice block, and
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the gel box was then filled with cold transfer buffer. Transfers were either ran on ice or in the
cold room (4°C) at 100 volts for 45 minutes (one gel) or 50 minutes (2 gels). Following the
transfer, membranes were dipped in methanol and dried on the lab bench for 15 minutes before
being immunoblotted.
Antibody Detection: A general antibody detection procedure is described in this section. For
detailed conditions for each antibody, refer to Table 1-1. Dried membranes were soaked briefly
in methanol and non-specific proteins were blocked for 1 hour in either StartingBlock Buffer or
5% Blotting Grade Blocker Non-fat Dry Milk/0.1% TBS-T (0.5 M Tris-HCl pH 7.5, 0.14 M
NaCl, 2.7 mM KCl, 0.1% Tween 20). Membranes were washed three times for 5 minutes in
0.1% TBS-T. Primary antibodies diluted in either StartingBlock Buffer or 5% BSA (#A4503)
from Sigma were incubated on the membranes overnight at 4°C with rotation in sealed plastic
bags to minimize antibody consumption. Membranes were washed 3 times with 0.1% TBS-T for
5 minutes and incubated for 1 hour in horseradish peroxidase-conjugated secondary antibody.
Membranes were then washed 3 times with 0.1% TBS-T for 10 minutes. It was found that
washing more stringently during this step greatly diminished non-specific background during
exposure. Membranes were incubated with West Pico or West Dura SuperSignal
chemiluminescence substrate (Pierce) for 5 minutes. Blots were exposed to autoradiography film
and processed on an automated film developer. If the chemiluminescent conditions were not
known, West Pico was applied first. If no signal was apparent, the blot was rinsed with 0.1%
TBS-T, and West Dura (diluted by 40% with PBS) was applied. Signal was usually observed
with one of these conditions, and rarely was a more stringent detection reagent applied. Blots
presented in this dissertation are representative of findings from at least two biological replicates.
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1.3.5 RNA interference
Cells were plated at 2 x 105 cells/well of a 6-well plate late in the day. Cells were transfected 24
hrs after seeding.

siGENOME SMARTpool siRNAs (Dharmacon) (50 nM) were transfected

with 0.1% DharmaFECT reagent according to the manufacturer’s instructions. For p53
knockdown the transfection media remained on the cells for 24 hours, at which time cells were
washed with PBS and fresh media was replaced.

Longer incubations resulted in visually

apparent toxicity under a microscope. All experiments were controlled with a non-targeting
siRNA SMARTpool (scrambled). Protein was harvested after 72 hours. Levels of proteins,
targeted to knockdown, was analyzed by western blotting and knockdown was apparent by 48
hours and persisted at 72 hours post-transfection. For TSC2 knockdown, cells were transfected
with transfection media for 24 hrs, followed by replacement with normal media. Cells were
treated with the indicated drugs 36 hrs after transfection. Twenty-four hrs later, protein was
harvested and western blot analysis was used to analyze protein levels.
1.3.6 Over-expression of WT and Mutant Raptor.
p53-/- TSC2-/- MEFs were plated in 6 well plates at a density of 2 x107 cells per well.
Transfection was performed 24 hrs later with 3ug DNA using polyjet (SignaGen Laboratories)
maintaining a ratio of 1:3 of DNA: polyjet. After 24 hrs, cultures were split into two 6 well
plates. After 12 hrs, cells were treated with TdR or PTX + TdR. Twenty-four hr after treatment,
cells were lysed for western blot analysis. Vectors used for transfection, pBABE Hygro-empty
vector (ID-1765), pBABE-myc Raptor (ID- 18116) and pBABE myc-Raptor S722A/S792A (ID18117) were originally made in the laboratory of Dr Reuben Shaw (Gwinn et al., 2008) and were
purchased from Addgene.
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1.3.7 Cellular growth assay
Adherent cells were seeded at a density of 20,000 cells/well of a 12-well plate and allowed to
adhere overnight. Conditions were usually plated atleast in duplicate and experiments were
performed at least twice. Fresh media containing drugs were added the next day. Experiments
typically lasted 72 hours after drug treatment. Following the incubation period, cells were
washed 1x with PBS, trypsinized in 1.5 ml 1x trypsin-EDTA, and 1 ml of a single-cell
suspension was counted electronically using a Z1 Coulter Particle Counter (Beckman Coulter
Brea, CA). Data is presented as percent cell growth of experimental samples relative to controls
grown in the absence of drug.
1.3.8 Total RNA Isolation
Total RNA was extracted from HCT116 cells grown to 75% confluency on a 100 mm tissueculture dish using TRIzol Reagent according to the manufacturers protocol. All materials and
reagents used were sterile and RNAse-free. Diethylpyrocarbonate (DEPC) H2O (0.01% v/v)
was prepared by incubating at room temperature overnight and autoclaving before use. Pipettes
were cleaned with RNAse ZAP (Invitrogen), and crosslinked with a UV Stratalinker 2400
(#400075 Stratagene La Jolla, CA). Cells were placed on ice, washed 1x with cold PBS, and
lysed directly in 2 ml cold TRIzol Reagent. Cells were scraped, the slurry was transferred to a 14
ml round bottom Falcon tube, and the sample was incubated at room temperature for 5 minutes.
An aliquot (400 µl) of chloroform was added to the sample in the fume hood. The sample was
shaken vigorously for 15 seconds and incubated at room temperature for 3 minutes. The sample
was spun at 7,000 rpm for 15 minutes at 4°C. The mixture separated into 3 phases. RNA
remained exclusively in the aqueous upper phase. This aqueous phase was transferred to a fresh
14 ml tube and 1 ml of isopropanol was added to precipitate the RNA. This sample was
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incubated at room temperature for 10 minutes before being centrifuged at 7,000 rpm for 10
minutes at 4°C. The supernatant was removed, and the RNA pellet was washed 1x with 75%
ethanol in DEPC H2O. The sample was mixed and spun at 7,000 rpm for 5 minutes at 4°C. The
ethanol was removed and spun again to remove excess ethanol. The pellet was re-suspended in
200 µl DEPC-treated H2O. For storage purposes, 75 µl dissolved RNA was suspended in 225 µl
100% ethanol and stored at -80°C. This sample could then be re-precipitated and solubilized if
necessary. RNA concentration and purity was determined using the NanoDrop ND-1000
spectrophotometer (NanoDrop Technologies Wilmington, DE). Pure RNA has an OD260/280 of
2.0. The OD260/230 ratio was also used as a secondary indicator of RNA purity, and values
below the range of 1.8-2.2 indicated the presence of copurified contaminants. RNA integrity
was also determined by resolving RNA on a 1% TAE agarose gel at 100 volts for 30 minutes and
then staining with ethidium bromide. A distinct banding pattern and intensity difference between
28s and 18s rRNA indicated that the RNA was intact.
cDNA Synthesis: cDNA was reverse-transcribed from 3 µg of total RNA using the SuperScript
III First-strand Synthesis System from Invitrogen. SuperScript III Reverse Transcriptase is
similar to the Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV RT), but has
been engineered to diminish RNase H activity and enhance thermal stability. RNA was mixed
with a final concentration of 5 µM oligo(dT)20 primer and 1 mM dNTP mix in a volume of 10 µl
adjusted with DEPC-H2O. The mixture was incubated at 65°C for 5 minutes, then placed on ice
for at least 1 minute. The cDNA synthesis mix was prepared in a separate tube by combining 2
µl of 10x RT buffer (200 mM Tris-HCl pH 8.4, 500 mM KCl), 4 µl 25 of mM MgCl2, 2 µl of 0.1
M DTT, 1 µl of RNaseOUT (40 U), and 1 µl of SuperScript III Reverse Transcriptase (200 U)
per reaction. Ten µl of the cDNA synthesis mix was added to the RNA/primer mixture, the tube
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was gently mixed, and cDNA was reverse-transcribed by incubating at 50°C for 50 minutes. The
reaction was terminated by incubating at 85°C for 5 minutes before being held on ice. One µl of
RNase H (2 U) was added to each tube and the tube was incubated for 20 minutes at 37°C.
cDNA was stored at -20°C until use.
Primer design:
Primers to amplify the p21, Puma, HDM2, Bax, Pig3, TSC2, Sestrin2, 4EBP1, NFκB2, PCNA,
HSP70, hTERT, EGFR, MDM2, Axl and β-actin were designed with a 50-60% GC content,
melting temperature between 55-75°C, and were 18-30 nucleotides in length. Six random
nucleotides were added upstream of the restriction site on the 5’ end to allow for recognition and
digestion by restriction enzymes. Strings of 3 or more G’s, C’s, or T’s were avoided in the 3’
end, but 1 G or C was placed at the 3’ end to help tack down the primer during annealing.
Lyophilized primers were dissolved in HPLC-grade H2O to stock concentrations of 100 µM and
were further diluted in HPLC-grade H20 to a working stock concentration of 15 µM before being
added to Polymerase Chain Reactions (PCR). Primers were routinely stored as 100 µM stocks at
-20°C as well as 15 µM working stocks in single-use aliquots. Sequences of primers are listed in
table 1-2.

1.3.9 Chromatin Immunoprecipitation (ChIP)
Formaldehyde cross-linking and chromatin shearing The ChIP assay was adapted from Bronder
et al (Bronder & Moran, 2003). Approximately 1 x 107 cells per condition were crosslinked at
room temperature with 1% formaldehyde for 10 minutes, the reaction was then quenched for 5
minutes by the addition of 0.125 mM glycine. Cells were washed twice with PBS, scraped,
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washed in buffer I containing 10 mM HEPES pH 7.5, 0.5 mM EGTA pH 7.5, 10 mM EDTA pH
8.0, 0.25% Triton X-100, then in buffer II containing 10 mM HEPES pH 7.5, 0.5 mM EGTA pH
7.5, 1 mM EDTA pH 8.0, 200 mM NaCl. All ChIP buffers contained 1 µγ/µΛ aprotinin, 1
µγ/µΛ leupeptin, 1 µγ/µΛ pepstatin, 1 mM PMSF, 0.2 mM Na3VO4 and 10 mM NaF. Cells were
lysed in lysis buffer containing 25 mM Tris pH 7.5, 5 mM EDTA pH 8.0, 150 mM NaCl, 1%
Triton X-100, 0.1% SDS, 0.5% Na Deoxycholate. Aliquots of 2 x 106 cells in 600 µΛ lysis
buffer were sonicated with a Diagenode bath bioruptor for a total of 20 minutes with consecutive
duty cycles of 30 seconds on, 30 seconds off at 4oC (5 minute cycles repeated a total of 4 times).
These conditions were found to yield DNA fragments less than 1000 bp in size.
1.3.9.1 Immunoprecipitation
Lysates corresponding to 2 x 106 cells were precleared for 1 hour at 4oC with a 50% slurry of
protein G-Sepharose (Amersham Biosciences) beads previously blocked with 8 µγ of BSA and
either 5 µγ of sonicated lambda DNA or 6 µγ of sonicated salmon sperm DNA, then incubated
with 2 µγ p53 Ab-6 (Calbiochem) antibody or 2 µγ IgG (Millipore) antibody overnight.
Antibody-protein-DNA complexes were captured by the addition of 30 µΛ of 50% blocked
protein G-Sepharose bead slurry for 1 hour at 4oC. Beads were pelleted at 4,500 x g for 5
minutes at 4oC and the supernatant from the IgG immunoprecipitation was saved and the DNA
contained within was referred to as input DNA. Beads were washed extensively twice with RIPA
buffer (150 mM NaCl, 50 mM Tris pH 8.0, 0.1% SDS, 0.5% Na Deoxycholate, 1% NP- 40),
once with High Salt Buffer (500 mM NaCl, 50 mM Tris pH 8.0, 0.1% SDS, 1% Na
Deoxycholate), once with LiCl Buffer (250 mM LiCl, 50 mM Tris pH 8.0, 0.5% Na
Deoxycholate, 1% NP-40), and twice with TE (10 mM Tris pH 8.0, 1 mM EDTA pH 8.0) for 10
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minutes each at 4oC rotating end-over-end. Protein-DNA complexes were eluted with elution
buffer (2% SDS, 10 mM DTT, 0.1 M NaHCO3) while rotating end over end at 25oC for 15
minutes and the cross-links were reversed by the addition of 0.2 M NaCl and incubation at 65oC
overnight. DNA was treated with 10 µγ of RNase for 30 minutes at 37oC and with 20
µγ Proteinase K in 10 mM Tris pH 7.5, 5 mM EDTA pH 8.0, 0.25% SDS for 1 hour at 42oC,
phenol-chloroform extracted, ethanol-precipitated and dissolved in 100 mL TE.
1.3.9.2 Quantitative PCR (Q-PCR)
Quantitative PCR was performed with 1µL of input DNA or ChIP DNA for each 25 µL
reaction containing 12.5 µL Quantitect SYBR Green PCR Master Mix (Qiagen) and 0.3 µΜ of
each primer.. The amplification conditions were 95oC for 15 minutes, 40 cycles of 95oC for 45
seconds, for the noted Tm of each primer, for 45 seconds, 72oC for 45 seconds with a plate read,
and concluding with a 5 minute extension at 72oC and a melting curve from 45oC to 100oC.
Absolute quantities were calculated using a standard curve ranging from 100 ng to 0.8 ng of
input DNA. The sequences of the primers flanking the p53 binding sites of the p21 promoter are;
p21

3’RE-

Fwd

-5′-GAGGTCAGCTGCGTTAGAGG-3′,

Rev-5′-

TGCAGAGGATGGATTGTTCA-3′ and Tm used was 58 oC.
1.3.10 m7GTP-CAP pulldown
To determine whether pemetrexed treatment enhanced residence of 4EBP1 at mRNA with a m7guanosine CAP, cell lysates were incubated with m7GTP-sepharose beads, which have been
previously shown to bind both eIF4E and 4E-BP1 (Holz, Ballif, Gygi, & Blenis, 2005).
Following the indicated drug treatments, cells were lysed on ice for 30 min in IP buffer (25 mM
HEPES pH 7.5, 1% NP40, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 50 mM NaF, 1 mM
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PMSF, 0.1% 2- mercaptoethanol, and 1x Roche Complete Protease Inhibitor Tablet). Cleared
lysate (500 µg) was incubated with 40 µl of a 50% slurry of m7GTP-Sepharose (GE
Lifesciences) for 2 hr at 4°C with rotation. Cap complexes were washed with IP buffer four
times, resuspended in Laemmli Sample Buffer, and boiled for 5 min before being resolved on a
12.5% SDS-PAGE gel and immunoblotted as described above.
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Table 1-1 Antibody sources and conditions

Antibody

Company

Catalog#

MW

Blocking

1°Ab

2° Ab

β-actin
p-S172 AMPK
AMPK
p-S792 Raptor
Raptor
p-S1387 TSC2
TSC2
p-T389 S6K1
S6K1
p-T70 4EBP1
p-T37/46 4EBP1
4EBP1
p-S473 AKT
p-T308 AKT
AKT
eIF4E
Rictor
p-S2448 mTOR
mTOR
p-T246 PRAS40
PRAS40
Rheb
Sestrin2
p53
Ac-382 p53
Ac-379 p53
p-S15p53
p-S20p53
p-S46p53
p-S37 p53
p-S 392 p53
p21
MDM2/HDM2
Bax
p-S345Chk1
Chk1
p-T68Chk2
Chk2
p-S139H2A.X
H2A.X
Axl
NFkB2

Abcam
Cell signaling
Cell signaling
Cell signaling
Cell signaling
Cell signaling
Cell signaling
Cell signaling
Cell signaling
Cell signaling
Cell signaling
Cell signaling
Cell signaling
Cell signaling
Cell signaling
Cell signaling
Cell signaling
Cell signaling
Cell signaling
Cell signaling
Cell signaling
Abcam
Protientech grp
Calbiochem
Cell signaling
Cell signaling
Cell signaling
Cell signaling
Cell signaling
Cell signaling
Cell signaling
BDPharminogen
Santa Cruz
Oncogene
Cell signaling
Cell signaling
Cell signaling
Cell signaling
Cell signaling
Cell signaling
Cell signaling
Santa Cruz

8226
2532S
2531S
2283
2282
5584
3990
9234
2708
9455S
2855
9452
9271
4056
9272
2067
9476
2971
2983
2640
2610
Ab92313
10795-1-AP
OP43
2525
2570
9284
9287
2521
9289
9281
556430
813
PC66
2348
2345
2662
2661
9718
7631
8661
sc-7386

42
62
62
150
150
250
250
70
70
15-20
15-20
15-20
60
60
60
25
180
290
290
40
40
21
55
53
53
53
53
53
53
53
53
21
90
20
56
56
62
62
15
15
15
15

Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)
Starting block (SB)

1:5000 (SB)
1:1000 (SB)
1:500 (SB)
1:5000 (SB)
1:1000 (SB)
1:1000 (SB)
1:1000 (SB)
1:500 (SB)
1:1000 (SB)
1:1000 (SB)
1:1000 (SB)
1:1000 (SB)
1:1000 (SB)
1:1000 (SB)
1:1000 (SB)
1:1000 (SB)
1:1000 (SB)
1:1000 (SB)
1:1000 (SB)
1:1000 (SB)
1:500 (SB)
1:1000 (SB)
1:1000 (SB)
1:100 (SB)
1:1000 (SB)
1:1000 (SB)
1:1000 (SB)
1:1000 (SB)
1:1000 (SB)
1:1000 (SB)
1:1000 (SB)
1:1000 (SB)
1:500 (SB)
1:1000 (SB)
1:1000 (SB)
1:1000 (SB)
1:1000 (SB)
1:1000 (SB)
1:1000 (SB)
1:1000 (SB)
1:1000 (SB)
1:1000 (SB)

1:10000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
1:2000 (SB)
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Table 1-2 Primer sequences used for RT-qPCR

S.N

Genes

1

p21

2

PIG3

3

PUMA

4

BAX

5

TSC2

6

Sestrin2

7

NFkB2

8

PCNA

9

HSP70

8

hTERT

9

Axl

8

EGFR

9

MDR1

10

Rheb

110

β-actin

121

18S

Primer Sequences
Fwd-5’GACCTGTCACTGTCTTGTACCCT-3'
Rev- 5'GGTAGAAATCTGTCATGCTG GTCTG-3’
Fwd-5’TCTCTGAAGCAACGCTGAAATTC- 3’
Rev-5’GTAGGATCCGCCTATGCAGTCTA-3’
Fwd- 5'TGTGAATCCTGTGCTCTGCC-3’
Rev- 5'TTCCGGTATCTACAGCAGCG 3'
Fwd-5’TCTGACGGCAACTTCAACTG3’
Rev-5’ACAGGGACATCAGTCGCTTC3’
Fwd-5'TCGTGTTCCTGCAGCTCTACCATT-3'
Rev-5'ACCGCTCAAAGGACTGTGACTCAT-3'
Fwd-5’ACAAGTGTTGTGGCCTT CCTGAAC-3'
Rev-5'ATGGGTGAATGGCAAGTAGGAGGT-3
Fwd-5'GGG GCA TCA AAC CTG AAG ATT TCT-3
Rev-5′TCC GGA ACA CAA TGG CAT ACT GT-3
Fwd-5'AGGTGTTGGAGGCACTCAAG 3'
Rev-5'GTAGGTGTCGAAGCCCTCAG 3'
Fwd-5'ACCAGCCAAAGCAAGTTTATGT 3'
Rev- 5'ACTGGTCCTCCTTGTTTTTGAA 3'
Fwd-5' CTT GGC TTT CAG GAT GGA GTA GCA-3'
Rev-5'-GGC TTC AAG GCT GGG AGG AAC-3' .
Fwd-5’TGT TTG GTG TTT CTG GGA CA-3′
Rev-5′- TCG CAG GAG AAA GAG GAT GT-3′
Fwd-5’ AGCCTCCAGAGGATGTTCAA-3′
Rev- 5′ GGAATTCGCTCCACTGTGTT-3’
Fwd-5′ CCCATCATTGCAATAGCAGG-3′
Rev-5′ GTTCAAACTTCTGCTCCTGA-3′
Fwd-5' GGCTGGGTTACAGCTGATTG-3’
Rev-5’CTGACACGGACATCGAGCTA-3’
Fwd-5' CACGAAACTACCTTCAACTCC-3'
Rev-5' TCATACTCCTGCTTG CTGATCC-3'
Fwd-5’ GTAACCCGTTGAACCCCATTCG
Rev-5’ CATCCAATCGGTAGTAGCGACG
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1.3.11 Immunoprecipitation and Kinase Assays
HCT116 cells were plated at 2x106 cells/ 15 mm dish and allowed to adhere for 48 hrs. Cell
were harvested, lysed and immunoprecipitation was performed with 1mg protein under lower
salt conditions (100mM) as suggested previously using anti-Raptor and anti-Rictor antibodies
(37) . Immunoprecipitation of mTORC1 or mTORC2, and subsequent in vitro kinase assays
were carried out essentially as following:, the cells were lysed with lysis buffer (50 mM TrisHCl, pH 7.5, 100 mM NaCl, 0.3% CHAPS, and 1 mM EDTA, 10 mM β-glycerophosphate, 1
mM Na3VO4) supplemented with 1× Complete Protease Inhibitor Mixture from Roche Applied
Sciences. The supernatant from the centrifugation at 15,000 × g for 20 min at 4 °C was
immunoprecipitated using indicated antibodies and protein G- or protein A-Sepharose 4FF beads
(Amersham Biosciences). The immunoprecipitates were washed three times with the lysis
buffer. For in vitro kinase assay, the immunoprecipitates were further washed with wash buffer B
(20 mM Tris-HCl, pH 7.5, 10 mM MgCl2). The immunoprecipitates were then mixed with 0.5
µg of recombinant 4EBP1(cat# SRP0253 from Sigma Aldrich) and 0.5 µg of recombinant Rheb
(cat# SRP0225 from Sigma Aldrich) for mTORC1 in kinase buffer (20 mM Tris-HCl, pH 7.5, 10
mM MgCl2, 0.2 mM ATP) and incubated for 20 min at 37 °C. The kinase reaction was stopped
by the addition of 1× SDS sample buffer (3% SDS, 5% glycerol, 62 mM Tris-HCl, pH 6.7) and
subsequent incubation at 95 °C for 5 min. The proteins were resolved by SDS-PAGE and
transferred onto a nitrocellulose membrane. All proteins were detected by Western blotting.
GTPγS was purchased from Millipore. All antibodies used for western blot of IPs were from Cell
Signaling, Inc.
1.3.12 Competative peptide block for antibody specificity
Same set of protein lysates or immunoprecipitaes are run on SDS-PAGE in duplicate and
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proteins are transferred onto the PVDF membrane. Then, membrane is cut vertically in two parts
separating the two sets of samples. One membrane is incubated overnight at 4°C with 1:500
dilutaion of α-Rheb antibody and other membrane is incubated with 1:500 dilution of α-Rheb
Abs + cometetive Rheb-peptide solution (Rheb antibodies are preincubated with 500ng or 1µg of
Rheb-peptide for 30 min at RT). Secondary antibody incubation and exposure to the Licore was
done as suggested above in the immunoblotting section.
1.3.13 Overexpression of HA-TSC2 and Flag-Sestrin2
HCT116 p53 null cells were transfected with 3 µg DNA using Polyjet (DNA:Polyjet at 1:3).
Cells were lysed and immunoblotted 48 hr after transfection. For m7GTP pulldowns, cells were
plated in 10 cm dishes and transfected using 3 µg DNA; 48 hr later, cells were lysed in m7GTP
buffer. 4EBP1-eIF4E complexes were captured on m7GTP beads, as described (Holz et al.,
2005). Samples were resolved on 12.5% SDS-PAGE gels. Flag-Sestrin2 plasmid was obtained
from Dr. Andrei Budanov and HA-TSC2 was purchased from Addgene (Plasmid 24939,
deposited by Dr Kunliang Guan (Inoki, Li, Xu, & Guan, 2003).
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Chapter 2

2

Deletion and hot-spot mutations of p53 enhances mTORC1 activity by
decreasing TSC2 expression and lysosomal localization

2.1

INTRODUCTION

AKT, AMPK and mTORC1 are three main nodes of the central control system for responses
against metabolic changes and/or metabolic stress in the cells, which branch out into a number of
signaling forward and feedback loops. An equally important tumor suppressor protein, p53, is
thought to also play direct and indirect roles in influencing these pathways, although the
understanding of the mechanism of this control is limited. This chapter will investigate the
molecular mechanism of regulation of p53 on mTORC1 signaling and the importance of its
functional status in control of mTORC1 in human colon and lung carcinoma cells.
2.1.1 Discovery and structure of the tumor suppressor p53
p53 was first identified in 1979 as a phosphoprotein that co-immunoprecitated along with SV40
large and small t antigen, with sera from mice or hamster bearing SV40- induced tumors. This
co-immunoprecipitated protein traveled at 53000 daltons on sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS- PAGE) (Linzer & Levine, 1979). Linzer et al. Later, a
temperature sensitive mutant of the SV40 large T-antigen gene was found which caused the
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accumulation of p53 after a temperature shift. This observation suggested that p53 was involved
in SV40-mediated transformation and thus p53 was hypothesized to have oncogenic properties
(Linzer & Levine, 1979). Subsequent rigorous studies on p53 and SV40 showed that this
accumulation of p53 was actually the result of inactivation of p53 due to binding with large Tantigen rather then being involved in induction of the tumors directy. In 1984 when p53 was
reconstituted in a p53 null Ab-MuLV-transformed cell line, the expression of p53 was found to
be essential for tumor cells to exhibit a fully transformed phenotype, manifested in lethal tumors
in syngeneic mice (Rotter, Wolf, & Nicolson, 1984; D. F. Wolf, Harris, & Rotter, 0926). In
1983, Oren et al. cloned the p53 gene and did genetic manipulation of its sequence; they studied
the consequences of such manipulations on cell growth and survival (Oren & Levine, 1983).
Later they studied the mechanism of varying levels of p53 in transformed and non transformed
cells (Reich, Oren, & Levine, 1983) and suggested that levels of p53 are regulated at the level of
mRNA as well as the protein stability level. Until then the mechanistic role of p53 in cancer
progression was not clear. However, in 1989, Levine and group published a landmark paper
which demonstrated p53 as a tumor suppressor gene. This led to change in understanding of p53
function and its role in preventing tumor progression. Later studies by Levine's group supported
the idea of p53 being a tumor suppressor and suggested that the p53 proto-oncogene can act
negatively to block transformation (Finlay, Hinds, & Levine, 1989)
The p53 gene is located on the short arm of human chromosome 17 (17p13) and consists of 11
exons spanning approximately 20 kb of DNA (Benchimol et al., 1985; Lamb & Crawford, 1986).
The p53 protein consists of 393 amino acids organized into four functional domains (Fig 2-1).
The amino terminus of p53 contains two acidic transactivation domains, amino acids 1-42 and
43-60 (Fields & Jang, 1990) that play an important role in the transactivation mechanism of its
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target genes; various transcription factors, e.g, TATA binding proteins (TBP) and TBP
associated factors (TAFs) bind to these regions (Seto et al., 1992; Thut, Chen, Klemm, & Tjian,
1995). The p53 transactivation domain has one nuclear export sequence located at amino acids
12-27 containing two serine residues (serine 15 and serine 20), which are known to be
phosphorylated after DNA damage, resulting in nuclear retention of p53 (Y. Zhang & Xiong,
2001) and both of these phosphorylation sites play an important role in deciding the functional
fate and stability of p53. Downstream from the transactivation domain there is a proline rich
domain (amino acids 64-92). This domain consist of five repeats of the src homology 3 (SH3)
binding motif PXXP where P represents proline and X any other amino acid (Walker & Levine,
1996). This region has been linked to p53-mediated apoptosis but suggested to be dispensable for
transactivation and cell growth arrest (Sakamuro, Sabbatini, White, & Prendergast, 1997). The
proline rich sequence is followed by a DNA binding domain that stretches from amino acids 102
to 292 and enables p53 to specifically bind to a specific consensus binding sequence (p53
response element, p53RE) within gene promoters (Kern et al., 1991). Typically these sequences
contain two copies of the 10 bp motif 5′-PuPuPuC(A/T)(T/A)GPyPyPy-3′ separated by 10-13
bps where Pu is a purine base and Py is a pyrimidine base (el-Deiry, Kern, Pietenpol, Kinzler, &
Vogelstein, 1992). The DNA binding domain contains the majority of the mutational hotspots in
human cancer; the most frequently occurring mutations are in the peptides that make the closest
contacts with DNA, explaining why many p53 mutants are unable to bind DNA (Cho, Gorina,
Jeffrey, & Pavletich, 1994) or binds to complete different and newly recognized targets (also
discussed in chapter 4).
The C-terminal region of p53 consist of a flexible linker and a tetramerization domain. The
linker region connects the central core domain (N terminal domain) to the tetramerization
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domain, a 32 amino acid peptide required for the formation of tetramers. p53 binds to DNA in
tetramer form (Jeffrey, Gorina, & Pavletich, 1995). The tetramer is formed from 4 identical
monomers. Each monomer contains a turn, a β-strand, a second turn and an α-helix. Two
monomers form a dimer in which the α-helix is anti-parallel to the β-strand in the corresponding
monomer. Tetramers are formed by two dimers interacting through their α-helices and therefore
the p53 tetramer is known as a dimer of dimers (Jeffrey, Gorina S, and Pavletich,N.P., 1994).
This tetramerization is required for efficient p53 transactivation in vivo and subsequent growth
suppression (Pietenpol et al., 1994). A nuclear export sequence (NES) is located at amino acids
340-351 within the oligomerization domain and tetramerization masks the NES resulting in
nuclear retention of p53 (Stommel et al., 1999). The extreme C-terminal basic domain, amino
acids 363-393, was initially thought to be a negative regulator of sequence specific binding
(Hupp & Lane, 1995). However it is widely accepted that p53 binds nonspecifically to DNA via
the C-terminal domain (CTD) and then slides along the DNA searching for p53 consensus
sequences and that, therefore, the CTD promotes DNA binding (McKinney, Mattia, Gottifredi, &
Prives, 2004). There are three known nuclear localization signals within p53, one located in the
flexible linker sequence and the other two within the CTD (Addison et al., 1990; Shaulsky et al.,
1990).
2.1.2 Functional importance of p53
The p53 pathway can rapidly respond to cellular stimuli, especially to stresses that endanger
genomic instability.

p53 is known as “the guardian of genome” (Deppert, 2007; Efeyan &

Serrano, 2007) or “cellular gatekeeper” (Levine, 1997) because of its central role in coordinating
the cellular responses to the broad range of cellular stress factors. p53 functions as a mediator
and often decision maker for deciding whether the cell should respond to stress with cell cycle
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arrest, senescence, DNA repair, cell metabolism changes or apoptosis. All these decisions are
mediated through the transcription activation or repression of p53 target genes (B. Vogelstein,
Lane, & Levine, 2000; Vousden & Lane, 2007). As a transcription factor, p53 upregulates and
down-regulates a broad spectrum of genes, thus regulation of p53 demands very tight and finely
tuned controls (Menendez, Inga, & Resnick, 2010).
The conventional models for the regulation of p53 function are focused on three mechanisms:
p53 stabilization induced by ATM/ATR mediated phosphorylation after DNA damage,
sequence-specific DNA binding, and target gene activation by docking of p53 on the gene
promoter or interaction with transcriptional machinery. Some recent studies suggest that the
regulation of p53 cannot be categorized solely by these three levels of regulation (Iwakuma &
Lozano, 2000; Marine et al., 2006; Menendez et al., 2010). This chapter will focus not on the
mechanisms of control of p53, but rather on the mechanism of the p53 dependent regulation of
mTORC1 in cancer cells.
2.1.3 AKT- AMPK- mTORC1 Pathway
As a evolutionary mechanism, cells respond to changes in the intracellular and extracellular
environment by altering either gene expression or by the even faster and often transient set of
effects collectively known as signal transduction. The expression of a protein is regulated firstly
at the transcriptional level with the synthesis of RNA from DNA and secondly at the
translational level in which protein-encoding information in mRNA is read. As a very integral
and efficient process, translation demands substantial amounts of energy and cellular material
(Calkhoven, Muller, & Leutz, 2002). Before initiating the process of growth and proliferation,
cells must ensure the availability of resources of energy and required raw material like amino
acids, nucleic acids, etc. It is necessary for cells to keep an account of the energy status of the
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cells before committing to growth and proliferation.
A key pathway that senses and responds to change in environment is the AKT-AMPK-mTORC1
cascade. AKT and AMPK are antagonistic in this pathway and have opposing regulatory effects
on the signaling through mTORC1, which in turn controls initiation of cap-dependent translation
(Fig. 2-2). AKT, also known as Protien Kinase B, is a downstream effector for PI3K, which
directly phosphorylates TSC2 (Tuberous sclerosis complex 2) on the number of residues
including Ser 939, Ser 981 and Thr 1462. (Cai et al., 2006; K. Inoki, Li, Zhu, Wu, & Guan,
1011; Manning, Tee, Logsdon, Blenis, & Cantley, 2002; Potter, Pedraza, & Xu, 2002).
Although TSC2 is an important target of AKT but it is not the sole target for this kinase. Recent
studies have shown that AKT can positively regulate mTORC1 by phosphorylating PRAS40
(Proline-rich AKT substrate 40), a recently discovered binding partner and inhibitor of mTORC1
(Y. Sancak et al., 2007; Vander Haar, FAU, Bandhakavi S FAU - Griffin, Timothy,J., FAU, &
Kim, 0424). In the presence of growth signal, AKT is phosphorylated at Ser-473 (by mTORC2)
and Thr-318 (by PI3K) and activated. Activated AKT phosphorylates TSC2 and/or PRAS40.
This phosphorylation of PRAS40 leads to conformational changes of PRAS40 causing
dissociation from the mTORC1 complex. Dissociation of PRAS40 from the mTORC1 complex
causes activation of mTORC1 signaling to its downstream targets, suggesting PRAS40 to be an
inhibitor of mTORC1. Prior studies proposed this phenomenon to be mediated through 14-3-3
binding of the phosphorylated PRAS40 (Oshiro et al., 2007; Vander Haar et al., 0424; L. Wang,
Harris, Roth, & Lawrence, 2007). Inhibition of mTORC1 upon dissociation of PRAS40 was
nicely demonstrated by in vitro kinase assays done by Sancak Y et al. using immunoprecipitated
mTORC1 complex and recombinant S6K1 as a substrate (Y. Sancak et al., 2007).
Thus, AKT can regulate and activate mTORC1, independent of TSC2 by phosphorylating and
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dissociating an mTORC1 inhibitor PRAS40.

Interestingly, PRAS40 also contains a TOR

signaling motif that has been proposed to negatively regulate the mTORC1 activity by
competing with the binding of 4EBP1 and S6K to Raptor (L. Wang et al., 2007). Therefore,
PRAS40 is a direct inhibitor of mTORC1 that antagonizes the activation of mTORC1 by
Rheb.GTP (Y. Sancak et al., 2007). Because the TSC1-TSC2 complex is absent in some lower
eukaryotes, higher eukaryotes might have evolved a TSC1/2 complex-Rheb.GTP regulation
module to fine tune the regulation of mTORC1 for more complex and suddenly changing
environmental stimuli . Due to its critical role, mTORC1 is tightly regulated by forward and
feedback mechanisms. Some recent studies have proposed that PRAS40 is not only an inhibitor
of mTORC1 but also a substrate. mTORC1 mediated phosphorylation of PRAS40 inhibits its
inhibitory activity and augments the removal of inhibition on signaling downstream from
mTORC1(Fonseca, Smith, Lee, MacKintosh, & Proud, 2007; Oshiro et al., 2007; L. Wang et al.,
2007). This was proposed to be a positive feedback mechanism for AKT induced mTORC1
signaling. As TSC2 is an inhibitor of mTORC1, TSC2 null mouse embryonic fibroblasts have
constitutive mTORC1 signaling, and show insensitivity towards insulin-mediated activation of
AKT.

AKT signaling is largely inhibited due to a negative feedback mechanism, suggesting

that hyperactive Rheb can overcome PRAS40-mediated inhibition of mTORC1 (Y. Sancak et al.,
2007).
When the TSC1/2-Rheb-GTP-mTORC1 module of signaling is regulated by AKT, activated
mTORC1 also participates in regulation of the activity of insulin-PI3K-AKT signaling by at least
one feedback mechanism. Some early studies suggested that activated mTORC1 suppresses AKT
signaling by inhibition of insulin receptor substrate 1(IRS1) (Haruta et al., 2000; Takano et al.,
2001). Recent studies suggested that S6K, the downstream target of mTORC1, when
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phosphorylated, further phosphorylates and represses IRS1 (Harrington et al., 2004; Um et al.,
2004). It is becoming increasingly clear and accepted that this feedback regulation is not only
important for maintaining cell homeostasis but also plays an important role in insulin resistant
diabetes and in cancer therapeutics by rapamycin analogs (Easton, Kurmasheva, & Houghton,
2006; Um, D'Alessio, & Thomas, 2006). Whereas insulin-PI3K-AKT signaling senses the
availability of growth hormones and promotes growth and anabolic processes, the cell has an
antagonist effector molecule for this mechanism to maintain the cell's energy homeostasis called
AMP-activated protein kinase (AMPK).
2.1.4 AMP- activated protein Kinase (AMPK)
AMPK is a central metabolic switch found in all eukaryotes wthat regulates glucose and lipid
metabolism in response to alteration in nutrients and intracellular energy status. Activation of
AMPK in response to diminished energy (ATP) in cells promotes catabolic processes to generate
ATP, while inhibiting anabolic processes that consume it (Hardie, 2007). On a daily basis,
mammalian cells are exposed to factors that can lead to genetic abnormalities in the PI3K- AKT
and MAPK signaling pathways that lead to constitutive activation of cell proliferation and
growth pathways through mTORC1 (Hanahan & Weinberg, 2000; Hanahan & Weinberg, 2011;
Hay & Sonenberg, 2004; Shaw & Cantley, 2006). AMPK mediates an endogenous regulatory
mechanism and negatively controls cell growth and proliferation and thus represents a effective
and new approach for cancer therapeutics (W. Wang & Guan, 2009).
2.1.4.1 AMPK sensitivity for AMP: ATP levels
Today we know that AMPK recognizes the ratio of AMP:ATP and is very sensitive to this ratio
in the cell (Hardie & Hawley, 2001). Initially it was thought that AMPK is allosterically
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modulated by adenosine-5'-monophosphate (AMP) (Yeh, Lee, & Kim, 1980). The AMPK is
sensitive to the AMP:ATP and , to a lesser extent, the ADP:ATP ratio. In cells ratio of ADP:ATP
is maintained by an enzyme adenylate kinase which maintains the reaction of ADP to AMP and
ATP

in equilibrium (2ADP ↔ ATP+ AMP). Healthy cells keep the ATP:ADP ratio at

approximately 10:1 by ATP synthase (ADP + Pi → ATP). The driving force for ATP synthase
comes from the downhill flow of protons across the inner mitochondrial membrane, a gradient
maintained by oxidative phosphorylation pumping protons against this gradient (Yoshida,
Muneyuki, & Hisabori, 2001)
2.1.4.2 Interplay between ATP synthase and adenylate kinase
ATP synthase disrupts the equilibrium imposed by adenylate kinase in that is it drives the above
equation towards increasing levels of ATP. Therefore, to maintain equilibrium, the adenylate
kinase reaction is driven from the right to left, generating ADP from AMP. The adenylate kinase
reaction together with ATP synthase reaction maintains the ATP:AMP ratio at approximately
100:1 under the conditions of ATP homeostasis. When cells are under stress, the consumption of
ATP increases and in order to maintain equilibrium, the adenylate kinase reaction is driven from
left to right giving rise to an increased level of AMP in the process. AMPK is a heterotrimeric
kinase complex composed of a catalytic (α) subunit and two regulatory (β and γ) subunits.
Under energy starvation conditions, when glucose or the ATP/AMP ratio decreases below a
threshold, AMP binds to the γ subunit leading to the phosphorylation of the catalytic (α) subunit
at Thr 172 (Hawley et al., 2010).
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Figure 2-2. Schematic diagram of mTORC1 upstream and downstream targets.
Where does p53 fit in this pathway?
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Phosphorylated and activated AMPK phosphorylates TSC2 at Ser1387 (D. M. Gwinn et al.,
2008) and turns on its GAP (GTPase activating protein) activity towards Rheb. Biochemical
studies confirmed that Rheb-GTP is a substrate of TSC2. Increase in GTPase activity of TSC2
leads to conversion of Rheb-GTP into Rheb-GDP (Garami et al., 2003; K. Inoki, Li, Xu, &
Guan, 2003; T. Sato, Nakashima, Guo, & Tamanoi, 2009; Tee, Manning, Roux, Cantley, &
Blenis, 2003b; H. Zhang et al., 2003). Rheb-GTP is an essential factor for mTORC1 kinase
activity even in vitro (T. Sato et al., 2009). In the absence of TSC2 function, Rheb GTP levels
increase leading to hyperactivity of mTORC1 (Roccio, Bos, & Zwartkruis, 2000). Recently, it
was shown that phosphorylation of Raptor by AMPK is required for the inhibition of mTORC1
activity (D. M. Gwinn et al., 2008). This study discovered that AMPK negatively regulates
mTORC1 pathway by phosphorylating two proteins upstream of mTORC1 leading to the
concept that activation of AMPK can be used for mTORC1 inhibition.
2.1.5 mTOR
mTOR (mammalian target of rapmycin), a 290 KDa Ser/Thr kinase of the phsophatidylinositol
3-kinase related protein kinase (PIKK) family, is a highly conserved, nutrient-responsive
regulator of cell growth and proliferation.

mTOR is present as two biochemically and

functionally distinct complexes: a complex with Raptor known as mTORC1 or a complex with
Rictor known as mTORC2 (Wullschleger, Loewith, & Hall, 2006; Y. Zhang, Billington, Pan, &
Neufeld, 2006). A major source of information and knowledge about mTOR came after the
discovery of the antifungal and immunosupressent drug rapamycin, a macrocyclic lactone, which
is a potent and specific inhibitor of mTOR. Rapamycin forms an intracellular complex with the
peptidyl-prolyl cis–trans isomerase FKBP12 (FK506-binding protein). This drug/receptor
complex binds to the FRB domain of mTOR located N-terminal to the kinase domain (Fingar &
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Blenis, 2004). Although the mechanism of mTORC1 inhibition by rapamycin is still poorly
understood but some studies suggest that it could be due to weakening of Raptor-mTOR
interactions (Kim et al., 2002; Murakami et al., 2004). Prior studies focused on understanding the
influence of TOR on overall metabolism, used transcriptional profiling of rapamycin treated
yeast, drosophila and mammalian cells; the results suggested that the inhibition of mTORC1 by
rapamycin affects translation of approximately 5% of all genes in the genome (Hardwick,
Kuruvilla, Tong, Shamji, & Schreiber, 1999).

Guertin et al. reported that treatment with

rapamycin mimics the signals of glucose and amino acid starvation, which clearly suggested the
critical role of TOR complexes in energy sensing pathways (Guertin, Guntur, Bell, Thoreen, &
Sabatini, 2006; Hardwick et al., 1999; Peng, Golub, & Sabatini, 2002)
Rapamycin inhibits mTORC1 signaling. Interestingly, effects of rapamycin on the two targets of
mTORC1 are different. Whereas rapamycin strongly inhibits phosphorylation of S6K1, it’s
effects on 4EBP1 phosphorylation are minimal after short intervals of exposure. 4EBP1 is an
essential protein for inhibition of mTORC1 mediated cap-dependent translation initiation (Fig. 23). Also, it has been shown that tumors develop resistance towards Rapamycin or Rapalogs and
re-occurrence of cancer is prevalent with this drug treatment (Vignot, Faivre, Aguirre, &
Raymond, 2005). mTORC2 is insensitive to Rapamycin upon short exposure but mTORC2
complex diminishes upon longer exposure of Rapamycin. mTORC1 is composed of at least four
subunits: mTOR, mLST8/Gbl, PRAS40, and Raptor (Reiling & Sabatini, 2006). The 36 kDa
protein mLST8/GL interacts with the TOR kinase domain but has no intrinsic catalytic activity.
It consists almost entirely of seven WD40 repeats, a motif known to facilitate protein–protein
interaction and signal transduction (Kim et al., 2003; T. F. Smith, Gaitatzes, Saxena, & Neer,
1999). Seven WD40 repeats can also be found in Raptor in addition to a novel RNC domain and
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three HEAT repeats, also known to facilitate protein-protein interaction (Hara, Maruki, Long,
Yoshino, Oshiro, Hidayat, Tokunaga, Avruch, & Yonezawa, 0820a; Kim et al., 2002). Raptor
acts as a scaffold for the recruitment of the 4EBP1 and P70S6K1 substrates to mTORC1 (Nojima
et al., 2003; Schalm, Fingar, Sabatini, & Blenis, 2003). mTORC2 plays a very important role in
the feedback regulation of the mTORC1. Increased levels of P-389 S6K1 downstream of
mTORC1 leads to the single site phosphorylation of Rictor (T1135) that in turn exerts a negative
regulatory effect on the mTORC2 dependent phosphorylation and activation of PI3K/AKT. This
way mTORC1 can directly regulate mTORC2 and vice-versa (Dibble, Asara, & Manning, 2009).
mTORC2 is believed to be rapamycin insensitive. However, recent findings show that prolonged
(>24h) rapamycin treatment can disrupt mTORC2 assembly and function by sequestering newly
synthesized mTOR molecules (Sarbassov, Ali, Kim, Guertin, Latek, Erdjument-Bromage,
Tempst, & Sabatini, 2004a; Sarbassov et al., 2006). Rictor shares conserved domains among
eukaryotes, but their functions have so far not been elucidated (Jacinto et al., 1206; Sarbassov,
Ali, Kim, Guertin, Latek, Erdjument-Bromage, Tempst, & Sabatini, 2004b). The domain
structure of the TOR complex is quite complex and sophisticated suggesting the probability of
many other proteins are likely to interact, perhaps transiently, an indication that there may be a
much more complex mechanism of mTORCs regulation than currently understood. mTORC1 is
active when the energy status of the cell is high. However, AMPK is activated when the cell is
under energy stress, limiting mTORC1 activity. This antagonistic regulation by mTORC1 and
AMPK critically decides cell fate and whether to allow cell growth is allowed or whether cell
growth is suppressed based on insufficient energy charge.
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Figure 2-3. Regulation of Cap dependent translation by mTORC1 target, 4EBP1and
S6K1.
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2.1.6 AMPK activators
Recently, AMPK activators have been studied as potential chemotherapeutic drugs due to the
role of AMPK in cell growth control and its signaling crosstalk between critical metabolic and
oncogenic pathways. Treatment of MEFs with an AMPK activator, 5-aminoimidazole-4carboxamide-1-β-D-ribofuranoside (AICAR) inhibits mTORC1 activity and cell growth (Jones
et al., 2005). AICAR mediated activation of AMPK was also found cytotoxic in Acute
Lymphoblastic Leukemia (ALL) cells via inhibition of mTORC1 pathway and increased
expression of cell cycle inhibitors and apoptotic proteins, p53 and p27 (Sengupta et al., 2007).
Use of Metformin, a LKB1-dependent AMPK activator (D. Gwinn et al., 2008) is associated
with a statistically significant lower incidence of cancer in those diabetic patients using this drug
versus patients with similar disease on other therapeutic agents (Libby et al., 2009). There was a
detailed discussion on AICAR in chapter 1 of this thesis. Intraperitoneal injections of metformin
in mouse models of lung tumorigenesis activated AMPK and inhibited mTORC1 in liver tissue,
but in lung tissues mTORC1 was inhibited due to inhibition of insulin-lime growth factor-I
receptor (IGF-1R/IR) mediated signaling (Memmott et al., 2010). Metformin inhibits mTORC1
activity in MCF-7 cells in an AMPK dependent manner (Zakikhani, Dowling, Fantus,
Sonenberg, & Pollak, 2006).
Studies from this laboratory recently showed (Racanelli, Rothbart, Heyer, & Moran, 2009;
Rothbart, Racanelli, & Moran, 2010) that pemetrexed, an antifolate, also activates AMPK and
leads to inhibition of the mTORC1 pathway. In this thesis we demonstrate for the first time that
this effect of PTX, although affected by loss or mutation of p53, is still p53-independent and
mTORC1 inhibition is easily observed regardless of p53 status.
We recently showed that pemetrexed, an AMPK activator has a strong effect on both
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downstream targets of mTORC1, S6K1 and 4EBP1 (Racanelli et al., 2009; Rothbart et al., 2010).
Treatment with an AMPK activator not only blocks the mTORC1 signaling but also modifies
lipid synthesis, apoptosis and many major pathways involved in cell survival and growth
(Hardie, 2007; Mihaylova & Shaw, 2011). Due to involvement of AMPK in several other
catabolic and metabolic processes, the activation of AMPK leads to a multifaceted attack on
tumor cells. Thus, AMPK activators can be used as chemotherapeutic agents.
2.1.7 TSC1/TSC2 complex
Tuberous sclerosis (TSC) is an autosomal dominant genetic disease with an estimated prevalence
of about 1 in 6000 newborns, which is caused by the loss of function of either TSC1 or TSC2
tumor suppressor genes. Loss of function of these genes leads to the formation of benign but
progressively growing tumors in several vital organs including kidney, brain, heart and skin.
The tumors that form in the brain can lead to mental retardation and then seizures, causing poor
quality of life and ultimately, death. The tumor-like growths formed in this disease are named
hamartomas in the brain, skin, kidneys, heart and other organs. Common clinical features are
facial angiofibromas, renal angiomyolipomas, hypopigmented macules, cardiac rhabdomyomas,
and cortical tubers and subependymal glial nodules in the brain. The greatest source of morbidity
is the brain tumors, which cause seizures in 80-90% of affected individuals, mental retardation in
about half of affected individuals, and behavioral abnormalities (mostly autism) in over half of
affected individuals. (Cheadle, Reeve, Sampson, & Kwiatkowski, 2000; Gomez MR, Sampson
JR, Whittemore VH. 1999; Young & Povey, 1998) Two genes causative of TSC have been
identified, TSC1 and TSC2. TSC1 is located on chromosome 9q34 (van Slegtenhorst et al.,
1997) and encodes a 130 kDa protein named hamartin while TSC2 ((Identification and
characterization of the tuberous sclerosis gene on chromosome 161993)The European

95

Chromosome 16 Tuberous Sclerosis Consortium, 1993) is located on chromosome 16p13.3 and
encodes a 200 kDa protein named tuberin. A variety of mutations have been reported in these
genes, which include point mutations, large deletions/ rearrangement/ insertion for TCS2 and
insertion, deletion, nonsense and splicing mutation for both the genes. (Reviewed in (Cheadle et
al., 2000; Young & Povey, 1998). TSC1 contains two coiled-coil domains, which have been
shown to mediate binding to tuberin (Hodges et al., 2001) the TSC1/TSC2 heterodimer has been
shown to function as a tumor suppressor (Plank, Yeung, & Henske, 1998; van Slegtenhorst et al.,
1998). Histological studies of tumor lesions of TSC patients show some diversity, however, the
tumors that arise as a result of loss of function of either TSC1 or 2 shares common features
suggesting that TSC1 and TSC2 are involved in the regulation of the same pathway which feeds
into the cell cycle, cell growth control, and vesicular trafficking and adhesion (van Slegtenhorst
et al., 1998). Some recent studies showed that the TSC1/TSC2 heterodimer is involved in the
regulation of cell growth and proliferation downstream of PI3K- AKT in a signaling pathway
feeding into mTORC1 in both D. melanogaster and mammalian cells, suggesting that
TSC1/TSC2 are a regulator of the mTORC1 pathway (K. Inoki, & Guan 2003; Manning &
Cantley, 2003). Within the TSC1- TSC2 complex, TSC1 stabilizes TSC2 (Benvenuto et al.,
2000; Chong-Kopera et al., 2006) while TSC2 acts as GTPase activating protein (GAP) for the
small GTPase Rheb (Ras homolog enriched in brain) (Garami et al., 2003; K. Inoki, Li, Xu, &
Guan, 2003; T. Sato, Nakashima, Guo, & Tamanoi, 0721; Saucedo et al., 2003; Stocker et al.,
2003; Tee & Blenis, 0123; Y. Zhang, Saucedo, Ru, Edgar, & Pan, 2003). GTP bound Rheb
potently activates mTORC1 (Y. Sancak et al., 2007).

When active TSC1-TSC2 complex

converts Rheb-GTP to Rheb-GDP and inhibits mTORC1, thus, loss of TSC2 promotes cell
growth and tumorigenesis. TSC2 has multiple sites for AKT, MAPK, RSK, and extracellular
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signal-regulated kinase (ERK) phosphorylation (Ballif et al., 2005; Dan et al., 2002; Liu, Cai,
Espejo, Bedford, & Walker, 2002; Manning et al., 2002; Roux, Ballif, Anjum, Gygi, & Blenis,
2004; Tee, Manning, Roux, Cantley, & Blenis, 2003a), all of which appear to be inhibitory to its
function. It was clear that in the presence of growth factor or insulin stimulation AKT blocks the
TSC2 mediated inhibition of mTORC1 by its phosphorylation at several sites (K. Inoki, Li, Zhu,
Wu, & Guan, 2002; Manning et al., 2002), but the mechanism by which that AKT mediated
phosphorylation inhibits TSC2 tumor suppressor function is still unknown. Also, there are
several contradictory studies which suggest that TSC2 can be located in the cytoplasm (Nellist et
al., 1999),the membrane portion of cell (Wienecke, Konig, & DeClue, 1995) or even in nucleus
(Lou, Griffith, & Noonan, 2001). This clearly suggests that the possible mechanism central to
control of TSC2 could be the translocation of the TSC1-TSC2 complex between cellular
compartments.

To address this question Cai et al. (Cai et al., 0609) fractionated nuclear,

cytoplasmic and membrane fractions and showed that tuberin subcellular translocation is
dependent on AKT mediated Ser/Thr phosphorylation of TSC2 and thus dependent on the status
of the growth factors available to cells. They also showed that upon growth factor stimulation
14-3-3 proteins mediate the translocation of TSC2 into the cytosol; however, TSC1 enhances
TSC2 retention at the membrane. The most interesting finding of this study was that upon growth
factor stimulation, Rheb and TSC2 co-localization are disrupted, suggesting that the regulation of
TSC2-Rheb-GTP on mTORC1 is mechanistically regulated by the translocation of TSC2
between cytosol and membrane bound Rheb-GTP. They suggested that when TSC2 and Rheb
are co-localized, TSC2 GAP activity converts Rheb GTP into Rheb GDP and in the absence of
Rheb- GTP, mTORC1 signaling is not activated (Cai et al., 2006). A follow-up study (J. Zhang
et al., 2013) from the same group was done to understand the mechanism of interaction of
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TSC1/TSC2-Rheb-mTORC1. They showed that the tuberous sclerosis complex localizes to
peroxisomes, including TSC1, TSC2, and also Rheb. This signaling node regulates mTORC1 in
peroxisomes in response to reactive oxygen species (ROS). This study also suggested that
peroxisome-localized TSC2 functioned as a GTPase for Rheb-GTP and converted it to RhebGDP in response to ROS leading to mTORC1 inhibition; this mTORC1 inhibition was
diminished in cells expressing peroxisome-localization deficient mutants of TSC2 (J. Zhang et
al., 2013). Menon et al. in their very recent study addressed the similar question of how TSC2Rheb regulates mTORC1 in the presence of growth factor and amino acid availability conditions.
They showed that upon insulin stimulation there is no change either in the GAP activity of TSC2
or in the stability of the TSC complex (Menon et al., 2014). It has been known before that both
low levels of growth factors or amino acids can inhibit mTORC1 activity (Y. Sancak et al.,
2010b). Study of Menon et. al (Menon et al., 2014) added further understanding of how these
two factors (insulin and amino acids) are quite independent of each other in regulating the
localization of the TSC complex and mTORC1 to the lysosome. They also showed that activity
of the PI3K-AKT pathway induces the dissociation of the TSC complex from the lysosome in an
AKT dependent manner. This sophisticated study unified the mechanism by which independent
pathways affect the recruitment of mTORC1 and the TSC complex to Rheb at the lysosomal
surface and raises the concept that lysosomal localization serves to integrate growth signals and
the decision between survival or proliferation (Menon et al., 2014). This suggest that the
presence or absence of TSC2 function plays an important role in deciding the control of
PI3K/AKT vs mTORC1 on S6K1 (Jaeschke et al., 2002).
2.1.8 Rheb
Rheb is a small GTPase initially isolated as a Ras homolog enriched in brain (Yamagata et al.,
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1994). Rheb expression was also induced in quiescent fibroblast cells after the addition of serum
(Yamagata et al., 1994). In addition, Rheb expression was induced in PC12 cells, a cell line
derived from a pheochromocytoma of the rat adrenal medulla after the addition of EGF or FGF
(Yamagata et al., 1994). Rheb has been found to be highly conserved during evolution and was
found to play critical roles in cell growth, cell cycle, autophagy and amino acid uptake (Aspuria
& Tamanoi, 2004; Patel et al., 2003). Rheb is a monomeric 21 KDa protein which belongs to the
Ras superfamily of GTPases (Wennerberg, Rossman, & Der, 2005). For a long time, Ras
superfamily G-proteins were classified into one of five subfamilies, Ras, Rho, Rab, ARF, and
Ran (depending on what for the classification?); members of each subfamily share high sequence
homology in their effector domain and they also have similar functions (Bourne, Sanders, &
McCormick, 1991; Mackay & Hall, 1998; Moore, 1998; Moss & Vaughan, 1998; Schimmoller,
Simon, & Pfeffer, 1998; Vojtek & Der, 1998). Rheb proteins are highly conserved during
evolution and are found from yeast to humans but are absent in plants. Mammalian cells have
two different Rheb genes: RHEB1 and RHEB2 (also called RHEBL1) but lower eukaryotes such
as yeast or Drosophila have only one gene. The translation products of these two genes share
54% identity and 74% similarity and it is thought that they perform similar functions. However,
their tissue expression profiles differ, with Rheb1 ubiquitously expressed while Rheb2
expression is more limited (Saito, Araki, Kontani, Nishina, & Katada, 2005). For the purposes
of this dissertation study, only Rheb1 will be discussed further. Recently, Rheb has received
significant attention, partly because Rheb proteins play roles in regulating growth and cell cycle,
an effect thought due to its role in the insulin/mTOR/S6K signaling pathway.

Rheb acts

downstream of AKT and activates S6K phosphorylation dependent on TOR. Rheb is known to
be an activator of mTORC1 (Aspuria & Tamanoi, 2004; T. Sato, Nakashima, Guo, & Tamanoi,
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2009; Tee, Manning, Roux, Cantley, & Blenis, 2003b). Like other Ras superfamily proteins,
Rheb also activates downstream effectors only when bound with GTP. All Rheb proteins contain
short stretches of sequences involved in the recognition of the guanine ring and phosphates of
guanine nucleotides, known as G1 – G5 boxes, (Aspuria & Tamanoi, 2004). Tamanoi’s group
have made a number of contributions to the understanding of Rheb proteins. They showed that
Rheb family members share some very critical features (Urano, Tabancay, Yang, & Tamanoi,
2000) first, an arginine residue corresponding to the glycine at the 12th codon of Ras is
conserved in all the Rheb homologues. Second, they have very similar effector domain
sequences in which 10 of the 17 residues are identical, and 4 of the remaining residues are
similar. Third, they all terminate in the CAAX motif (C is cysteine, A is an aliphatic amino acid,
and X is the C-terminal amino acid that is usually methionine, alanine, serine, glutamine, or
cysteine) that is required for farnesylation (Clark et al., 1997; Urano et al., 2000; Yang, Urano, &
Tamanoi, 2000) a posttranslational modification, important for membrane localization and
function of Rheb.
2.1.8.1 Rheb Expression and cancer
Rheb is frequently overexpressed in human carcinoma and has been shown to markedly sensitize
the epidermis of transgenic mice overexpressing Rheb in basal epidermal keratinocytes; these
mice show squamous carcinoma induction following a single dose of Ras-activating carcinogen
7,12-dimethylbenz(a)anthracene (Lu et al., 2010). A meta-analysis of previously published
cancer cytogenetic and transcriptional databases suggested that the chromosome 7q36.1–q36.3
region containing the RHEB gene is frequently amplified in some human cancer histologies: an
increased RHEB expression was observed in liver, lung and bladder cancers.

A direct

correlation between Rheb mRNA levels and breast cancer prognosis and progression has been
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shown by microarray database mining (Jiang & Vogt, 2008). Studies done to determine the
significance of Rheb in the oncogenic transformation of chicken embryonic fibroblast suggested
that Rheb played an essential role in oncogenic transformation (Jiang & Vogt, 2008). The
expression of Rheb Q64L and N153T in these fibroblasts induced morphological changes,
including increased size and vacuolization, and conferred upon the cells the ability for anchorage
independent growth.
2.1.8.2 Subcellular localization of Rheb
The initial studies on Rheb were mainly done using ectopicly overexpressed Rheb; some of these
studies indicated that Rheb localizes on perinuclear and vesicular structures. (Buerger, DeVries,
& Stambolic, 2006; Saito et al., 2005; Takahashi, Nakagawa, Young, & Yamanaka, 2005). There
have been reports of Rheb localizing to several endosomal membrane fractions: lysosomes,
peroxisomes, and mitochondria. A literature consensus on the location of Rheb in the cell has
not yet been reached. Sudies done by Sancak et al using overexpression of Rheb showed that
exogenously expressed Rheb is localized in lysosomal membranes, based on colocalization with
the lysosomal marker LAMP2 (Y. Sancak et al., 2010a). Later this observation was confirmed
using antibodies to detect endogenous Rheb (Menon et al., 2014). Subcellular membrane
localization of Rheb is dependent on its farnesylation and postprenylation modification events
including Rce1 cleavage and Icmt-mediated carboxyl methylation (Hanker et al., 2010;
Takahashi et al., 2005).
2.1.8.3 Interconversion of Rheb-GTP and Rheb-GDP
As with other Ras superfamily members, Rheb binds to both guanine nucleotides GTP and GDP
as reported in rat, S. pombe and M. drosophila (Yamagata et al., 1994; Yan et al., 2006; Zheng et
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al., 2011). Extensive biochemical studies with S. pombe suggested that Rheb binds to GDP
(Zheng et al., 2011). This binding was specific to guanine nucleotides as excess GDP or GTP
competed with bound GTP but this was not seen with CTP, UTP or ATP. It is also well known
that Rheb has an intrinsic GTPase activity (Zheng et al., 2011). Some studies showed that the
rate of GTPase activity of Rheb was much slower than seen with Ras but some studies reported
these rates to be comparable (Yamagata et al., 1994). TSC2, upon activation, works as a GTPase
activating protein and enhances the intrinsic GTPase activity of Rheb. In the presence of excess
GTP, GDP dissociates form Rheb suggesting that Rheb shuttles between GDP-bound and GTPbound forms (Zheng et al., 2011).

2.1.9 Sestrin1/2
The GADD (Growth arrest and DNA damage) genes that are induced in response to genotoxic
treatments encode several functionally distinct proteins.

The proteins encoded by these genes

are centrally involved in adaptive or detrimental responses to cellular stresses (Fornace, 1992;
Fornace, Jackman, Hollander, Hoffman-Liebermann, & Liebermann, 1992; M. L. Smith &
Fornace, 1996). One very recently added gene in the list of GADD genes is Sestrin2 also known
as Hi95. Budanov et al., while studying the genes affected by long term oxidation stress,
reported the Hi95 gene to be involved in regulation of cell viability in response to genetic and
oxidative stress conditions (A. V. Budanov et al., 2002). Oxygen homeostasis is tightly regulated
and controlled by an oxygen sensing mechanism and by oxidative stress responsive genes, which
are induced to compensate for oxygen deficiency (hypoxia). In order to identify novel genes
induced under prolonged hypoxic conditions, Budanov et al. compared gene expression profiles
in human glioblastoma A172 cells maintained under normoxic conditions and following
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prolonged hypoxia, using microarrays (A. V. Budanov et al., 2002). Hi95 was one of the genes
to be induced under this hypoxia; this was of interest because of the strong homology to the p53
responsive gene PA26, a GADD gene (Velasco-Miguel et al., 1999). Budanov et al further
demonstrated that this induction of Hi95 was p53-independent after hypoxia but was p53dependent after DNA damage (A. V. Budanov et al., 2002). Hi95 induction in MCF7 cells
suppresses growth, sensitizing them to DNA damaging drug and serum deprivation but
protecting them from H2O2 treatment and ischemia. Hi95 is now called sestrin 2. Sestrin1 and
Sestrin2 have been recently described as p53 target genes (A. V. Budanov et al., 2002; Peeters et
al., 2003; Velasco-Miguel et al., 1999) involved in the regulation of mTORC1. DNA damage
and oxidative stress induce Sestrin1 and Sestrin2 and show cytoprotective function (A. V.
Budanov, Sablina, Feinstein, Koonin, & Chumakov, 2004). Recent studies by Budanov and
Karin showed that sestrin1/2 also play important roles in the inhibition of mTORC1. Exogenous
expression of Sestrin1/2 activates AMPK and TSC2 phosphorylation and lead to mTORC1
inhibition. They showed that induction of p53 by genotoxic stress induces Sestrin2 which
further leads to activation of AMPK and TSC2 leading to inhibition of mTORC1 and they
concluded that sestrin1/2 work as the connecting link between AMPK and TSC2 (A. V. Budanov
& Karin, 2008b). This chapter also involves the role of Sestrin 2 on p53 and its regulation on
mTORC1.
2.1.10 Raptor
Raptor, the regulatory associated protein of mTOR not only interacts with mTORC1 but also
with mTORC1 substrates S6K1 and 4EBP1. These two proteins interact with Raptor via a
domain known as a TOR signaling motif and become phosphorylated by the mTORC1 kinase
domain. Therefore Raptor works as a scaffold protein that facilitates the recruitment of the
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substrates of mTORC1. This recruitment allows phosphorylation by mTORC1 of S6K1 at a
single site, Thr389, and of 4EBP1 at 4 different sites (Ser65, Ser70, Ser37/46) (Fingar et al.,
2004;, Maruki, Long, Yoshino, Oshiro, Hidayat, Tokunaga, Avruch, & Yonezawa, 2002;
Loewith et al., 2002; Ma & Blenis, 2009; Nojima et al., 2003; Schalm & Blenis, 2002; Schalm &
Blenis, 2002; Schalm et al., 2003). mTORC1 mediated phosphorylation of S6K1 is essential for
the assembly of the eIF3 translation initiation complex Fig. 2-2 (M. K. Holz, Ballif, Gygi, &
Blenis, 2005b). On the other hand, 4EBP1 is a strong translational repressor which binds to the
complex of capped mRNA with initiation factor eIF4E, blocking further enucleation of the
translational initiation complex by other factors.

Only after phosphorylation of 4EBP1 by

mTORC1 will 4EBP1 release eIF4E and allows its interaction with other factors, prompting the
initiation of cap dependent translation (Ma & Blenis, 2009).
In a very important paper, Gwinn et al showed that activation of AMPK leads to
phosphorylation of TSC2 at Ser1387 and of Raptor at Ser792 leading to inhibition of mTORC1
kinase activity (D. M. Gwinn et al., 2008). Although Ser792 phosphorylation is important for
the regulation of mTORC1, it is not the only modification of Raptor. Using tandem mass
spectrometry, Raptor was found to be is phosphorylated at six different phosphorylation sites
mainly in two clusters (cluster1, Ser696/Thr706 and cluster 2 Ser855/Ser859/Ser 863/Ser877).
This observation was confirmed with site-specific antibodies for these sites. This raises the
question of whether AMPK activators, which can strongly phosphorylate Raptor at Ser792, may
inhibit mTORC1. The 3rd chapter of this dissertation will be discussing whether, PTX, which
activates AMPK and robustly phosphorylate Raptor at Ser 792 leads to inhibition of mTORC1.
2.1.11 p53 mutations and cancer
p53 is mutated in approximately 50% of human cancers, making it the most commonly mutated
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gene in human malignancies (B. Vogelstein, 1990). As described above, p53 is capable of
triggering apoptosis or growth arrest, both of which aid in maintaining genome stability. Due to
the involvement of p53 in these pathways which protect the cell from transformation, extensive
research has been done to understand the impact of the presence of mutant p53 in the genome.
The majority of p53 mutations in human cancers disrupt the ability of p53 to bind to DNA (Kato
et al., 2003). In a study including 280 tumors containing p53 with somatic base substitution
mutations, 98% of the mutations fell within a 600 base pair region of p53 encompassing exons 5
through 8 (amino acids 110-307). Out of the 280 analyzed, 227 were from solid tumors. Colon,
esophagus, breast and non-small cell lung cancer contained the highest number of mutations
(Hollstein et al., 1991). In heterozygous cells, a mutant p53 allele can alter the function of the
wild-type p53 allele, either by having a dominant negative effect on wild-type p53, or by
resulting in gaining new oncogenic properties, independent of the wild-type p53 allele (Baker et
al., 1989). Analysis of tumors containing allelic deletions in the short arm of chromosome 17,
the region encoding p53, showed that the remaining allele contained point mutations indicative
of loss of heterozygosity (Baker et al., 1989). Upon co-translation of mutant p53 and wild-type
p53, mutant p53 was found to oligomerize with wild-type p53, driving it to a mutant phenotype
characteristic of a dominant negative effect (Milner & Medcalf, 1991). Transfection of mutant
p53 into p53 null tumors resulted in lethal tumors, demonstrating that mutant p53 may gain
oncogenic properties (D. Wolf, Harris, & Rotter, 1984).
2.1.12 Interplay between p53-TSC2-Sestrin2 and mTORC1
Feng et al. showed that upon DNA damage induced by etoposide, p53 competent cells show
activation of AMPK followed by inhibition of mTORC1. They suggested that, under genotoxic
stress, p53 negatively regulates mTORC1 via p53 dependent activation of AMPK (Feng, Zhang,

105

Levine, & Jin, 2005). It was not known, before this thesis, whether un-stimulated endogenous
levels of p53 have any effects on mTORC1 regulation. Later it was reported that activation of
p53 by DNA damaging agent leads to increase in TSC2 (Feng et al., 2007) and sestrin2 (A. V.
Budanov et al., 2002) mRNA and protein levels in p53 competent cells. Budanov et al showed
that upon overexpression of exogenous Sestrin2, AMPK mediated phosphorylation of TSC2
increases, leading to decrease in mTORC1 activity.

These investigators suggested that

Serstrin1/2 was an essential participant in the interaction of TSC2 and AMPK for TSC2
phosphorylation and activation (A. V. Budanov & Karin, 2008a).
All these studies cumulatively suggest that the involvement of p53 in mTORC1 pathway could
be multimodal and dependent on the type of stress stimulant. Most of these studies are done
either by activation of p53 using DNA damaging drugs or by introducing ectopic TSC2,
sestrin1/2 or AMPK.

2.2

FOCUS OF THIS CHAPTER

In this chapter, we focus on understanding the differences in control of mTORC1 activity in the
presence and absence of p53 and followed those observations onto the effect of mutant p53 on
control of mTORC1.
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2.3

RESULTS

2.3.1 mTORC1 activity is suppressed by basal p53 function in an AMPK independent
manner.
Feng et al (Feng et al., 2005) established a connection between p53 and mTORC1 when they
showed that stabilization of p53 by the DNA damaging agent VP16 (etoposide) suppressed the
phosphorylation of the mTORC1 target S6K1 in MEFs and that this effect does not occur in
MEFs lacking p53. We observed the same phenomena for HCT116 colon carcinoma cells
isogenic for p53 deletion, ie, S6K1 becomes hypophosphorylated in wt HCT116 cells treated
with VP16 but not in the HCT116 cell line devoid of p53 (p53 -/-) treated with VP16 (Fig. 24A). However, a second very significant effect was evident: untreated p53 (-/-) HCT116 cells
displayed a robust hyperphosphorylation of S6K1 at T389 over that in HCT116 with p53
function (Fig. 2-4A). The effect of DNA damage on mTORC1 activity was shown by Feng et al.
(Feng et al., 2005) to be mediated by AMPK activation; however, the stimulation of mTORC1
with loss of p53 in untreated cells was not due to differences in the activation of AMPK, as the
phosphorylation of AMPK at S172 was independent of p53 (Fig. 2-4B).
There was a substantial decrease in the 4EBP1 detected in 7mGTP pulldowns in HCT116 p53 -/cells (Fig. 2-5A), an index of unphosphorylated 4EBP1 capable of binding to capped mRNA; the
level of elF4E on these beads was identical in p53 +/+ and -/- cells. Others have shown that
4EBP1 is phosphorylated at as many as four residues by mTORC1 and that electrophosesis in
high percentage acrylamide gels can resolve several 4EBP1 species as indicated in the lysate
section of Fig. 2-5A (Gingras, Raught, & Sonenberg, 2001; Herbert, Tee, & Proud, 2002; M. K.
Holz, Ballif, Gygi, & Blenis, 2005a; Ma & Blenis, 2009). The lowest band in western blot from
lysates (Fig. 2-5A) represents unphosphorylated 4EBP1 and the higher bands (α, β, and γ)
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represent species with progressively higher phosphorylation states; the phosphorylated forms are
shunted to the proteasome and degraded (Ma & Blenis, 2009).
The diminution of the unphosphorylated form of 4EBP1 was also observed as lower levels of the
fastest migrating band detected in immunoblots of lysates from p53 -/- HCT 116 compared with
wt p53 HCT116 (Fig. 2-5A). These data suggest that the basal level of p53 in HCT116 cells has
a substantial suppressive effect on mTORC1 activity, and that deletion of p53 releases mTORC1
from this control.
In order to understand whether this difference in total levels of 4EBP1 in p53 +/+ and -/- cells is
completely due to increased phosphorylation and decreased stability of the protein or its is
partially due to transcriptional differences as, p53 is a transcription factor, we analyzed mRNA
levels of 4EBP1. p53 +/+ and p53-/- HCT116 cells were grown in RPMI media + 10% dFBS
and were harvested 24 hrs later cells in Trizol; mRNA was extracted followed by cDNA
synthesis. Real Time qPCR analysis showed that 4EBP1 transcript levels were 3-4 fold lower in
the absence of p53 suggesting that p53 was directly or indirectly involved in the transcriptional
regulation of 4EBP1 (Fig. 2-5B). Therefore, we hypothesized that p53 regulates 4EBP1
transcription and would be binding to the 4EBP1 promoter. In order to test our hypothesis, we
did in-silico analysis to find probable p53 binding site on 4EBP1 promoter. We found that
almost 1000 bp upstream of promoter there is a probable p53 binding half site. Thus we
performed chromatin immunoprecipitation (ChIP) using anti-p53 antibody followed by DNA
precipitation and Q-PCR, however, we did not find any increase in the binding of p53 at the
4EBP1 promoter compared to IgG control for nonspecific binding (data not shown). This
suggested that p53 indirectly but positively regulates 4EBP1 mRNA transcription without
binding to 4EBP1 promoter.
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Figure 2-4. mTORC1 activity is suppressed by p53 in an AMPK independent
manner.
A) HCT116 cells isogenic for p53 were treated with DMSO or VP16. 24 hrs later
whole cell lysates were analyzed for P-T389 S6K1, as an indicator of mTORC1
activity using immunobloting. Levels of p53 and actin were checked as well. B)
Levels of activated AMPK measured by P-ser172 AMPK, are unaffected by the status
of p53.
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Figure 2-5. Difference in 4EBP1 transcript and protein levels in p53 WT and null
HCT116 cells.

.

A)Translation repressor species of 4EBP1 is diminished upon loss of p53; HCT116 p53
wt and null cells were grown in RPMI for 24 hrs followed by 7m-GTP pull down. B)
4EBP1 transcript levels are 3 fold higher in the presence of p53; HCT116 WT and null
cells were grown as above followed by RNA extraction, cDNA synthesis and real time
qPCR. Shown in B is combined data from three individual experiments
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2.3.2 Negative regulation of mTORC1 by p53 is also seen in other carcinoma cell lines.
To determine whether this effect of endogenous p53 on mTORC1 was peculiar to HCT116 or
was more general, we tested other carcinoma cell lines. H1299 lung carcinoma cells with
ponesteron-A inducible wt p53, when induced with ponesteron for 24 hrs, showed remarkable
decrease in phosphorylation of S6K1 (Fig. 2-6A). The hypophosphorylated species of 4EBP1
was also increased in cells induced with ponesteron-A, in comparision to uninduced cells, seen
as the shift of the band towards down and increase in the intensity of lowest band (Fig. 2-6). We
examined the activity of mTORC1 in other carcinoma cell lines with wt p53 after transfection of
siRNA pools directed against p53. In the NSCLC lines H460 and A549 and in HCT116 (Fig. 26B), the endogenous wt p53 levels were largely eliminated by siRNA treatment and,
concomitantly, p-T389 S6K1 was enhanced and the level of unphosphorylated 4EBP1 was
reduced, indicating a higher mTORC1 kinase activity upon loss of p53. We concluded that the
endogenous level of p53 in several carcinoma cell lines was exerting a marked controlling effect
on mTORC1.
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Figure 2-6. Negative regulation of mTORC1 by p53 is more of a generality
amongst various cancer cells.
A) Lung cancer cells H1299, consists of ponasteron inducible p53 vector, were
induced with ponetsron for 24 hrs followed by immunoblotting to analyze P-T389
S6K1 and 4EBP1 levels as an indicator of mTORC1 activity. B) p53 was knocked
out using siRNA inference in HCT116, H460 and A549 cells. Cells were harvest and
lysed 48 hours after p53-siRNA transfection. As an indicator of mTORC1 activity PT389 S6K1 and 4EBP1 migration was analyzed by using specific antibodies by
immunobloting

112

2.3.3 Mutation of p53 also causes hyperactivity of mTORC1.
Human tumors lose p53 function most commonly due to mutation in one allele followed by loss
of the other from the genome.

Hence, we tested whether hyperactivity of mTORC1 was

observed in carcinoma cells with a single allele of mutant p53 in the same genetic background.
For this, p53-/- HCT116 colon carcinoma cells were stably transfected with three mutant p53
species commonly seen in clinical samples, namely R175H, R248W, and R273H (Fig. 2-7).
These same mutant p53 species and also V143A were stably transfected into H1299 small cell
lung carcinoma cells and were compared with H1299 cells bearing a ponasterone-A-inducible wt
p53 gene (Fig. 2-9). In HCT116 (Fig 2-7A), mTORC1 targets S6K1 and 4EBP1 were as
hyperphosphorylated in cells bearing any of these p53 mutant forms as they were in p53 null
cells. Likewise, the binding of 4EBP1 to m7GTP beads in lysates of the mutant p53-bearing
carcinoma cells was minimal and comparably decreased from that seem in p53 wt cells as that in
p53-null cells (Fig. 2-7B).

The effect of loss or mutation of p53 on 4EBP1 levels was also

observed at the transcriptional level as the level of 4EBP1 mRNA was interestingly quite low in
p53-/- and mutant p53 expressing cells in comparison to wt p53-bearing isogenic HCT116 (Fig.
2-8)
Ponasterone-A induced wt p53 in H1299 reduces mTORC1 activity as seen by the decreased
phosphorylation of S6K1 and 4EBP1, and increased levels of unphosphorylated 4EBP1 (Fig. 29A). Like p53 null H1299, mutant p53 bearing H1299 also showed minimal binding of 4EBP1
to m7GTP beads in lysates in compassion to isogenic cells expressing inducible wt p53 (Fig. 29B). Like HCT116, loss or mutation of p53 lead to decreased levels of 4EBP1 mRNA levels in
H1299 cells (Fig. 2-10).
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We concluded that several mutant p53 could not reinstate the control of mTORC1. Despite the
high levels of p53 expression typical of p53 mutant tumors, hyperactivity of mTORC1 was
equivalent to that in p53 null cells. Hence, one of the functions of wild-type p53 is to exert a
control on mTORC1 that is missing in the mutants.
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Figure 2-7. Mutations in the DNA binding domain of p53 enhance mTORC1 activity
equivalently to loss of p53.
Expression and phosphorylation of S6K1 and 4EBP1 were determined by immunoblotting
of HCT116 p53-/- cells stably transfected with hot spot mutants of p53 (A), The binding of
4EBP1 to m7GTP bound beads is severely depressed in HCT116 cells stably transfected
with p53 mutants in comparison to HCT116 with WT p53 (B).
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Figure 2-8. Mutations in the DNA binding domain of p53 decreases 4EBP1 mRNA
4EBP1&
expression to the level comparable to loss
of p53.
mRNA&relatve&to&ac<n&

HCT116 cells were6& grown in the same conditions (RPMI + 10%dFBS) for 24 hours to allow
the 60% confluency
followed by RNA extraction, cDNA synthesis and RT-qPCR analysis to
5&
determine the levels of 4EBP1. The expression of 4EBP1 in cells stably transfected with
4&
mutant p53 was compared
with p53+/+ and p53-/- cells. mRNA levels are normalized to actin.
(plotted as ±sd, n=3).
Data
suggested that mutant p53 overexpression does not compensate for
3&
loss of wt p53 function and the mRNA levels of 4EBP1 in mutant p53 is as low as in p53-/2&
cells.
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Figure 2-9. Mutations in the DNA binding domain of p53 enhance mTORC1
activity equivalently to loss of p53.
The expression and phosphorylation of S6K1 and 4EBP1 were determined by
immunoblotting of H1299 cells stably transfected with hot spot mutants of p53 and
compared H1299 transfected with an inducible p53 construct (A), The binding of
4EBP1 to m7GTP bound beads is severely depressed in H1299 cells stably transfected
with p53 mutants in comparison to H1299 expressing Ponasteron-A inducible WT p53
(B).
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Figure 2-10. Mutations in the DNA binding domain of p53 in H1299,
decreases 4EBP1 mRNA expression, comparable to loss of p53.
H1299 cells were grown in the same conditions (RPMI + 10%dFBS) for 24
hours to allow the 60% confluency followed by RNA extraction, cDNA
synthesis and RT-qPCR analysis to determine the levels of 4EBP1. The
expression of 4EBP1 in H1299 stably transfected with mutant p53 was
compared with H1299 expressing ponasteron-A inducible WT p53 and
parental H1299. mRNA levels are normalized to actin. (plotted as ±sd, n=3).
Induction of WT p53 increases the levels of 4EBP1 mRNA in comparison to
mutant p53 expressing cells as well as p53 null cells.
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2.3.4 In-vitro kinase assay of mTORC1 immunoprecipitated from p53 null cells showed
higher mTORC1 kinase activity.
When we saw the higher cellular mTORC1 activity in p53 null cells than that in p53 competent
cells, we tested if this difference could be seen in-vitro. In order to address this question we
performed in vitro kinase assays. We immunoprecipitated mTORC1 from p53 +/+ and -/HCT116 cells under low salt condition (Y. Sancak et al., 2007) using Raptor antibodies. Here,
low salt condition refers to 100mM NaCl in wash buffer used for washing the bead-antibodymTORC1 complex. This condition was used in order remove nonspecific protein sticking to
beads, yet preserving the weak and transient but specific mTORC1 interacting proteins in the
complex. The kinase assays were performed using Rheb-GTPγS as an essential cofactor and
recombinant 4EBP1 as substrate (described in methods and materials) (Fig. 2-11A). The levels
of P-T37/46 4EBP1 were analysed by immunoblotting using phosphospecific antibodies for this
modified residue of 4EBP1. We found that mTORC1 immunoprecipitated from p53 -/- cells was
catalytically more active and able to phosphorylate 4EBP1 to significantly higher levels than was
mTORC1 from p53+/+ cells (Fig. 2-11A). Three independent experiments were performed and
immunoblots were quantified using Licore imaging and quantitation. Data complied from all
three experiments is represented as a bar graph with standard deviations representing the
variation among replicate biological repeats (Fig. 2-11B).
In vitro kinase assays on mTORC1 complexes immunoprecipitated with antibody against
Raptor indicated that the mTORC1 isolated from p53 -/- HCT116 cells was more catalytically
active than that from p53 +/+ cells (Fig 2-11A,B). Hence, the differences responsible for the
enhanced kinase activity of mTORC1 from p53 -/- cells in either the components of this complex
or the post-translational modifications of these components were at least partially stable to
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immunoprecipitation. The composition of the isolated IPs was investigated. The level of Raptor
and of the AMPK-dependent phosphorylation of Raptor at S792 were equivalent in Raptor IPs
from p53 wt and null cells (Fig 2-12A, B left panels). Although the level of mTOR seen in
lysates was unchanged (Fig 2-12A, right panel), the amount of total mTOR associated with
Raptor was enhanced in p53 deficient cells (Fig 2-12A,B left panels). The Raptor-bound mTOR
had higher p-S2448, a modification catalyzed by S6K1, but this appears to reflect the higher
levels of mTOR bound to Raptor (Fig 2-12A, left panel). Although the levels of PRAS40 and of
p-T246 PRAS40 were unchanged in lysates of p53 null cells, the binding of total and p-T246
PRAS40 to anti- raptor IPs was lower in p53 null cells (Fig. 2-12A, left panels and B right
panel). Contrary to the levels of the other components, the levels of TSC2 were substantially
decreased in lysates of p53-null cells (Fig. 2-9A, right panel,), as they also were in lysates of all
of the mutant p53s studied (Fig. 2-7A). Apparently as a result of these lower expression levels
of TSC2, the level of TSC2 in the IPs from p53 null cells was decreased compared to that in p53
wt cells (Fig. 2-12A, left panels, B right panel). Overall, there were higher levels of mTOR in
mTORC1 complexes in p53 null HCT116 cells and a lower content of PRAS40 and TSC2 bound
to mTORC1, factors that would each promote higher mTORC1 kinase activity.
In order to confirm that these differences are mTORC1 specific, immunoprecipitation under
same conditions and buffer was performed using anti-Rictor antibodies and the component of
mTORC2 complex were observed using immunoblotting (Fig. 2-13). The levels of Rictor in
lysates as well as in IPs were the same in both p53+/+ and -/- cells (Fig 2-13 left and right
panels). The levels of mTOR and S-2448 mTOR were also equivalent in both lysates and IPs
from both cell lines (Fig 2-13 left and right panel). Interestingly, we found more phosphorylation
of AKT at Ser473 and T308 in the lysates of p53 competent cells (Fig. 2-13, right panel).
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Figure 2-12. The enhanced kinase activity of the mTORC1 complex is retained
during immunoprecipitation in cells lacking p53.
(A) The components of the mTORC1 complex differ between p53+/+ and p53-/cells. Anti-Raptor immuneprecipitates from isogenic HCT116 cells were probed
with antibodies against the indicated proteins; lysates were probed in parallel. (D)
The level of Raptor, PRAS40, and TSC2 in p53-null HCT116 cells was measured by
densitometry from 3 independent experiments and expressed (±sd) relative to the
level in p53 wt control cultures.**p=0.0045 for mTOR, *p=0.0117 for PRAS40,
*p=0.040 for TSC2.
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Figure 2-13. The differences in mTORC1 components are specific to it and not
seen in mTORC2.
mTORC2 was immunoprecipitated in the same way as mTORC1 using anti-Rictor
antibody. Immunoblotting was performed on immunoprecipitate and levels of
Rictor, P-S2448 mTOR and mTOR were analyzed (left panel). Lysates from which
IP was performed, were probed to analyze the levels of various components of
mTORC2 (right panel)
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2.3.5 Higher Rheb bound to mTORC1, immunoprecipitated from p53 null cells under
low salt conditions
In our immunoprecipitation studies, we found higher Rheb bound to the mTORC1,
immunoprecipitated from p53 null cells (see below). Others have not successfully detected
endogenous Rheb in mTORC1 immunoprecipitates. Therefore, when we detected the band at
the size corresponding to Rheb (21 KD) we set out to confirm whether the band detected in our
studies is indeed Rheb or it is a non-specific band. We tested this by performing a competitivepeptide blocking experiment. The principle behind this experiment is that, in the presence of
excess Ab-specific peptide (against which antibody has been raised), antibody will not be able to
bind to the corresponding protein band on the immunoblot due to competitive binding of peptide
with the antibody. Thus, the blot incubated with antibody (-competitive peptide) will show
signal at the correct size, suggesting the presence of the corresponding protein, while the blot
incubated with antibody (+ competitive peptide) will not. In this experiment we probed the
lysates of p53 null and competent cells with either anti-Rheb antibody alone or Ab + peptide
solution (i,e. anti-Rheb antibody pre-incubated for 30 minutes with 100ng or 1µg of Rhebepitope peptide). The blot incubated with anti-Rheb antibody in the absence of peptide showed
the presence of band at 21kD, however the blot incubated with anti-Rheb antibody, preincubated with Ab + 1µg peptide solution, showed the absence of this band (Fig. 2-14). This
indicated that the peptide competed with the Rheb present in the lysates and that the 21 KDa
band was indeed Rheb. We concluded that the antibody we used for the detection of Rheb is
indeed specifically binding to Rheb.
mTORC1 complexes, immunoprecipitated from p53 -/- and +/+ cells were equally
divided and loaded in duplicate on SDS-PAGE gels followed by transfer onto the PVDF
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membranes. One blot (representing 1 set of protein samples) was incubated overnight with
Rheb-antibody alone and other blot (representing a second identical set of the protein samples)
was incubated with Rheb-antibody with 1µg of competitive peptide (Ab+ peptide solution).
After incubation with the secondary antibody followed by detection on a Licore, we found that
the blot incubated with anti-Rheb antibody in the absence of competitive peptide, showed the
Rheb band at 21 Kd, in immunoprecipitate from p53-/- cells, however this band was not present
on the blot incubated with Ab + peptide (Fig. 2-15). This indicated that higher Rheb is bound to
the immunoprecipitate from p53 null cells than to that from p53 competent cells.
In our studies, the mTORC1 immunoprecipitation was done using wash buffer with 100
mM NaCl concentration. We hypothesized that the probable cause of unsucessful attempts of
detecting Rheb in mTORC1 immunoprecipitates by others, was the use of wash buffers with salt
concentartions too high to allow survival of these complexes. We also hypothesized that Rheb
interacts with mTORC1 transiently so that with the use of high salt concentrations (150 mM to
500mM) as previously used by others would be immunoprecipitaion conditions too stringent to
catch loosely bound interactions. Therefore, we preformed mTORC1 immunoprecipitation from
lysates of p53 -/- and +/+ cells, using increasing concentration of NaCl (from 50 to500 mM) in
the wash buffer. Rheb was detectable in the mTORC1 complex, immunoprecipitated at 50mM
and 100mM salt-wash buffer, but, with the increase of the salt concentration in the wash buffer,
binding of Rheb with mTORC1 complex was decreased and completely vanished at 500mM salt.
To confirm the mTORC1 specific binding of Rheb, nonspecific mouse IgGs (same species as of
α-Raptor antibody) were used for immunoprecipitation as a negative control. We saw that Rheb
was immunoprecipitated only under low salt conditions and only in IPs done with anti-Raptor
antibody (Fig. 2-16). This suggests that Rheb loosely interacts with the mTORC1 complex and
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this interaction is higher in p53-/- cells. This could be due to higher Rheb levels in lysosomal
membranes of p53 null cells, as suggested by Catherine Bell’s experiments (data not shown).
The mRNA and protein levels of Rheb are equivalent in p53 null and competent cells (Fig. 2-17,
2-14 respectively). As expected, under 500 mM salt condition, PRAS40 binding was remarkably
decreased as previously shown by Sancak et al. (Y. Sancak et al., 2007) (Fig 2-17).
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Figure 2-14. Rheb peptide block shows the specificity of the α-Rheb
antibody.
p53 null and wt HCT116 cells were seeded and harvested fater 24 hrs. 25 µg of
cell lysates from p53 +/+ and -/- cells were loaded in triplicate. Proteins were
transferred on the PVDF membrane. Membrane was blocked using start block and
cut into three strips, A, B, C. A) Incubated with α-Rheb antibody ; B) α-Rheb
antibody + 100ng peptide; C) α-Rheb antibody + 1ug peptide . All three
membranes were simultaneously incubated with secondry antibody and signal was
detected by Licor.
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Figure 2-15. Higher Rheb is bound to mTORC1 complex immunoprecipitated
from p53 null cells.
Immunoprecipitation was performed using lysates from p53 +/+ and -/- HCT116
cells. Immunoprecipitates were divided equally and ran on SDS-PAGE gels in
duplicate followed by transfer on PVDF memebranes A) Left blot was incubated
with α-Rheb antibody + 1ug peptide solutaion, overnigh at 4 degree. B) This was
incubated only with α-Rheb antibody (-peptide) overnight at 4 degree. Secondry
antibody incubation and detection by licore was done simulationously. The red
arrow indicates the Rheb band at the size of 21 kD.
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Figure 2-16. At 100mM or low salt condition of wash buffer, Rheb is detectable
and higher in the immunoprecipitates of p53 null cells.
p53 null and wt HCT116 cells were seeded and harvested fater 24 hrs.
Immunoprecipitaion was perfroemd using α-Raptor antibody and wash buffers with salt
concentration as indicated. Immunoblotting was performed to analyze Raptor, p-S792
Raptor, mTOR, p-S2448 mTOR, PRAS40, p-T246PRAS40 and Rheb using
corresponding antibodies and signal was detected by Licor.

129

Rheb mRNA levels
relative to actin

S2:

Figure 2-17. Steady state mRNA levels in p53 null and competent cells.
HCT116 p53-/- and +/+ cells were grown in triplicates in the same conditions
(RPMI + 10%dFBS) for 24 hours to allow the 60% confluency followed by
RNA extraction, cDNA synthesis and RT-qPCR analysis to determine the levels
of Rheb. Data is plotted after normalization to actin (plotted as ±sd, n=3).
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2.3.6 The transcript and protein levels of TSC2 and Sestrin 2 are lower in p53 null
HCT116 cells.
We found that the levels of TSC2 bound to the mTORC1 complex are lower in p53 null cells
than to that in p53 competent cells. It was not known whether the uninduced, basal level of p53
can regulate these two genes. Therefore, we asked if the total levels of TSC2 and sestrin2 would
be decreased upon loss or mutation of p53. Steady state mRNA levels of TSC2 and Sestrin2
were measured by RT-qPCR. mRNA was extracted from HCT116 p53 competent or null cells
followed by cDNA synthesis. Real time q-PCR analysis showed that levels of TSC2 are
approximately 2 fold lower in p53 -/- cells than in p53 +/+ cells (Fig. 2-18, left panel). This
apparent transcriptional effect was even larger in the case of Sestrin2 where p53+/+ cells express
almost 5 fold higher levels of Sestrin2 mRNA than p53-/- cells (Fig 2-18, right panel). Previous
reports have also indicated an effect of p53 on levels of TSC2 mRNA (Feng et al., 2007) and
DNA-damaging drugs were reported to increase Sestrin2 mRNA (A. V. Budanov et al., 2002).
We further investigated if this difference was translated into protein levels. Indeed, we saw
significantly lower levels of TSC2 and Sestrin2 protein levels in p53 -/- HCT116 cells (Fig. 219).
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Figure 2-18. Steady state mRNA levels of TSC2 and Sestrin2 are lower in the
absence of p53.
p53 +/+ and p53-/- HCT116 cells were grown in the same conditions (RPMI +
10%dFBS) for 24 hours to allow the 60% confluency followed by RNA
extraction , cDNA synthesis and RT-qPCR analysis to determine the levels of
TSC2 (left panel) and sestrin2 (right panel). mRNA levels are normalized to
actin.
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Figure 2-19. Protein levels of TSC2 and Setsrin2 are reduced to great extent
upon loss of p53.
p53 +/+ and p53-/- HCT116 cells were grown in the same conditions (RPMI +
10%dFBS) for 24 hours to allow the 60% confluency. Cells were harvested and
lysed. Immunoblotting was performed in order to analyze the levels of TSC2,
Sestrin 2 and p53. Actin is shown as a control for equal protein loading across
the samples. Data represents three individual biological repeats, run on the SDS
page and immunoblotted at the same time.
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2.3.7 The levels of TSC2 mRNA and protein increased upon activation of p53 by DNA
damaging drug etoposide suggesting p53 transcriptional regulation of these two
genes.
In order to confirm if the levels of TSC2 were regulated by p53, we treated HCT116 p53+/+
cells with etoposide, a conventional method of inducing DNA damage leading to activation of
p53 and its transcription activity. HCT116 p53+/+ and p53-/- cells were treated with DMSO or
etoposide (VP16, 20µM) for 24 hrs. Cells were harvested and processed further for
immunoblotting or RNA extraction. Upon RT-qPCR analysis we found that the levels of TSC2
mRNA were increased by almost 2 fold in cells treated with VP16 in p53 wt cells but not in cells
treated with VP16 genetically null for p53 (Fig. 2-20A). The protein levels of TSC2 were also
increased after VP16 treatment only in p53 +/+ cells but not in p53-/-cells (Fig. 2-20B). Hence,
we show here that activation of AMPK can lead to increase in the levels of AMPK dependent
phosphorylation of TSC2 at S1387 (Fig. 2-20B). We conclude that upon activation of p53 after
VP16 treatment, the increased levels of TSC2 and Sestrin2 allow the interaction of activated
AMPK and TSC2 and the phosphorylation of TSC2 at Ser1387.
2.3.8 Carcinoma cells that are p53 null or that express only mutant p53 have decreased
levels of TSC2 and Sestrin2
HCT116 and H1299 cells expressing mutant p53 were studied to compare their TSC2 and
Sestrin2 mRNA and protein levels with their isogenic p53 null and wt p53 cells. The steady-state
levels of TSC2 and Sestrin2 mRNA were determined by RT-qPCR. Both mRNA populations for
TSC2 and for sestrin2 were decreased with loss or mutation of p53 (Fig. 2-21). The protein
levels of TSC2 were also diminished in both HCT116 and H1299 cells without p53, or with
mutant p53 (Fig. 2-22).
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Figure 2-20. Levels of TSC2 mRNA and protein increased upon
activation of p53 after etoposide treatment.
HCT116 p53+/+ and -/- cells were treated with either DMSO or VP16 (20µM)
for 24 hours. (A) Cells were harvested to extract RNA followed by RT-qPCR
to determine steady state levels of TSC2 mRNA. mRNA levels are normalized
to actin mRNA levels. (B) Cells were harvested and lysed followed by
immunoblotting to analyze the levels of P-T1387 TSC2 , TSC2 and p53. Actin
is used a marker for equal protein loading.
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Figure 2-21. Carcinoma cells that are p53 null or that express only mutant
p53 have decreased levels of TSC2 and Sestrin2 mRNA.
Cells were grown in the same conditions (RPMI + 10%dFBS) for 24 hours to
allow the 60% confluency followed by RNA extraction , cDNA synthesis and
RT-qPCR analysis to determine the levels of TSC2 (left panel) and sestrin2
(right panel). mRNA levels are normalized to actin (plotted as ±sd, n=3). Data
suggests that either loss or mutation of p53 leads to decreased levels of these
two mRNA species in both colon carcinoma cells HCT116 cells as well as in
lung carcinoma cells H1299.
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Figure 2-22. Protein levels of TSC2 and Setsrin2 are reduced to great extent
upon mutation in p53 and is comparable to loss of p53.
Cells were grown in the same conditions (RPMI + 10%dFBS) for 24 hours to allow
the 60% confluency. Cells were harvested and lysed. Immunoblotting was
performed in order to analyze the levels of TSC2. Actin is shown as a control for
equal protein loading across the samples. Cells expressing mutant p53 or p53-/cells have remarkable decrease in TSC2 level (A) HCT116 cells, (B) H1299 cells.
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2.3.9 Complementation of the control of the mTORC1 pathway in p53 null cells by TSC2
and Sestrin2.
Because of the centrality of TSC2 to the control of mTORC1 kinase activity and to the role of
Sestrins in the activation of TSC2 by AMPK (A. V. Budanov & Karin, 2008a), we questioned
whether the hyperactivity of mTORC1 seen in p53 -/- HCT116 cells was due to the lower levels
of TSC2 and Sestrin2. When FLAG-tagged Sestrin 2 or HA-TSC2 were individually transfected
into p53 -/- HCT116, the phosphorylation of S6K1 was reduced almost to the levels seen in wt
HCT116; when both constructs were co-transfected, the level of p-T389 S6K1 was identical to
that in wt HCT116 (Fig. 2-23A).

Likewise, transfection of TSC2 or Sestrin2 or of both

constructs into p53 -/- HCT116 returned the level of 4EBP1 seen in 7mGTP pulldowns back to
that seen in p53 +/+ HCT116 (Fig 2-23B). We concluded that the enhanced mTORC1 activity
seen in p53 null cells was due to diminished function of TSC2 due to lower levels of TSC2 itself
and of lower levels of Sestrin2.

138

Figure 2-23. Complementation of the control of the mTORC1 pathway in p53
null cells by TSC2 and Sestrin2.
Increasing the levels of TSC2 and Sestrin2 in p53 null cells reverses the elevated
mTORC1 activity in p53 null cells. (A) FLAG-tagged Sestrin2, HA-TSC2, or an
empty vector were transfected into p53-/- HCT116 cells and p-T389 S6K1 was
determined by immunoblotting. (B) Exogenous TSC2 and Sestrin2 restores 7mGTP
cap binding in p53 null cells. 7mGTP pulldown assays were performed on p53-/HCT116 cells following transfection as in (A); bound 4EBP1 and eIF4E were
detected by immunoblot
.
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Figure 2-24. Proposed model depecting the mechanism of p53 mediated
regulation of mTORC1.
A) p53 wt cells have more TSC2, more PRAS40, less Rheb and less mTORC1
complex present at lysosomal membrane. Due to higher TSC2 levels Rheb
mediated activation of mTORC1 will decline, causing lower mTORC1 activity
in p53 wt cells. B) In the absence of p53, TSC2 levels are low, PRAS40 levels
bound to mTORC1 are low and levels of Rheb on the lysosomal membrane is
high, leading to higher mTORC1 activity.
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2.3.10 Discussion
The single most frequent genetic change in human tumors is mutation of the p53 gene at
positions that alter the transcriptional activity of the protein. Typically, mutation in one allele is
followed by a loss of the other allele, with major changes in levels of transcriptional targets of
the wt protein. As a less frequent event, some tumors have lost both alleles of this gene. We
show here that either mutations of p53 that modify its transcriptional function or complete loss of
the gene upregulates mTORC1 activity. The intermediate step that mediates this upregulation
appears to be lower expression of TSC2, a previously suggested transcriptional target of p53
(Feng et al., 2007) and Fig.20, 21, 22). The fact that replacement of TSC2 levels by transfection
reverses the effect of p53 loss on mTORC1 activity argues for this causal relationship. These
observations are supported by the studies done by my colleague Catherine Bell. In her studies of
subcellular fractionation and confocal microscopy, she showed that p53 null cells have lower
levels of TSC2 and increased levels of Rheb localized in the lysosomal membrane, the site of
mTORC1 activity (data not shown). This observation suggested that the decreased levels of
TSC2 in p53 null cells resulted in a lower distribution of TSC2 to lysosomal membranes and that
this effect is, surprisingly, associated with an enhanced level of Rheb in fractions containing both
mTOR and Raptor, presumably representing the active mTORC1 complex (Fig. 2-24). These
differences in lysosomal localization of TSC2 and Rheb are more obvious in cells completely
lacking TSC2 expression, i.e., TSC2-null MEFs (Experiments done by Ms. Bell and data not
shown). The current literature suggests that redistribution of TSC2 to lysosomal membranes
plays an intrinsic role in control of mTORC1 activity. Interestingly, by causing a primary
decrease in TSC2 levels at the lysosomal membrane, we also observed the redistribution of Rheb
(experiment of Catherine Bell, data not shown). Two recent papers suggest the involvement of
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another p53 target, the Sestrins, in mTORC1 localization at lysosomal membranes (Parmigiani et
al., 2014).

We observed the reinstatement of control of mTORC1 following exogenous

expression of Sestrin2 in p53 null cells, apparently a reflection of the enhanced efficiency of the
residual levels of TSC2 in p53-null cells in the presence of higher Sestrin2. This interpretation
reflects the current view of a dynamic equilibrium of the binding of TSC2 at the lysosomal
membrane, affecting mTORC1 activity.
We have used immunoprecipitation (this thesis), membrane fractionation (Catherine Bell)
and confocal microscopy (Catherine Bell) to study effects of p53 on the distribution of
components of mTORC1.

All three approaches indicated that the decrease in TSC2 levels in

p53 null cells is followed by a decreased occupancy of TSC2 at the position of active mTORC1.
The effect of p53 loss on enhanced Rheb colocalization with mTORC1 was indicated by
membrane fractionation and confocal microscopy. This phenomenon was also captured in IPs
done at low (100mM) NaCl concentration in wash buffer, but not at high salt-wash buffer, as
would be expected for a transient interaction. Decreases in PRAS40 were detectable in IPs,
when these immunocomplexes were washed with lower levels of salt (Y. Sancak et al., 2007), as
were higher distribution of mTOR into Raptor complexes; these redistributions were not obvious
from membrane distribution studies or confocal microscopy, but reflected the changes in
mTORC1 activity in p53 null cells.
The enhancement of mTORC1 we observed in p53 null cells was also seen in carcinoma
cells expressing mutant p53s at the very high levels of this protein usually found for such
mutations, a fact that emphasizes the centrality of the p53-driven transcriptional program in
control of mTORC1 activity. There have been prior indications that AMPK-mediated TSC2
control of mTORC1 depends on p53 function and involves the p53 target Sestrin2. Feng et al
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showed that stabilization of p53 by DNA damaging agents caused phosphorylation and
activation of AMPK, leading to mTORC1 inhibition; these effects were TSC2 dependent (Feng
et al., 2005). A recent study (H. Wang et al., 2008) demonstrated that this DNA damage-initiated
effect on AMPK involved ATM effects on p53 and p63, as well as DNA- PK; these effects of
DNA damage are clearly distinct from those reported here. The effect isolated by our studies is
clearly not one which involves activation of p53 by a DNA damage effect, seen by Feng et al.,
but rather an activity mediated by the low steady state levels of wt p53. These effects, which are
downstream of and not mediated by AMPK, represent distinctly different level of involvement of
p53 in control of mTORC1 activity. Therefore, we concluded that loss or mutation of p53
enhances mTORC1 activity by decreasing the TSC2 expression and its localization at lysosomal
membrane as depicted in Fig. 2-24.
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Chapter 3

3

Involvement of p53 in pemetrexed-activated AMPK mediated inhibition of
mTORC1

3.1

INTRODUCTION

In the previous chapter we determined the effects of p53 on mTORC1 regulation and concluded
that p53 negatively regulates mTORC1 activity via regulating the expression of TSC2 and
Sestrin2. We also showed that there were differences in the components of the mTORC1
complex in p53 +/+ and -/- cells, including more mTOR and less TSC2 and PRAS40 in p53-/cell in comparison to p53 +/+ cells, which would contribute to the higher mTORC1 activity in
p53 compromised cells. A very interesting finding by my colleague Catherine Bell, suggested
that p53 competent cells have decreased Rheb and increased levels of TSC2 at the lysosomal
membranes, apparently leading to decreased mTORC1 activity in these cells. It is clear from
these data that, upon loss of p53, negative regulation of mTORC1 is relieved leading to an
increase in cell growth and proliferation. This correlation of p53 and mTORC1 is evident in
most cancers where function of WT p53 is diminished or lost and mTORC1 activity is high. As
most cancers show hyperactive mTORC1, mTORC1 inhibition offers a very attractive and
promising approach for targeted chemotherapy.
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This chapter is focused to understand the molecular mechanism of an AMPK activator
pemetrexed (PTX), which inhibits mTORC1. Our lab has shown that PTX inhibits AICARFT, a
second folate dependent enzyme in de novo purine synthesis which when inhibited, causes robust
buildup of its substrate ZMP (Racanelli, Rothbart, Heyer, & Moran, 2009; Rothbart, Racanelli,
& Moran, 2010). ZMP is an AMP mimetic and thus can activate the central energy sensor of the
cell, AMPK. Our lab also showed that this activation of AMPK by PTX inhibits mTORC1 in an
LKB1 independent manner (Racanelli et al., 2009; Rothbart et al., 2010). Whereas the majority
of lung cancers have a p53 null or p53 mutant phenotype, our studies in chapter two suggests that
mTORC1 activity increases to a significant level upon loss or mutation of p53. Because PTX is
active against lung cancers and also can inhibit mTORC1, we wanted to understand if PTX
mediated inhibition of mTORC1 is modulated by p53 status. Therefore the focus of this chapter
is to understand the role of p53 in PTX-mediated activation of AMPK and inhibition of
mTORC1. In the pursuit of an understanding of how activation of AMPK by pemetrexed PTX
would behave in the presence and absence of p53 function, we compared it with another AMPK
activator, AICAR. This chapter also shines light upon the mechanism whereby two AMPK
activators that initially activate AMPK via ZMP accumulation, can lead to two different
downstream effects based on their ability to activate p53. Therefore, this chapter builds a bridge
between our findings from chapter 2 and a long-standing question of how PTX is so effective
against lung cancers. This chapter also lays a platform for understanding the effects of PTX on
gain-of-function mutant p53 in chapter 4.
3.1.1 Accumulation and Stabilization of p53 by Post Translational Modifications (PTMs)
Normally, p53 is maintained at very low concentration due to its relative short half-life of
approximately 20 minutes, much less than that of mut p53 (Strano et al., 2007). p53 is rapidly
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turned over in unstressed cells through its interaction with MDM2, a RING family type E3
ligase, which promotes poly-ubiquitination and proteasomal degradation (Honda, Tanaka, &
Yasuda, 1997). Therefore, after a genotoxic stress or a variety of other cellular insults, levels of
p53 immediately increase by stabilization of the p53 protein. Kastan et al. showed that, after the
genotoxic stress of IR-induced DNA damage, protein levels of p53 increased, apparently due to
by a post-translational mechanism (Kastan, Onyekwere, Sidransky, Vogelstein, & Craig, 1991).
Human p53 harbors an array of serine (S)/ threonine (T) phosphorylation sites that span the
entire protein, but these sites are highly concentrated in the N terminal transactivation and Cterminal regulatory domains (Fig. 3-1). It has been shown that the phosphorylation of p53 at
Ser15 and possibly at ser20 causes p53 accumulation by blocking the interaction between
MDM2 and p53 thereby inhibiting its degradation (Shieh, Ikeda, Taya, & Prives, 1997; Siliciano
et al., 1997; Toledo & Wahl, 2006).

PTMs of p53 have been extensively investigated;

modifications can include phosphorylation, acetylation, methylation, ubiquitination, adenylation
and/or sumoylation (Reviewed in (Toledo & Wahl, 2006). After different cellular stresses,
several of these PTMs are thought to act as a barcode dictating the multiple cellular functions of
p53. p53 phosphorylation at the N terminus has been reported to have significant redundancy; a
single residue can be phosphorylated by several kinases and one kinase can phosphorylate
several residues (J. P. Kruse & Gu, 2009). This section will address the literature on those
phosphorylation sites that are investigated in this chapter. Fig. 3-1 summarizes the known PTMs
of p53. This chapter also compares the effects of two AMPK activators and a DNA damaging
agent on the phosphorylation levels of several key p53 residues and what is known about the
consequences of these phosphorylation events on p53 stability and transactivation is summarized
below.

146

P
S6

P P P
T18 S20 S46

TAD1/2
(1-43-60)

A
K120

PRD
(64-92)

S9 S15 S33 S37 T55 T81
P P
P P P P

U
P A
S314 K320

P
S150

DBD
(102-292)

DBD
(102-292)

L

S149S151
P P

S215
P

K305S315
A P
S313
P

4DE
(324-356)

N
M
U P S
A S378 U
K372 K386
N
M
P U P U P
S366 A S376 A S392
K370 K382

CTRD
(363-393)
K373 K381
A T377 A T387
U P U P
M
N

Figure
3-1.Post-translational
Post-translational
modifications
p53.of the post translational
Figure 2-2.
modifications
of p53. Aofmap
modifications of p53 where each residue known to be modified is shown. Phosphorylation (P)
sites are indicated in yellow, acetylations (A) in pink, ubiquitination (U) in grey, methylation
A(M)map
of and
theneddylation
post translational
in as blue
(N) in green. modifications of p53 where each residue
known to be modified is shown. Phosphorylation (P) sites are indicated in
yellow, acetylations (A) in pink, ubiquitination (U) in grey, methylation (M)
in as blue and neddylation (N) in green. Red circles indicate the
phosphorylation sites and green circles indicate acetylation sites, analyzed in
the studies of this chapter.

22

147

Figure 3-2 Schema of mTORC1 pathway.
This is a schematic representation of AKT-mTORC1-AMPK pathway.
Black arrows show activating phosphorylation events and red arrows show
inhibitory events.
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3.1.1.1 Serine 15 and serine 20
The most studied post-translational modifications of p53 are serine 15 and serine 20
phosphorylation. These phosphorylation sites have had the attention of the p53 community not
only because the biology of these phosphorylation sites is complex but also because they are
believed to be crucial in manipulating the stability and trans-activation of p53 (Siliciano et al.,
1997; Toledo & Wahl, 2006). The E3 ligase, MDM2, interacts with amino acids 18-23 of p53,
and phosphorylation at serine 15 is thought to block this interaction and promotes the
accumulation of p53 (Shieh et al., 1997). However, there is a diverse and contradictory literature
about the importance of ser15 phosphorylation in the transactivation of p53. Fuschs et al
suggested that phosphorylation of serine 15 is not required for p53 accumulation or
transcriptional

activation

but

rather

that

S15

phosphorylation

enhances

subsequent

phosphorylations on neighboring residues (Fuchs, O'Connor, Fallis, Scheidtmann, & Lu, 1995).
Serine 15 lies within a nuclear export signal and phosphorylation of S15 results in nuclear
retention of p53 (Zhang & Xiong, 2001). Lambert et al. showed that after IR, phosphorylation of
serine 15 increases which in turn increases the ability of p53 to recruit and associate with the
transcriptional co-activator proteins CBP and p300 (Lambert, Kashanchi, Radonovich,
Shiekhattar, & Brady, 1998). The acetyltransferase activity of p300 recognizes the C- terminal
domain of p53 as a substrate resulting in acetylation at lysines 373 and 382 enhancing the
sequence-specificity of p53 binding to DNA (Gu & Roeder, 1997a). Several kinases have been
linked to the phosphorylation of serine 15, including ATM, ATR, AMPK, DNA-PK, ERK, p38
and CDK9 (Reviewed in (Toledo & Wahl, 2006). Phosphorylation of serine 20 also aids in p53
accumulation and nuclear retention in a similar fashion as was described for serine 15
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phosphorylation, as both residues lies within the nuclear export sequence region. However, it has
been reported that S20 phosphorylation also is not required for p53 stabilization and activation
(Chehab, Malikzay, Stavridi, & Halazonetis, 1999). Chk1, among several other kinases, have
been identified to be capable of phosphorylating serine 20 and, rather surprisingly, other than
facilitating p53 stabilization, no further functions of this modification have been elucidated
(Shieh, Ahn, Tamai, Taya, & Prives, 2000a). Studies with mice containing serine to alanine
mutations in p53 at ser15 or ser 20 or both showed the redundancy in the functional requirement
of the phosphorylation of these two residues. Individual mutations in gene knock-in experimental
mice only showed a marginal difference in the stability and transactivation activity of p53.
However, mice bearing both ser15/20 mutations of showed a more severe phenotype, including
tissue specific reduced apoptotic capacity, compromised replicative senescence and a latent
development of a spectrum of tumors (Chao, Herr, Chun, & Xu, 2006; Toledo & Wahl, 2006).
3.1.1.2 Serine 37
Dohoney et al showed that, following DNA damage by UV- or γ-irradiation, p53 is stabilized
and phosphorylated at a number of residues, including serines 15 and 37. Phosphorylation at
serine 37 appears to be important in p53-dependent transcription after UV and IR treatment.
Mutating this serine residue to an alanine significantly impairs the transactivating ability of p53
in a MDM2-luciferase reporter assay (Dohoney et al., 2004). A previous study in which the Nterminal domain of p53 was fused to the DNA-binding domain of the yeast GAL4 protein,
showed that phosphorylation of S15, but not S37, is critical for p53-dependent transactivation
(Dumaz & Meek, 1999)
Sequence-specific DNA binding of p53 is also enhanced when serine 37 is phosphorylated.
Serine 37 phosphorylation has been reported to be important for the transactivation and pro150

apoptotic activities of p53 (Li et al., 2006). The phosphorylation of serine 37 was shown to
stimulate the interaction between p53 and the transcriptional coactivators p300 and PCAF which
acetylate p53 at lysine 382 and lysine 320, respectively, activating the sequence-specific DNAbinding of p53 (K. Sakaguchi et al., 1998).
3.1.1.3 Serine 46
Phosphorylation of serine 46 has been implicated in p53-dependent apoptosis. A study in which
knock-in mice expressing the human p53 gene with a S46A mutation were compared with mice
expressing the wild-type human p53 gene. These mice were generated by homologous
recombination and LoxP/Cre-mediated deletion to introduce a Ser46 to Ala missense mutation
into the human p53 knock-in allele in mice (p53hki(S46A)). This study suggested a modest
reduction in p53 mediated transcription activation of some pro-apoptotic targets and
compromised apoptosis in MEFs and embryonic stem cells from these mice (L. Feng, Hollstein,
& Xu, 2006). When p53 S46 is mutated to an alanine, mouse embryonic fibroblasts (MEFs) and
mouse e mbryonic stem cells had a reduced ability to induce apoptosis after UV treatment when
compared to cells containing wild-type p53. Mayo et al. showed that during mild VP16-induced
DNA damage, serine 46 is not phosphorylated and p53 thereby activates the transcription of
MDM2 inducing the autoregulatory feedback loop.

After extensive VP16-induced DNA

damage, serine 46 is phosphorylated and the transcriptional activation by p53 becomes more
extensive, for instance, PTEN transcription is activated and increased apoptosis was observed.
These results were confirmed by genetic manipulation studies. A nonphosphorylatable serine 46
to alanine p53 mutant (S46A) targeted the MDM2 promoter in preference to that for PTEN. A
serine 46 to aspartate mutant (S46D, a phosphorylation mimic) targeted PTEN in preference to
MDM2. Thus this study concluded that phosphorylation of S46 is essential and sufficient for

151

choosing PTEN as a target gene over MDM2. This must be in order to overcome the induction
of MDM2 and the formation of the autoregulatory feedback loop of MDM2-p53 (Mayo et al.,
2005).
3.1.1.4 Serine 392
Studies done by Sakguchi et al suggested that phosphorylation of serine 392 significantly
enhanced tetramer stability, possibly through hydrogen bonds between the phosphorylated
residue and the N-terminal region of p53 (K. Sakaguchi et al., 1997). DNA binding and
transcription activation of p53 is also enhanced after phosphorylation of serine 392 during UV
treatment (Keller, Zeng, Wang, Zhang et al., 2001a). Phosphorylation of the C-terminal S392
following UV-radiation activates specific DNA binding through stabilizion of the p53 tetramer
(Matsumoto, Furihata, & Ohtsuki, 2006).

For a long time it was believed that S392

phosphorylation is a response to DNA damage induced by UV radiation but a group recently
showed that phosphorylation of Ser392 can also occur during the induction of p53 by a range of
stimuli including treatment of cells with the MDM2 inhibitor, Nutlin 3a. (Cox & Meek, 2010).
Phosphorylation of serine 392 appears to be important for the anti-proliferative activity of p53.
When SV3T3 mouse cells were transfected with p53 containing an alanine at this residue, this
mutant p53 was unable to suppress colony formation as compared to cells transfected with wildtype p53 (Milne, Palmer, & Meek, 1992).
3.1.1.5 Acetylation
Lysine acetylation is a powerful mechanism for activating function. It has been said to work at
three levels in the case of p53: 1) it promotes p53 stabilization by blocking ubiquitination; 2) it
inhibits the formation of the HDM2/HDMX repressive complex at the promoter of target genes
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and thus alleviates promoter inhibition; 3) it assists in the recruitment of transcription cofactors
at the promoter for p53 transcriptional activity. Of the nine acetylation sites have been identified
for p53, six are lysine residues (K370. K372, K373,K381, K382 and K386) in the C- terminal
regulatory domain. These sites are shown to be acetylated by CBP/p300 and ubiquitinated by
HDM2 (J. Kruse & Gu, 2008; Nakamura, Roth, & Mukhopadhyay, 2000). Histone acetyl
transferases which are responsble for these modifications include the structurally related p300,
CBP, p300/CBP associated factors (PCAF) and the MYST (named for the members MOZ,
Ybf2/Sas3, Sas2 and Tip60) family of HATs, Tat-interactive Protein of 60 kDa (TIP60) and
human Males absent On the First (hMOF) (J. Kruse & Gu, 2008; Sykes et al., 2006; Sykes,
Stanek, Frank, Murphy, & McMahon, 2009). It has been shown that p53 can be modified by
acetylation both in vivo and in vitro and the site of p53 that is acetylated by its co-activator,
p300, resides in a C-terminal domain known to be critical for the regulation of p53 DNA
binding. Therefore, the acetylation of p53 at this region can dramatically stimulate its sequencespecific DNA-binding activity, possibly due to an acetylation-induced conformational change
(Gu & Roeder, 1997a; Luo et al., 2004).
A seventh lysine residue, K320, in the tetramerization domain is acetylated by PCAF (J.
Kruse & Gu, 2008). Acetylation of this residue promotes p53-mediated activation of CyclinDependent Kinase inhibitor 1A (CDKN1A), commonly known as p21, results in cell cycle arrest
and thus favors cell survival (Knights et al., 2006). More recent studies have discovered two
new additional sites of acetylation, K120 and K164 which are in the DNA binding domain and
are acetylated by TIP60/hMOF (Sykes et al., 2006) and CBP/p300 (Tang, Zhao, Chen, Zhao, &
Gu, 2008) respectively. Nevertheless, despite all the studies suggested that acetylation of the Cterminal domain plays a critical role in p53 mediated processes, mice expressing acetylation-
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deficient p53 generally did not exhibit any major depression in cell cycle control, apoptosis or
tumor suppression (L. Feng, Lin, Uranishi, Gu, & Xu, 2005). This observation is in accordance
with the fact that only rarely do human cancers have mutations in the C-terminal domain of p53
(http://p53/free.fr/).
3.1.2 Transcriptional Regulation by p53
As described in the previous section, p53 contains a DNA binding domain which specifically
binds the p53 response element (p53RE) within promoter regions of its genes, and a C-terminal
domain which has been shown to non-specifically bind DNA and then coordinate the linear
search of DNA for p53REs (el-Deiry, Kern, Pietenpol, Kinzler, & Vogelstein, 1992; McKinney,
Mattia, Gottifredi, & Prives, 2004). This section will briefly describe the mechanisms whereby
p53 regulates gene transcription.
3.1.2.1 p53 Response Element
The p53RE contains two copies of the 10 bp motif 5′-PuPuPuC(A/T)(T/A)GPyPyPy-3′ separated
by 10-13 bps where Pu is a purine base and Py is a pyrimidine base (el-Deiry et al., 1992; Miner
& Kulesz-Martin, 1997). It has been shown that tetrameric p53 is able to recognize, bind and
transactivate genes from noncanonical consensus sequences containing only half of the
consensus sequence (Jordan et al., 2008). Overall, the literature suggests that different p53RE
have different binding affinities for p53. A study using a red-white p53 reporter system in
Saccharomyces cerevisiae measured the ability of p53 to transactivate a reporter gene from
various p53REs. It was shown that there is as much as a 1000-fold difference between the
transactivation from weaker p53RE to stronger p53RE. The p21 promoter has two p53Res
located 1.2 and 2.4 kb upstream of the transcriptional start site. The sequence of the upstream
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p21 p53RE has the highest affinity for p53, while the p53RE within the BAX promoter has the
weakest affinity (Inga, Storici, Darden, & Resnick, 2002). The promoters of three other p53regulated cell cycle genes, cyclin G, 14-3-3 and GADD45 also have quite high binding affinities,
compared with that of the proapoptotic genes PUMA, BAX and p53AIP (Weinberg, Veprintsev,
Bycroft, & Fersht, 2005). Posttranslational modifications of p53 and p53 binding partners also
contribute to the diversity of the transcriptional response. For instance, the phosphorylation of
serine 46 discussed above has been shown to selectively induce p53 to transactivate the proapoptotic gene p53-regulated Apoptosis Inducing Protein1 (p53AIP). In the latter study, the
authors selected the p53 binding sequences from the human genome using in-silico analysis and
cloned and found a novel mitochondrial protein designated as p53AIP. They showed that the
expression of p53AIP can be induced by wt p53 after DNA damage in MCF-7 cells. The
induction of p53AIP led to enhanced apoptosis and this phenomenon was dependent on the
phosphorylation of p53 at Ser46 (Oda et al., 2000).
3.1.2.2 Transcriptional Initiation
For successful transcriptional initiation, the chromatin around a promoter must be modified to
form an open chromatin structure (euchromatin) that allows the general transcriptional initiation
machinery to bind to the DNA. The role of p53 in this process is critical. After p53 has bound to
the p53RE, histone acetyltransferases (HATs) are recruited to acetylate the histones surrounding
p53 (Lill, Grossman, Ginsberg, DeCaprio, & Livingston, 1997). P300/CBP are recruited to the
promoter following the interaction of CBP with the transactivation domain of p53. p300/CBP
acetylates the histones bound to DNA in the vicinity of p53, as well as the C terminal domain of
p53, increasing the activation of gene transcription (Gu & Roeder, 1997b). After the opening of
regional chromatin, the general transcription machinery can be recruited to form the preinitiation
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complex (PIC). p53 is known to act with several components of the PIC to initiate transcription.
The assembly of a complex containing p53, TBP, the TBP associating factors (TAF), TAFII60,
TAFII40 and TAFII250 appears sufficient to activate transcription.
The composition of the PIC required for transcriptional activation differs between genes
as well as between stress stimuli promoting transcription of a particular gene. Two examples of
this are the p21 and FAS promoters. Espinosa et. al showed that prior to any cellular stress, p53
is poised at the p21 promoter along with components of the PIC, TBP and paused RNA
polymerase (Espinosa, Verdun, & Emerson, 2003). After UV stress, levels of p53 bound to the
promoter increase,leading to completion of the transactivation process by p53-dependent
recruitment of TAFII250. This stimulates the phosphorylation of serine 2 in the C terminal
domain (CTD) of the paused RNA polymerase, converting it to the elongation form. In contrast
to p21, the FAS promoter does not contain a TATA box. Prior to any stress, p53 is also poised
on the FAS promoter, but the levels of paused RNA polymerase are significantly lower than
found at the p21 promoter (Espinosa et al., 2003). After UV treatment, p53 levels increase,
recruiting HATs and TAFII250 to the promoter. There is no net loss of paused RNA polymerase
at the promoter after the appearance of the elongation form, suggesting that the initiation and
elongation rates were similar.

The difference between these two promoters demonstrate a

strategic placement of p53 on the gene promoters depending on their role in cellular
mechanisms. Cell cycle genes, such as p21, are poised for rapid transcriptional activation after
cellular stress while the transcriptional activation of the proapoptotic gene Fas is slower due to
the lower levels of RNA polymerase poised at the promoter (Espinosa et al., 2003).
3.1.2.3 Transcriptional Elongation
After RNA polymerase is cleared from the promoter, other elongation factors are recruited to the
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promoter vicinity, some of which interact with p53. The phosphorylation of serine 392 of p53 is
often implicated in complexes with elongation factors and, as described above, this
phosphorylation promotes oligomerization of p53 and subsequent DNA binding (Hupp, Meek,
Midgley, & Lane, 1992; K. Sakaguchi et al., 1997). During the discovery that casein kinase 2
(CK2) is able to phosphorylate serine 392 of p53 after UV treatment, p53 was found to be in a
complex with subunits from the FACT (facilitated chromatin transcription) complex, a known
elongation factor (Keller, Zeng, Wang, Zhang et al., 2001b). It is also shown that the human pTEF (positive transcription elongation factor) is responsible for converting the paused RNA
polymerase to elongating polymerase through phosphorylation at serine 2 in the carboxy terminal
domain (Marshall, Peng, Xie, & Price, 1996). The Cdk9 kinase is the component of p-TEF
responsible for phosphorylating serine 5 of the CTD of RNA polymerase (Ramanathan et al.,
2001; Zhu et al., 1997). Cdk9 is known to interact with p53 and phosphorylate it at serine 392;
the stabilized p53 then promotes transcription of Cdk9, thereby promoting transcriptional
elongation in a feed-forward system (Claudio et al., 2006).
3.1.2.4 Transcriptional Repression
A less studied role of p53 is transcriptional repression. After binding to some promoters, p53
interacts with mSin3a recruiting HDAC1 (histone deacetylase), which removes the acetyl
moieties from the chromatin causing the chromatin to close around the promoter and repressing
transcription (Murphy et al., 1999). The physical binding of p53 to promoters may restrict the
binding of other transcription factors required for transcriptional activation. This is observed
during hypoxic stress: under these conditions p53 binds to the alpha-fetoprotein promoter,
inhibiting the binding of the transcriptional activator HNF3 and, hence, repressing transcription
(Y. I. Lee et al., 2000). Although the mechanism of transcriptional repression is not understood
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yet, the binding of p53 to the Rad51 promoter, repressing transcription of this gene, is critical to
homologous recombination during DNA damage (Arias-Lopez et al., 2006).
3.1.3 p53 Dependent Apoptosis
Yonish et al. demostrated the importance of p53 in the mechanism of apoptosis when they
showed that tumor cells null for p53 underwent spontaneous cell death after the introduction of a
wild-type p53 by transfection, suggesting that p53 was involved in the apoptosis pathway
(Yonish-Rouach et al., 1991). Bax was found to be a direct transcriptional target of p53 and the
first example of a proapoptotic gene directly regulated by p53 (Miyashita & Reed, 1995). The
restoration of p53 in murine leukemia cells caused an increase of Bax mRNA and protein levels
(Selvakumaran et al., 1994). Since then several other pro-apoptotic genes have been identified
that are regulated by p53, including p53AIP1, APAF1, Caspases 1, 6 and 10, FAS, PUMA, DR4
and DR5. Upon binding to the promoters of these genes, p53 activates transcription, thereby
promoting increased levels of the downstream components of the apoptosis cascade (Reviewed
in (Riley, Sontag, Chen, & Levine, 2008). Evidence for a role of p53 in the regulation of
apoptosis that was independent of transcription was first hypothesized after transcriptionally
inactive mutants of p53 were found to induce cell death (Haupt, Rowan, Shaulian, Vousden, &
Oren, 1995).

3.1.4 p53 senses cellular stresses induced by chemotherapeutic agents
Understanding of p53 as a cellular stress response protein, it was of interest to know how p53
responds to stresses induced by chemotherapeutic agents. Most cellular responses by p53 have
been studied after IR or UV exposure. Ionizing radiation, camptothecin and bleomycin directly
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and rapidly induce DNA strand breaks, promoting the accumulation of significant levels of p53
within one hour of treatment. Cells electroporated with DNaseI or the restriction enzyme AluI
also accumulated p53, leading to the conclusion that DNA strand breaks initiate p53-dependent
signaling pathways (Nelson & Kastan, 1994). Further analyses showed that as little as one DNA
strand break per cell was sufficient to induce a p53 dependent growth arrest (Huang, Clarkin, &
Wahl, 1996).
Much less is known about the p53 response to nucleotide pool deprivation. Linke
et al, for the first time proposed the concept that p53 could sense nucleotide levels and then
would become stabilized (Linke, Clarkin, Di, Tsou, & Wahl, 1996). In their experiments, WS1
embryonic skin cells containing wild-type p53, treated with antimetabolites inhibiting different
parts of de novo pyrimidine and purine synthesis resulted in a G1 cell cycle arrest. However,
p53 null cells slipped into early S-phase and then arrested. Interestingly, dNTP biosynthesis
inhibitors caused arrest in early S-phase regardless of p53 status. In the studies of Linke and
colleagues, the G1 arrest was reversed upon the addition of the limiting nucleotides and no
apparent DNA damage was detected by metaphase chromosome analysis, therefore, the p53
dependent nucleotide deficiency arrest was not caused by DNA damage (Linke et al., 1996).
Feng et. al have shown that DNA damage induced activation of p53 leads to phosphorylation and
activation of AMPK in a p53 dependent manner (Z. Feng, Zhang, Levine, & Jin, 2005). Whereas
finding of Jones et. al have suggested that upon metabolic stress, i.e upon glucose deprivation,
AMPK activation leads to phosphorylation of p53 at ser15. This ser15 phosphorylation of p53 is
required to induce AMPK mediated metabolic checkpoint and cell growth arrest (R. G. Jones et
al., 2005a). These two studies suggest that connection of p53 and AMPK but with different
theories. Former suggests that p53 mediated effects on mTORC1 are AMPK activation
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dependent and later suggest that AMPK mediated effects on cell growth are p53 and p53
phsophorylation at ser15, dependent. Cleraly these differences in the observation by two groups
could be due to different type of cell stresses used in the studies. A section of this dessertaion is
dedicated to understand the response of p53 under the treatment of DNA damaging agent VP16
and two AMPK activators, PTX and AICAR.
3.1.5 ATM/ATR regulation of p53
To protect the genome from genetic assault caused by environmental factors like radiation,
reactive oxygen species, ultraviolet light, and other environmental mutagens, cells have evolved
complex mechanisms, collectively referred to the DNA damage response. This pathway acts to
rectify DNA damage to allow the minimization of genetic infidelity. The cellular response to
DNA damage involves both repair mechanisms and checkpoint responses. Checkpoint responses
are thought to have evolved to delay the cell cycle progression in order to prevent error prone
DNA replication. Many of the published studies on the involvement of p53 in the DNA damage
response were done using radiation or DNA damaging agent such as etoposide (VP16).
Etoposide is a topoisomerase inhibitor, which forms a ternary complex with DNA and the
topoisomerase II. Topoisomerase II is a helicase, which unwinds the DNA during replication.
Thus binding of VP16 with topoisomerase stabilizes DNA and topoisomerase II complex,
prevents re-ligation of the DNA strands, and causes DNA double strand break.
ATM-Chk2 and ATR-Chk1 pathways play key roles in the DNA damage response (Sancar,
Lindsey-Boltz, Unsal-Kacmaz, & Linn, 2004). ATM and ATR are large kinases with sequence
similarity to the phosphatidylinositol-3-kinase (PI3K) family. Each of them phosphorylates
multiple protein substrates (Abraham, 2001). The two key, well-studied substrates are Chk1 and
Chk2 which are selectively phosphorylated by ATR and ATM, respectively. Chk1 and Chk2 are
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serine-threonine checkpoint effectors, that is, they are themselves phosphorylated early in the
checkpoint response, but then have activities as kinases, essential to the imposition of the G1/S,
or G2/M phase blocks in cell-cycle traverse (Bartek & Lukas, 2003) dependent on the intensity
and type of DNA stress.
The ATM–Chk2 and ATR–Chk1 pathways respond to different types of damaged DNA
structures (Fig.3-3). ATM is recruited to and activated primarily at DNA double-strand breaks
(DSBs) in conjunction with the MRE11:RAD50: NBS1 (MRN) sensor complex (J. H. Lee &
Paull, 2005; Paull & Lee, 2005; Suzuki, Kodama, & Watanabe, 2005) whereas ATR is activated
via recruitment to single-stranded DNA (ssDNA) upon single strand break in association with its
partner protein, ATRIP (Dart, Adams, Akerman, & Lakin, 2004; Lupardus, Byun, Yee, HekmatNejad, & Cimprich, 2002; Zou & Elledge, 2003). ATM and Chk2 are activated potently by
radiation and genotoxins that induce DSBs, but only weakly, if at all, by agents that block DNA
replication without inducing damage (Matsuoka et al., 2007). This piece of information is
important for the understanding and explanation of the later section of this chapter. In response
to DSBs, inactive subunits of ATM homodimerize, then autophosphorylate each other and
dissociate to form partially active monomers (Bakkenist & Kastan, 2003; Kastan & Bartek,
2004). ATM autophosphorylated at S1981 is often taken as an indicator of its activation.
Modification of this residue has been shown to be involved or at least linked to ATM activation
under most circumstances (Bakkenist & Kastan, 2003; Kastan & Bartek, 2004). However, this
residue is not essential for ATM function, at least in mice (Pellegrini et al., 2006). ATM
monomers are then recruited to the DSBs site with the MRN sensor complex where they can
locally act on multiple substrates. Of the several substrates for ATM, the two most important, or
at least the most studied, are H2AX (Fernandez-Capetillo, Lee, Nussenzweig, & Nussenzweig,
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2004) and ChK2 (Lukas, Falck, Bartkova, Bartek, & Lukas, 2003).

Figure 3-3. Schematic representation of activation of ATM-Chk2 and ATR-Chk1
pathway following genotoxic stress.
The ATM-Chk2 and ATR-Chk1 pathways are activated selectively by DSBs and by
tracts of ssDNA, respectively. Here, for clarity and simplicity multiple proteins
involved in the DNA repair mechanism are represented as DRPC = DNA repair
protein complex. Studies in later part of this chapter suggest that AICAR or VP16
treatments lead to DNA damage activating p53 and its transcriptional activity,
however, PTX might cause replication halt leaving p53 transcriptionally inactive.
This concept is presented here in the form of question marks in red color
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ATM phosphorylates Chk2 on T68, a residue located within an N-terminal
serine/threonine (SQ/TQ) rich motif (Ahn, Li, Davis, & Canman, 2002). Once the SQ/TQ motif
of one Chk2 molecule is phosphorylated, it interacts with the phosphopeptide-binding Fork-head
associated (FHA) domain of another, homodimerize transiently; autophosphorylation ensues
and ATM achieves a fully activated state (Ahn et al., 2002; Cai, Chehab, & Pavletich, 2009;
Oliver et al., 2006). It has been suggested that these activated Chk2 monomers dissociate from
the site of damage and disperse through out the nucleus to act on several substrates involved in
the response to DNA damage, which includes proteins involved in cell cycle progression, gene
transcription, and apoptosis (Lukas et al., 2003). One of the most studies substrates of Chk2
kinase is the p53 protein, which was shown to be phosphorylated at ser15 by Chk2 (Chehab,
Malikzay, Appel, & Halazonetis, 2000; Oliver et al., 2006; Shieh, Ahn, Tamai, Taya, & Prives,
2000b). ATM has been thought to activate p53 by directly phosphorylating it upon DNA
damage. ATM also phosphorylates MDM2 and MDMX, which regulate the stability of p53, and
thus is thought of as responsible for the stabilization of p53 upon DNA damage (Chen, Gilkes,
Pan, Lane, & Chen, 2005; Lavin & Kozlov, 2007). There is also increasing evidence that
supports the concept that ATM may have substrates and function in the cytoplasm (Lavin, 2008).
ATR–Chk1 signaling is also thought to be activated upon blockage of DNA replication.
Replication fork stalling generates ssDNA directly; however, this structure can also arise through
the action of nucleotide excision repair (NER) or at dysfunctional telomeres. As a result of
nucleotide depletion or DNA damage lesions caused by ultraviolet light, blockage of DNA
replication can occur, which causes the uncoupling of DNA polymerase from the replication
helicase, generating ssDNA tracts (Byun, Pacek, Yee, Walter, & Cimprich, 2005). These ssDNA
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tracts are rapidly coated by trimeric ssDNA binding protein complex and replication protein A
(RPA) and Chk1 are recruited at these tracts with ATR-interacting proteins (ATRIP) (Zou &
Elledge, 0626). However, it is important to remember that the ATR-ChK1 pathway is also
activated in response to DSBs after which nucleolytic strand resection exposes ssDNA. Serine 15
of p53 is phosphorylated by ATR after IR, UV or HU treatment. Kinase inactive mutants of
ATR interfere with phosphorylation of p53 in late S-phase during IR treatment and completely
suppress p53 phosphorylation after UV treatment, suggesting an important role of ATR in the Sphase checkpoint (Tibbetts et al., 1999). DNA breaks induced by camptothecin induce ATR
which in turn phosphorylates H2AX, an event required to recruit DNA repair proteins Mre11,
Rad50 and NSB1 (MRN) (Furuta et al., 2003). As the DSB response can be generated by
replication of damaged DNA, when leading strand DNA polymerase encounters single strand
nicks, it leads to activation of both ATM-Chk2 and ATR-Chk1 pathway. Thus, the effects of
ATM and of ATR are not mutually exclusive, especially when cells are exposed to genotoxic
stress, inducing ionizing radiation and most of the cytotoxic chemotherapy agents.
DNA damage induces cell cycle delays or arrest at the G1/S and G2/M transitions (the G1
and G2 checkpoints), and also causes a transient decrease in the rate of DNA synthesis (the intraS checkpoint). All these cell cycle delays are dependent on and carried out by different proteins
including p53, although it has been suggested that ATM and ATR have overlapping targets.

3.2

FOCUS OF THIS CHAPTER

In this chapter, I investigate the differential dependence of two AMPK activators on p53 in the
mechanisms whereby they inhibit mTORC1.

Surprisingly, while comparing these AMPK

activators, AICAR and PTX, we found that even after the similar initiation mechanism of AMPK
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activation (ZMP accumulation), some of the downstream signaling differs between the two
compounds, while some remains the same. We showed that whereas PTX-activated AMPK is a
p53 and thus TSC2-independent inhibitor of mTORC1, AICAR-activated AMPK leads to the
activation of TSC2 and thus suggests the involvement of TSC2 in the AICAR mediated
inhibition of mTORC1. It is also shown that this difference is due to the differences in p53
transcriptional activity following treatment with these drugs. AICAR causes an increase in the
levels of transcriptionally active p53, thus, allowing the p53 dependent increase of TSC2 and
sestrin2 levels, followed by AMPK-mediated (Sestrin2 is required for AMPK mediated
phosphorylation of TSC2 at Ser1387 (Gwinn et al., 2008; R. J. Shaw et al., 2004) activation and
phosphorylation of TSC2. On the other hand, p53 accumulating after PTX is transcriptionally
compromised. Even under the conditions of limited TSC2 function and hyperactive mTORC1,
PTX is effective and sufficient for inhibition of mTORC1 activity. This is due to the p53independent, AMPK-mediated phosphorylation of S792 Raptor by PTX, which is shown to be
necessary and sufficient for mTORC1 inhibition.
In order to understand the underlying mechanism of differential behavior of p53 under
these two AMPK activators, we compared these effects of these AMPK activators with those
coming on after treatment with the control DNA damaging agent, etoposide (VP16). We found
very interesting differences and similarities in the posttranslational modifications of p53 under
these treatments. We also observed the differences of the ATM/ATR mediated Chk2/ Chk1
activation which may explain the differences in the p53 transcriptional activity under these drug
treatments.
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3.3

RESULTS

3.3.1 Overactive mTORC1 in p53 null cells is suppressed by PTX.
HCT116 p53 +/+ and p53-/- cells were treated with PTX in the presence of TdR in order to
circumvent the effect of PTX on thymidylate synthase and restrict its effects to AMPK activation
and downstream mTORC1 signaling. Phosphorylation of the downstream targets of mTORC1
was suppressed in both HCT116 cells and their isogenic p53-null derivative after PTX treatment,
in response to activation of AMPK (Fig. 3-4). PTX activates AMPK to the same extent in both
p53+/+ and p53-/- HCT116 cells as determined by assessing phosphorylation using pThr172AMPK antibodies (Fig 3-6). The phosphorylation of T389 on S6K1 was diminished by
PTX treatment in both HCT116 p53 (+/+) and (-/-) cell lines (Fig. 3-4). An immunoblot with
phosphospecific antibody against 4EBP1 phosphoT70 indicates equivalent levels of suppression
of mTORC1 activity following PTX treatment of HCT 1116 cells with and without p53 function
(Fig 3-4). 4EBP1 detected with a pan-antibody showed multiple and much lighter bands in
untreated p53 null cells in comparison to wt p53 cells (Chapter 2-Fig. 2-5, Fig. 3-4) and (Holz,
Ballif, Gygi, & Blenis, 2005) and these bands shifted towards lower phosphorylation state after
PTX treatment in both p53 -/- and p53 +/+ cells. Using RT-qPCR, it was also noted that the level
of 4-EBP1 mRNA was significantly lower in cells null for p53 than in wild-type cells (Fig. 25B). Overall, it appears that PTX can inhibit mTORC1 activity independent of p53 status at the
level of both of its substrates, S6K1 and 4EBP1(Fig. 3-4). The effect of PTX on 4EBP1 binding
to capped mRNAs was assessed using the 7mGTP bead pull down assay; the results of these
experiments suggested that the levels of 4EBP1 bound to 7mGTP beads are increased
substantially after PTX treatment, independent of p53 status (Fig. 3-5), but that the amount of 4EBP1 accumulating in p53 null cells on capped RNA is decreased when p53 is lost.
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Nevertheless, treatment with PTX inhibits mTORC1 in a p53-independent manner, preserving
levels of hypophosphorylated 4EBP1 and prolonging the integrity of 4EBP1-elF4E complexes.
As hypophosphorylated species are the active inhibitor of cap-dependent translation initiation
and are not targeted by the proteasome, the binding of this species of 4EBP1 increased on
7mGTP beads, which mimic the 7mGTP cap of mRNA (Fig 3-5). Once again, the levels of
4EBP1 bound to beads in lysates from TdR-treated p53 WT cells is quite a bit higher than that
from TdR-treated p53 null cells, as shown previously in untreated p53 isogenic HCT 116
(Chapter 2-Fig. 2-5A). Overall, the effects of PTX on S6K1 phosphorylation are strong but the
effects on 4EBP1 seemed to be more extensive and are probably a greater contributing factor for
inhibition of mTORC1 signaling to cap-dependent protein synthesis initiation, in agreement with
experiments previously performed by Scott Rothbart in this laboratory (Rothbart et al., 2010) .
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Figure 3-4 Overactive mTORC1 in p53 null cells is suppressed by PTX.
PTX activates AMPK in p53 null cells and can reduce mTORC1 activity
in these cells.
p53+/+ and p53-/- HCT116 cells were treated with 1 µM PTX + TdR for 24
hrs. AMPK activation and phosphorylation of S6K1 and 4EBP1 were
assessed by immunoblotting
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Figure 3-2. PTX mediated increase in the 4EBP1 binding to
7mGTP beads is p53 status independent.
HCT116 wt and p53 null cells were treated with 1 µM PTX + TdR
for 24 hrs. m7GTP pull down was performed using sepharose beads
bound to m7GTP mimicking mRNA. Pulldowns were
immunoblotted to analyze the levels of bound 4EBP1 to the beads.
Lysates were probed to analyze the phosphorylation of S6K1 and
4EBP1.
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3.3.2 Unlike AICAR, PTX treatment does not lead to activation of TSC2 by
phosphorylation at Ser1387
AMPK is thought to negatively affect mTORC1 by two signals: activation of TSC2 GAP activity
following phosphorylation of TSC2 S1387 (Garami et al., 2003; Sato, Nakashima, Guo, &
Tamanoi, 2009; Tee, Manning, Roux, Cantley, & Blenis, 2003) and direct inhibition of
mTORC1 kinase by phosphorylation of Raptor at S792 (Gwinn et al., 2008). These events were
monitored after PTX- or AICAR treatment of HCT116 cells. The phosphorylation of AMPK at
T172 in either p53 WT or null HCT116 cells was equivalent after either PTX or AICAR and was
not p53-dependent (Fig 3-6). The AMPK-dependent phosphorylation of TSC2 at S1387 was seen
in HCT116 cells with WT p53 after AICAR treatment (Fig. 3-7A), but not after PTX plus
thymidine (Fig. 3-7B). In fact, the phosphorylation of S1387 of TSC2 was diminished in PTXtreated wt HCT116 cells, and the p-S1387 immunoblot had to be exposed longer to detect any
signal. The level of p-S1387 TSC2 in treated cells was clearly dependent on p53 function:
neither TSC2 nor p-S1387 TSC2 was easily detected in AICAR- or PTX-treated p53 -/- HCT116
(Fig. 3-7A,B). There was an increased expression of TSC2 in AICAR-treated p53-wt cells (Fig.
3-7A), which was not seen in p53 wt cells treated with PTX (Fig. 3-7B); this effect proved to be
due to differences in p53 transactivation after these drugs (discussed below). We drew the
conclusion that there was a defect in AMPK signaling to TSC2 in p53-null cells and PTX treated
cells due to a deficiency of TSC2. In contrast, robust inhibitory phosphorylation of Raptor was
observed after either AICAR or PTX and was unaffected by deletion of p53 in HCT116 cells
(Fig. 3-7). We observed some interesting effects in these experiments, which raised some
intriguing questions; 1) why does PTX-activated AMPK not phosphorylate TSC2, 2) why does
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PTX not cause an increase in TSC2 protein levels when TSC2 is clearly a target of p53 (Fig. 218 to 22, and Fig. 3-7B), and 3) How is PTX-mediated inhibition of mTORC1 independent of
TSC2 activation? Our later studies suggested that the answers to questions 1 and 2 are related, as
discussed below.
3.3.3 p53 stabilized by PTX is transcriptionally compromised
As shown previously (Z. Feng et al., 2007) Chapter 2, Fig 2-18 to 22), TSC2 is a transcription
target of p53. When we observed that the levels of TSC2 increased in wt p53 HCT116 cells after
AICAR treatment but not after PTX treatment and that p53 null cells have lower levels of TSC2,
the levels of p53 and its stabilization by AMPK activators were studied. In order to understand
the difference of effects of two AMPK activators on p53, the accumulation of p53 was examined
in HCT116 cells exposed to either PTX in the presence of thymidine or AICAR and these levels
were compared with those in cells treated with VP16, a widely used topoisomerase II inhibitor
known to damage DNA. PTX or AICAR caused the accumulation of p53 in HCT116 cells that
was similar to that seen in VP16 (Fig 3-8), although the levels of p53 in PTX-treated cells were
usually somewhat lower that in AICAR or VP16.

Likewise, AICAR caused a robust

enhancement of the level of several proteins whose genes were known to be p53 transcriptional
targets (Budanov et al., 0923; Z. Feng et al., 2007; Riley et al., 2008), namely p21, sestrin 2,
human mdm-2, and Bax (Fig. 3-8), and TSC2 (Fig. 3-7A), in a pattern identical to that seen after
DNA damage. Very surprisingly, the level of these proteins did not change in cells treated with
PTX (Figs 3-8, 3-7B respectively). RT-qPCR studies indicated that the steady-state levels of
mRNA for these genes reflected the protein levels seen after each drug; i.e., VP16 and AICAR
augmented the levels of p21, Sestrin 2, and TSC2. The steady state levels of human MDM2,
PUMA, PIG3, BAX, well known transcriptional targets of p53 mRNAs also showed a modest to
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substantial increase after VP16 and AICAR but there was no change in the mRNA for these p53
target genes after PTX (Fig 3-9). Thus, the transcriptional response of the p53 that accumulated
in PTX-treated cells, was severely compromised. Budanov et. al have shown that Sestrin2
promotes the AMPK-mediated activation and phosphorylation of TSC2 at Ser1387. Because
PTX-activated AMPK does not phosphorylate TSC2 at Ser1387 , it seemed that levels of TSC2
and Sestrin2 were not sufficient for AMPK-mediated phosphorylation of TSC2.
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Fig 5
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B
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Figure 3-3. PTX and AICAR mediated AMPK activation is p53
status independent.
B
PTX D
and AICAR both activate AMPK in cells with and without p53 to the
B same extent. p53+/+ and p53-/- HCT116 cells were treated with 1 µM PTX
+ TdR for 24 hrs or with 250 µM AICAR . AMPK activation was assessed
by immunoblotting using antibody against P-ser172 AMPK, where ND= no
drug treatment.
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B
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Figure 3-4. PTX and AICAR mediated AMPK leads to differential signaling
downstream of AMPK.
PTX and AICAR both activate AMPK in cells with and without p53 to the same extent.
p53+/+ and p53-/- HCT116 cells were treated with (A)1 µM PTX + TdR (B) 250 µM
AICAR for 24 hrs. AMPK mediated phosphorylation of TSC2 and Raptor was detected
by using anti- P-ser1387 TSC2 and P-ser792 Raptor antibodies by immunoblotting.
Total TSC2 and Raptor were also detected.

174

Figure 3-5. PTX causes accumulation of p53 but does not activate p53dependent transcription.
Wild-type HCT116 cells were treated with VP16, DMSO, or TdR, or
PTX + TdR, or AICAR (500 µM) for 24 hrs. Cell lysates were probed
for p53 and its transcriptional targets p21, Sestrin2, HDM2, and BAX by
immunoblot. PTX causes accumulation of p53 but does not activate p53dependent transcription.
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Figure 3-6. PTX stabilized p53 does not activate transcription of its target
genes.
Wild-type HCT116 cells were treated with VP16, DMSO, or TdR, or PTX +
TdR, or AICAR (500 µM) for 24 hrs. Total cell RNA was harvested followed by
cDNA synthesis and q-RT PCR to analyze steady state levels of mRNAs of p53
transcription targets; p21, HDM2, PUMA, PIG3, BAX, TSC2 and Sestrin2.
Three independent biological repeats combined and expressed (±sd) and P
values <.0001.
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3.3.4 PTX effects on mTORC1 are TSC2 and Sestrin2 independent.
TSC2 and Sestrin2 are two genes involved in the negative regulation of mTORC1 that are p53
transcription targets (Budanov et al., 0923; Z. Feng et al., 2007) chapter 2). As shown in Fig. 37B, after PTX treatment p53 transcriptional activity is compromised, an effect that mutes TSC2mediated inhibition of mTORC1.

We addressed if PTX effects were dependent on TSC2 and

sestrin2 levels. First, p53-/- MEFs and p53-/-, TSC2 -/- MEFs were treated with PTX and
mTORC1 signaling was observed at the level of pThr389 S6K in order to assess the effect of
deletion of TSC2.

mTORC1 activity was equally inhibited after PTX treatment in MEFs

whether or not they expressed TSC2, in spite of the fact that TSC2-/- MEFs showed higher
mTORC1 activity than TSC2 WT MEFs (Fig. 3-10A).

In related experiments, the effects of

PTX were compared in MEFs from WT or Sestrin 2 -/- mice; PTX mediated inhibition of
mTORC1 was unaffected by the genetic loss of Sestrin2 (Fig. 3-10B), again, in spite of the fact
that mTORC1 activity was higher in cells that had lost Sestrin 2 function. Because genetic
deletion of TSC2 is a lethal event unless done in a background of p53-/- mice, the above
experiments only allowed test of the effects of loss of TSC2 in a p53 null background. Hence,
we depleted TSC2 in p53 wild type HCT116 cells with pools of siRNA to isolate the effect of
TSC2 loss itself from the loss of p53.

Untreated HCT116 cells in which TSC2 was depleted

with siRNA had a substantial increment in mTORC1 activity as seen from the increased
phosphorylation of S6K1 and 4EBP1 (Fig. 3-11). Nevertheless, the hyperactive mTORC1 in p53
wt HCT116 cells with siRNA-depleted TSC2 was suppressed by PTX (Fig. 3-11), as was also
seen in p53-null HCT116 cells (Fig 3-4), TSC2 null MEFs in a p53 null background (Fig. 310A,), and Sestrin2-null MEFs (Fig. 3-10B). We concluded that enhanced activity of mTORC1
in p53 null cells is caused by the p53 dependence of transcription of TSC2 and Sestrin2 (Chapter
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2), but that PTX controlled mTORC1 even in cells null for TSC2, Sestrin 2 or p53 function.
3.3.5 PTX effects on cell growth are not affected by p53 or TSC2 loss, AICAR effects are.
WT HCT116 cells and their p53-null derivative were treated with PTX in the presence of
thymidine to determine whether p53 loss altered growth suppression by activated AMPK. These
experiments were also done in the absence of thymidine to determine the effect of p53 on PTX
activity against thymidylate synthase and activation of AMPK, conditions germane for clinical
use of this drug. There was no difference in the response to PTX between the p53 wild type and /- HCT116 cell lines under either condition (Fig. 3-12A), although a decrease in sensitivity in the
presence of thymidine was observed, as expected from previous experiments in this laboratory
(Rothbart et al., 2010). This would concur with the observation that PTX treatment in the
presence (Fig 3-8) or absence of thymidine (see below) did not activate the transcriptional
program of p53. In contrast, HCT116 cells wt for p53 function were more sensitive to AICAR
than HCT116 null for p53 (Fig. 3-12B), in accord with the fact that p53 increased leves of TSC2
in AICAR-treated cells, while PTX did not (Fig. 3-7). Nearly identical results were found using
MEFs with and without p53 and TSC2 function (Fig. 3-12 C,D). These observations suggested
that PTX mediated inhibition of mTORC1 was independent of p53 and TSC2 function, and this
fact was evident even at the level of cell growth. We concluded that suppression of growth by
AICAR in carcinoma cells would be muted by loss of p53, but that the loss of p53 or TCS2
would be without effect on therapeutics with PTX.
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Figure 3-7. Overactive mTORC1 in p53 null cells is suppressed by PTX,
independent of TSC2 and Sestrin2.
PTX decreases mTORC1 signaling in cells lacking p53 and TSC2, as well
as in cells lacking Sestrin2. TSC2+/+ and -/- MEFs, and Sestrin2+/+ and /- MEFs were treated with PTX + TdR for 24 hrs and p-T389 S6K1
evaluated by immunoblot.
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Figure 3-8. PTX inhibits enhanced mTORC1 activity after TSC2
transient knock down.
PTX controls mTORC1 activity in cells after TSC2 silencing. WT HCT116
cells were transfected with siRNA against TSC2 for 36 hrs, then were
treated with PTX + TdR for 24 hrs; p-T389 S6K1 and p-T70 4EBP1 were
determined by immunoblot.
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Figure 3-9. Growth inhibition by PTX was not affected by loss of p53 or TSC2.
(A) The presence of p53 does not influence cell proliferation after PTX
treatment.
Wt HCT116 (filled symbols) and p53-/- (open symbols) cells were treated with
PTX alone (circles) or PTX + TdR (inverted triangles) for 72 hrs before cells were
harvested and counted using a Coulter counter. (B) HCT116 cells with wt p53
show higher sensitivity to AICAR than HCT116 cells null for p53. HCT116
p53+/+ and p53-/- cells were treated with AICAR for 72 hrs and final cell numbers
were determined as in (A). In (A) and (B), each symbol is the mean ± sd of three
experiments, each of which was performed in duplicate. (C) PTX attenuates the
growth of wt MEFs and MEFs lacking p53 and/or TSC2 equally. The growth of
MEFs null for p53 (open circles) or null for both p53 and TSC2 (filled inverted
triangles) were compared with that of wild type MEFs (filled circles) after 72 hrs
exposure to increasing concentrations of PTX with thymidine. (D) MEFs lacking
TSC2 and/or p53 are less sensitive to AICAR. MEFS were treated with increasing
concentrations AICAR for 72 hr as in (C). The studies on growth inhibition in
HCT116 cells were performed by Richard Moran.
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3.3.6 Phosphorylation of Raptor is necessary and sufficient for suppression of mTORC1
in PTX-treated HCT116 cells.
Shaw and his colleagues have previously demonstrated that AMPK can regulate mTORC1 by the
phosphorylation of Raptor as well as the control by phosphorylation of TSC2 that was
discovered earlier (R. J. Shaw & Cantley, 2006; R. J. Shaw et al., 2004). Our data suggest that
PTX activated AMPK mediated inhibition of mTORC1 is TSC2 independent, which suggested
that phosphorylation of Raptor at Ser 792 by AMPK might be the affecting factor. To test
whether the phosphorylation of Raptor by AMPK was involved in and sufficient to suppress
mTORC1 kinase activity in the absence of TSC2 function, p53-/- TSC2 -/- MEFs were
transfected with a vector encoding wild type human Raptor or a construct for Raptor in which the
two serines phosphorylated by AMPK were mutated to alanines (AA Raptor, (R. J. Shaw et al.,
2004). The vectors carrying WT or AA Raptor resulted in expression of recombinant Raptor in
substantial excess over endogenous Raptor (Fig. 3-13). Raptor was phosphorylated at S792 in
vector transfected cells after PTX and even more so in PTX-treated cells transfected with WT
Raptor, but cells transfected with AA Raptor and treated with PTX showed a strong suppression
of pS792 Raptor. We drew the conclusion that the Raptor made from transfected Raptor vectors
was competing with endogenous Raptor for binding to mTORC1 complexes. Treatment of
MEFs transfected with empty vector or WT Raptor with PTX resulted in suppression of
mTORC1 kinase activity as seen by lower levels of phosphorylation of S6K1 at S389 and of
4EBP1 by phosphorylation at T70. However, neither of these phosphorylation events was
suppressed in AA Raptor-transfected cells after treatment with PTX (Fig 3-13).

Similar

dominance of Raptor phosphorylation was observed when p53 competent and p53 null HCT116
cells were transiently transfected with either empty vector, or vector containing WT or AA raptor
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(Fig 3-14). Both cell types when transfected with AA raptor followed by PTX treatment showed
no decrease in P-Thr398 S6K1 suggesting no inhibition of mTORC1 in the absence of raptor
phosphorylation (Fig. 3-14). Hence, we concluded that, as in MEFs lacking TSC2, in HCT116
cells the suppression of mTORC1 following PTX was mediated by phosphorylation of Raptor by
AMPK and that, in cells in which endogenous Raptor in mTORC1 complexes was replaced by a
mutant Raptor incapable of AMPK mediated phosphorylation, mTORC1 suppression after PTX
treatment did not occur.
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Figure 3-13. Phosphorylation of Raptor is necessary and sufficient for suppression of mTORC1 in
PTX treated cells.
TSC2-/- p53-/- MEFs were transfected for 36 hrs with pBABE-Hygro containing WT or AA
Raptor, then treated with PTX + TdR for 24 hrs. Phosphorylation of S6K1 and 4EBP1 were used
as indices of mTORC1 activity
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Figure 3-14. Phosphorylation of Raptor is necessary and sufficient for suppression of
mTORC1 in PTX treated HCT116 cells.
WT and p53 null HCT116 cells were transfected for 36 hrs with pBABE-Hygro containing WT
or AA Raptor, then treated with PTX + TdR for 24 hrs. Phosphorylation of S6K1 and 4EBP1
were used as indices of mTORC1 activity
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3.3.7 AICAR mediated inhibition of mTORC1 is TSC2 dependent
AMPK activated by both AICAR and PTX leads to the phosphorylation of Raptor. As shown in
Fig. 3-7A, phosphorylation of Raptor is necessary and sufficient for inhibition of mTORC1in
HCT116 cells and in MEFs treated with PTX. Hence, one would think that in TSC2 null cells,
AICAR mediated phosphorylation of raptor might also be sufficient for the inhibition of cell
growth. Contrary to this idea, AICAR mediated inhibition of cell growth is decreased by the loss
of p53 or of TSC2 and p53 (Fig. 3-12B,D). Thus, we compared PTX- and AICAR-activated
AMPK mediated phosphorylation of Raptor and TSC2. WT HCT116 cells were treated with
PTX in the presence of TdR or with AICAR (Fig. 3-15). The levels of p-Thr172 AMPK were
equivalent under both the treatments.

However, PTX-activated AMPK mediated

phosphorylation of Raptor to a greater extent than did AICAR treatment at the doses used in
these experiments (Fig. 3-15). As previously seen (Fig 3-7A), the level of phosphorylated TSC2
as well as total TSC2 increased under 250 µM AICAR treatment. This suggest that when TSC2
GAP activity is deficient in p53 null or TSC2 null cells, AICAR is less growth inhibitory due to
a weaker phosphorylation of Raptor and its dependence on TSC2 mediated inhibition of
mTORC1 (Fig. 3-12B,D) and equivalent growth inhibition may require a higher dose of AICAR
in absence of p53.

In cells competent for p53 function, AICAR causes both Raptor

phosphorylation and TSC2 phosphorylation, and growth inhibition was more intense. On the
other hand, PTX-activated AMPK only phosphorylates Raptor due to the deficit of TSC2
subsequent to the inactivity of p53 transcription caused by PTX, so that there is no difference in
potency in p53 WT or null cells (Fig. 3-12A,C). In order to probe the degree to which inhibition
of mTORC1 depends on activation of TSC2, the effect of deletion of TSC2 on the inhibition of
mTORC1 by AICAR was studied in p53-/- TSC2-/- MEFs. p53-/- TSC2+/+ MEFs showed
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almost equivalent inhibition of mTORC1 by PTX as did p53 -/- TSC2 -/- MEFs, while AICAR
was substantially less effective in p53-/- TSC2-/- MEFs (Fig. 3-16). This supported the concept
that AICAR-activated AMPK activates TSC2 GAP activity as well as directly inhibiting Raptor
function to inhibit mTORC1 but PTX relies only on phosphorylation of Raptor.
Hence, while one would predict that AICAR would be more active against p53 WT
tumors, it would substantially lose activity against p53 null tumors, and probably also tumors
bearing DNA binding domain p53 mutations (Chapter 2) and would be substantially less active
against tumors that had lost TSC2 function, such as tuberous sclerosis syndrome. On the other
hand, PTX would not be affected by loss of p53, nor by loss of TSC2 and should retain activity
against tumors with these genotypes.

3.3.8 Schema of differential signaling to mTORC1 by PTX- and AICAR-activated AMPK
AICAR activates AMPK via ZMP while also causing the accumulation of a transcriptionally
active p53, promoting the transcription of both Sestrin2 and TSC2. Consequently, AMPKcatalyzed phosphorylation of Raptor and TSC2 occurs and mTORC1 is inhibited (Fig. 3-17,
right). PTX, likewise, causes activation of AMPK via ZMP, but subsequent p53-dependent
transcription is defective. As a result, Sestrin2 and TSC2 levels are diminished and AMPK
cannot activate TSC2. Nevertheless, PTX-activated AMPK causes a robust phosphorylation of
Raptor sufficient to inhibit mTORC1 kinase (Fig. 3-17, left).
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Figure 3-16 AICAR mediated inhibition of mTORC1 is TSC2 dependent
p53-/- TSC2+/+ and p53-/- TSC2-/- cells were treated with 1 C2-/-ptor AI or 250 ere trea for 24
hrs. S6K phosphorylation was assessed by immunoblotting using antibody against P-T389 S6K1
as an indicator of mTORC1 activation.
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Figure 3-17. Proposed model for the differential effects of PTX and AICAR
(right) AICAR activates AMPK via ZMP while also causing the accumulation of a
.transcriptionally active p53, promoting the transcription of both Sestrin2 and TSC2.
Consequently, AMPK-catalyzed phosphorylation of Raptor and TSC2 occurs and mTORC1 is
inhibited. (left) PTX, likewise, causes activation of AMPK via ZMP, but subsequent p53dependent transcription is defective. As a result, Sestrin2 and TSC2 levels are diminished and
AMPK cannot activate TSC2. Nevertheless, PTX-activated AMPK causes a robust
phosphorylation of Raptor sufficient to inhibit mTORC1 kinase

190

3.3.9 Post-translational modifications of p53 following AMPK activation
Earlier sections of this thesis have shown that PTX stabilized p53 is transcriptionally inactive.
In order to reveal the cause of this phenomenon, we studied the post translational modifications
of the p53 under these treatments. The post-translational modifications of the p53 accumulating
in PTX-treated HCT116 cells were compared to those after AICAR or VP16. To assure that the
PTM-specific blots in these experiments reflected the stoichiometry of modification rather than
the level of p53, we first estimated the relative levels of p53 in control cells and cells after each
drug treatment, then loaded different volumes of lysates onto a gel to achieve equivalent loading
of p53. There were striking differences in the post-translational modification profiles of p53
after treatment with VP16 or either of the two AMPK-activating drugs (Fig. 3-18A): after VP16
treatment, p53 was modified at a number of residues that reflect the molecular events of the
DNA-damage response (Appella & Anderson, 2001; Siliciano et al., 1997), including N-terminal
acetylation at K373 and K382, and C-terminal phosphorylation at S20, S37, and S46. None of
these post-translational modifications was observed with either activator of AMPK, PTX or
AICAR. Like VP16, both AICAR and PTX induced phosphorylation of p53 at S392. The sole
modification observed that distinguished the transcriptionally inactive p53 in PTX-treated cells
from the transcriptionally active p53 in AICAR (and VP16) was phospho-S15, a modification
previously found essential for transcriptional response to p53 (Fig. 3-18A) (R. G. Jones et al.,
2005b; Siliciano et al., 1997).
3.3.10 Differential activation of Chk1 and Chk2 by AMPK activators
In order to understand the cause of the differences in the posttranslational modifications of p53
observed after, VP16, AICAR or PTX treatment, we studied the activation of the central effector
kinases ATM/ATR by studying the phosphorylation of their downstream targets Chk2 and Chk1,
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respectively. The phosphorylation of Chk1 did not occur after either AMPK activators, AICAR
or PTX, but was robust after DNA damage induced by VP16 (Fig. 3-18B). This difference in
phosphorylation of Chk1 might be the underlying explanation of the differences in the
posttranslational modifications of p53 between AICAR and VP16 such as Ser S20, S37, and S46
and acetylation at K373 and K382. However, phosphorylation of Chk2 was observed in both
treatments associated with p53 transcriptional activation, DNA damage by VP16 and AMPK
activation by AICAR, but not following PTX (with thymidine)(Fig 3-18B). Hence, it would
appear that the p53-dependent transcription following activation of AMPK by AICAR is
associated with phosphorylation of Chk2 and subsequent phosphorylation of p53 serine 15,
probably by Chk2 (Chehab et al., 2000; Oliver et al., 2006; Shieh, Ahn, Tamai, Taya, & Prives,
2000b) while PTX neither activates phosphorylation of Chk2 and p53 serine 15 nor p53dependent transcription. This in turn would suggest that ATM is activated by AICAR treatment
of HCT116 cells, as well as treatment with VP16.
3.3.11 Stabilization and phosphorylation of p53 at ser15 are ATM mediated.
p53 wt HCT116 cells, when pretreated with a specific inhibitor of ATM, Ku-60019, for 2 hrs
followed by treatment with either VP16, PTX + TdR, PTX, or AICAR showed decreases in the
p53 levels stabilized by these drugs; the levels of ser-15 phosphorylation of p53 was remarkably
decreased (Fig. 3-19), strongly implying that ATM was essential for S15 phosphorylation of p53.
Decrease in the levels of P-T68 Chk2 was also seen, an indicator of ATM inhibition by Ku60019. This suggested that although there are several perplexing differences in the effects of
these drugs on p53 and p53 activating pathway, they all directly or indirectly activate ATM and
leading to ATM mediated stabilization of p53. As PTX in the presence of thymidine stabilizes
p53 but does not show increases in the levels of p53 pS15, this suggested that although PTX
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stabilizes p53 in an ATM dependent manner, the cause of activation of ATM might be different
and thus leading to a different signaling than seen with VP16 or AICAR, as noted by the absence
of pS15 p53, pser345 Chk2, pT68 Chk2 and pS139 H2A.X. This suggests that in the absence of
DNA damage, p53 is transcriptionally inactive.
However, PTX in the absence of thymidine, causes DNA damage, leads to ATM dependent
increase in the levels of p53, pSer15 p53, pser345 Chk1 but it does not phosphorylate Chk2 at
Thr68.

This indicates that although PTX causes DNA damage and activates ATM, but

presumably due to some mechanistic differences in activation of ATM is leading to a differential
signaling downstream from ATM to p53 transcriptional activation and leaving p53
transcriptionally compromised. We propose that this mechanistic difference in actvation of ATM
could be due to difference in type and extent of genotoxic stress or DNA damage like DSBs vs
SSBs or replication halt.
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p53
p-S345 Chk1
Chk1
p-T68 Chk2
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Figure 3-18. Differential p53 post translation modification and Chk1 and Chk2
phosphorylation following AMPK activation.
P53 +/+ HCT116 cells were left untreated or treated with 20 µ5 VP16, or 1 µV PTX + TdR
or 500 µP AICAR for 24 hrs. (A) Cells were harvested and lysates were probed to assess the
levels of p53 under each treatment followed by densitometry to find p53 levels to calculate
the amount of protein need to be loaded to get equal levels of p53 loading. After loading
protein so that levels of p53 are equal, blots were probed for different posttranslational
modifications commonly known and correlated with p53 activation. (B) Equal amount of
protein loaded to assess the levels of phosphorylation of Chk1 and Chk2 by using antibodies
against P-ser345 Chk1 and P-T68 Chk2

.
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Figure 3-19. Pretreatment with ATM inhibitor Ku-60019 decreases levels of p53, P-serp53
and P-Thr68 Chk2 in all treatments.
p53 competent HCT116 cells were treated with Ku-60019 for 2hrs or left untreated followed by
treatment either with VP16, AICAR or PTX with or without TdR. Lysates were probed for the
assessment of p53, P-ser15 p53, PThr68 Chk2 and Chk2 using corresponding antibodies.
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3.3.12 Binding of p53 and presence of Acetyl Histone 4 at p21 promoter is equivalent after
PTX or AICAR treatment
As p53 accumulated after PTX treatment was not activating the transcription of its target genes,
we decided to analyze whether this p53 was binding to the promoter of p21. We performed
Chromatin Immunoprecipitation (ChIP) studies using α-p53 antibody to measure the relative
occupancy of p53 at p21 promoter. We found that the levels of p53 bound to p21 promoter after
VP16 treatment increased several fold. Although the levels of p53 bound to the p21 promoter
after PTX treatment were lower than after VP16, they were equivalant to that after AICAR
treatment, which were sufficient to transcriptionally activate p21 (Fig. 3-20, blue bars). The
presence of p53 at the p21 promoter without transactivating transcription. It led us to question
the next step required for promoter accessibility by the transcriptional machenary, namely the
recruitment of histone acetylases (HATs) to histones in the vicinity of the promoter, creating a
euchromatin structure. We performed ChIP using acetyl-histone H4 to analyze the presence of
acetylated hostones at the promoter region of the p21 gene, an indicator of euchromatin form of
gene. The levels of acetylated histone 4 occupancy at p21 were increased after VP16, PTX and
AICAR treatment (Fig. 3-20, green bars). As expected this increase was higher under VP16
treatment in comparision to that after AICAR and PTX treatment, which were equivalent (Fig. 320, green bars). This suggested that binding of p53 or recruitment of HATs at p21 promoter
were not the limitng factors for p53 transcriptional activity under PTX treatment (Fig. 3-20) and
that, hence, the deficit in PTX was further downstream in the transcriptional response.
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3.3.13 AICAR leads to a delayed DNA damage but PTX (with TdR) does not
Because it seemed that AICAR and VP16 both activated ATM, but PTX did not, it was of
interest to determine the generic question of whether the activation of AMPK resulted in DNA
damage. The initiation of DNA damage after AMPK activation was followed by observation of
phosphorylation of histone H2A.X and comparison with the time course of DNA damage with
VP16. H2A.X phosphorylation was robustly induced by as little as 3 hours exposure to VP16
and was maintained for at least 24 hr (Fig 3-21A).

This time course coincided with the

occurrence of robust Chk2 phosphorylation and equally robust and sustained phosphorylation of
p53 ser15, while Chk1 phosphorylation was more delayed in onset as was the accumulation of
p21 after treatment with VP16. Unlike the rapid time course of p53 S15 phosphorylation in
VP16-treated cells, the phosphorylation of p53 S15 was a delayed event in AICAR-treated cells.
Interestingly, and quite surprisingly, H2A.X phosphorylation was detected after AICAR
treatment on a time scale coincident with Chk2 and p53 ser15 phosphorylation, and p21
transcription (Fig 3-21A). Notably, the phosphorylation of H2A.X, of Ser15 and of Chk2 were
less pronounced after AICAR than after VP16, but they were easily measurable and appeared to
explain the transcription of p21 in AICAR. The time course of these events in cells treated with
PTX and thymidine indicated no H2A.X phosphorylation, no Chk1/ Chk2 activation, no p53 ser
15 phosphorylation and no p53-dependent transcription of the p21 gene at any time point studied
(Fig. 3-21B). We concluded that the difference between AICAR and PTX activation of AMPK
reflected a relatively weak and late-occuring but quite noticeable DNA damage response
coincident with Chk2 phosphorylation induced by AICAR, whereas this did not occur with PTX.
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3.3.14 PTX-activation of AMPK does not result in the DNA damage response, but PTX
inhibition of thymidylate synthase does.
The transcriptional response of the p53 target gene p21 coincided in time with increased levels of
pH2A.X, a common marker of DNA damage and/or replication halt, in AICAR-treated cells,
while PTX (in the presence of TdR) mediated activation of AMPK did not lead to DNA damage.
The primary target of PTX is thymidylate synthase, but the biochemical consequences of TS
inhibition on growth are prevented by thymidine (Taylor et al., 1992). Thus in the absence of
TdR, we can study the effect of PTX mediated thymidylate synthase inhibition as well as effects
on AMPK activation. We fully expected that the effects of PTX on thymidylate synthase would
induce DNA damage leading to stabilization of a transcriptionally competent p53 and set up
experiments to test whether this was the case. Under these conditions, a robust phosphorylation
of H2A.X was seen in HCT116 cells, indicating severe genotoxic stress (Fig 3-22).
Interestingly, the DNA damage or replication arrest induced by PTX led to phosphorylation of
Chk1 but Chk2 was not phosphorylated and, remarkably, p21 transcription still did not occur.
This was completely unexpected, but suggested that phosphorylation of Chk2 is necessary for
p53-mediated transcriptional activation of p21. Interestingly, an appreciable level of
phosphorylation of p53 S15 was seen, but this did not translate to transcriptional activation of
p21.
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Promoter of p21 seems to recruit HATs and Presence of RNA
Pol II through out the gene length suggesting normal initiation
of transcription

DMSO

VP16

TdR

PTX+TdR

ND

AICAR

Figure 3-20 Chromatin immunoprecipitaion suggest equivalent binding of p53 and
presence of acetylated histone 4 at p21 promoter after AICAR and PTX treatment.
p53 +/+ HCT116 cells were left untreated or treated with 20µM VP16, or 1 µM PTX +
TdR or 500 µM AICAR for 24 hrs. Cells were harvested and lysed followed by chromatin
immunoprecipiattion using α-p53 or α-Acetyl-histone4 antibody. Precipiated DNA was
used for realtime qPCR analysis to see the binding of p53 and acetylated-histone4,
respectively.
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p-T68 Chk2

p-T68 Chk2

Chk2
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Figure 3-21. AICAR leads to a delayed DNA damage but PTX (with TdR) does not.
WT HCT116 cells were treated with VP16 (20 μM) AICAR (500AR or PTX (1 μm +
Tdr (5.6 μm) for given time durations. Cells were harvested and lysates (A) from
VP16 and AICAR (B) VP16 and PTX + Tdr, treated cells were probed for P-Ser345
Chk1, Chk1, P-T68 Chk2, Chk2, P-S139 H2A.X, H2A.X, P-ser15p53 and p21 using
corresponding antibodies
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Fig. 3-22. PTX-activation of AMPK does not result in the DNA damage response, but PTX
inhibition of thymidylate synthase does.
Cells were either treated with VP16, PTX +/- TdR, AICAR or in combination of VP16 and PTX
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+/- TdR or VP16 and PTX . Cells were harvested and lysates were probed for the assessment of
p53, P-ser15 p53, p21, P-Ser139 H2A.X, H2A.X, P-Ser345 Chk1, P-T68 Chk2 using antibodies
against corresponding residues.

3.3.15 Blocking VP16 effects by pre-treatment with PTX.
The initial phases of phosphorylation of H2A.X were seen after six hr exposure to VP16 and this
exposure resulted in enhanced p21 transcription (Fig 3-23B).

When HCT116 cells were

pretreated for 20 hours with PTX plus thymidine prior to exposure to VP16 (Experimental
scheme Fig. 3-23A), remarkably, the DNA damage caused by VP16 was blocked, as was the
phosphorylation of Chk1 and the transcription of p21 (Fig. 3-23B). Chk2 phosphorylation was
not blocked by pretreatment with PTX and thymidine, conditions that activate AMPK but do not
inhibit thymidylate synthase. Hence, activation of AMPK even with phosphorylation of Chk2
and of S15 p53, was not sufficient for p53-dependent transactivation of p21 without DNA
damage.
When thymidine was not added to PTX in the medium, so that the genotoxic stress
subsequent to inhibition of thymidylate synthase occurred as well as activation of AMPK,
extensive H2A.X phosphorylation was seen, Chk1 phosphorylation was observed, and Chk2 was
not, but p21 transcription was not stimulated (Fig. 3-23B) as also seen before (Fig. 3-22). When
VP16 was added to cells pretreated for 20hrs with PTX alone, Chk1, Chk2 and ser15 p53
phosphorylation was seen and but there was still no p21 transcription was observed.
Interestingly, pretreatment with PTX (+ Tdr) blocks VP16 mediated DNA damage, suggesting
that PTX mediated activation of AMPK blocks cells from undergoing the events needed for the
development of DNA strand breaks after stabilization of Topoisomerase cleavable complexes
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with VP-16 (see Discussion). As PTX in the absence of thymidine, itself causes phosphorylation
of H2A.X, it was not clear from this data that whether PTX blocks VP16 mediated DNA
damage. Steady state levels of mRNA of p53 transcription target genes P21, MDM2, PUMA,
PIG3, BAX showed no increase upon VP16 treatment in cells pre treated with PTX (+/- TdR) for
20 hrs (Fig. 3-23C). However, cells treated with VP16 alone for 6hr or AICAR alone for 24 hrs
showed remarkable increase in the steady state levels of these above mentioned mRNA (Fig. 323C)
These data suggested that DNA damage and Chk2 phosphorylation were required for p21
transcriptional activation, that AMPK activation by PTX in the presence of thymidine was
insufficient for p53 transcriptional activation, that DNA damage by itself could be segregated
from p53-dependent transcriptional activation by whether or not Chk2 was activated and p53
S15 was phosphorylated. Overall, the effects of PTX (+/- TdR) interfered with those of VP16 ,
blocking the transcription activity of p53 induced by VP16.
3.3.16 PTX can block DNA damage effects even after prolonged exposure of VP16
PTX (+ TdR) can block DNA damage induced by 6 hr exposure of VP16, concomitant with the
block of p21 transcription induction. We asked whether PTX would be able to hold its blocking
effects under the prolonged exposure of VP16. P53 competent HCT116 cells were treated with
PTX (+ TdR) for 20 hrs followed by addition of VP16 at 6, 12 and 24 hrs before harvestation.
As expected, VP16 caused stabilization of p53 and induces the DNA damage by 6 hrs with an
increase by 12 and 24 hrs. This DNA damage was harmonized with the increase in p21 protein
levels (Fig. 3-24). Interstingly, we found that the PTX (+ TdR) can block the DNA damage
induced by VP16 for 12 hrs, however, by 24 hrs the effects of VP16 seems to start dominating
over PTX + TdR, indicated by some induction of p-S139 H2A.X at 24 hr VP16 treatment in cells
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pretreated with PTX+ TdR. This induction of p-S139 H2A.X was concur with increase in p21
levels suggesting that DNA damage is essential for VP16 mediated activation of p21
transcription by p53 (Fig. 3-24).
3.3.17 Blocking AICAR effects by PTX.
In order to understand if PTX, an AMPK activator can block the effects of another AMPK
activator, AICAR, that appeared to initiate a DNA damage response, we co-treated cells with
AICAR and PTX with both drugs added at the same time (experimental scheme, Fig. 3-25A).
As with VP16, PTX in the presence of thymidine blocked AICAR mediated DNA damage
indicated by phosphorylation of H2A.X, phosphorylation of ser15 p53 and Chk2, p21
transcription. In the absence of thymidine, PTX itself causes DNA damage thus it cannot be
interpreted from this data whether PTX blocks AICAR mediated DNA damage. Phosphorylation
of p53 S15 was observed with both PTX alone and PTX with AICAR treatment (fig. 3-25B).
AICAR mediated phosphorylation of Chk2 is blocked by PTX concomitant with block in
transcription of p21. Steady state levels of mRNA of p53 transcription target genes; P21,
MDM2, PUMA, PIG3, BAX shows no increase upon AICAR treatment when combined with
PTX (+/- TdR) (Fig. 3-25C).
We conclude that in the presence of the thymidine, PTX-activated AMPK neither cause DNA
damage nor allowed the DNA damage mediated by VP16 or AICAR, yet it blocks the p21
transcriptional response. Hence, in the absence of thymidine, PTX blocks thymidylate synthase
as well as activates AMPK and causes DNA damage or replication stress but still does not
activate transcriptional activity of p53. Surprisingly, the effects of PTX without thymidine
(AMPK and inhibition of thymidylate synthase) also block the effects of VP16 and AICAR on
p53 transcriptional activation. We concluded that the activation of p53 transcriptional activity
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depends on the type of genotoxic stress and DNA damage as well as the phase of cell cycle arrest
induced (see Discussion).
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Fig. 3-23. PTX blocks VP16 mediated transcriptional activation of wt p53 : p53 competent
HCT116 cells were treated alone either with VP16, PTX , AICAR with or without TdR or
VP16 was added to media in PTX (+/- TdR) after 20hrs as shown in (A) . Cells were harvested
6 hrs later for (B) protein analysis by immunoblotting, (C) steady state mRNA analysis using
RT-qPCR. Experiment is replicated twice showing similar patterns of changes in mRNA levels.
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Figure 3-24. PTX (+TdR) blocks DNA damage and p21 trasncription even after
prolonged exposure to VP16.
p53 wt HCT116 cells were treated with PTX + TdR for 24 hrs or left untreated followed by
addition of VP16 (20µM) for indicated time points. Cells were harvested and lysed for immunoblotting to analyze p-S139 H2A.X, an indiator of DNA damage and p21.
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Figure 3-25. PTX limits AICAR mediated transcriptional activation of wt p53
p53 competent HCT116 cells were treated alone either with VP16, AICAR or PTX with or
without TdR or with combination of AICAR and PTX (+/- TdR) for 24 hrs as described in (A)
followed by protein analysis by immunoblotting (B) , steady state mRNA analysis by RTqPCR(C).
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3.3.18 The effects of PTX plus TdR are caused by the PTX, not by thymidine.
PTX in the presence of thymidine blocks VP16 and AICAR mediated DNA damage, indicated
by decreased levels of p-S139 H2A.X in cells pretreated with PTX + TdR followed by VP16 or
AICAR treatment (Fig. 3-23,24,25). However, in the absence of thymidine, PTX itself causes
genotoxic stress, shown by increased levels of p-S139 H2A.X (Fig. 3-23,24,25). Thus, we asked
the question whether the DNA damage block seen by PTX + TdR, is due to PTX mediated
effects or is an effect of TdR present in the media, originaly added to circumvent the effects of
PTX on thymidylate synthase inhibition. p53 competent HCT116 cells were pretreated with PTX
(+ TdR) or TdR for 20 hrs followed by addition of VP16 6hr prior to cell harvest or were
cotreated with AICAR and PTX (+ TdR) or TdR. As expected, VP16 and AICAR mediated
induction of DNA damage and p21 protein levels were blocked only in cells pretreated with PTX
(+TdR) and not with TdR only (Fig. 3-26). This suggested that PTX mediated activation of
AMPK leads to some interesting yet unclear signaling events, which do not allow the DNA
damage to take place, presumably due to cell cycle arrest at G1 phase.
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Figure 3-26. VP16 and AICAR induced DNA damage and p21 transcription is blocked
by PTX, not TdR.
p53 wt HCT116 cells were treated with PTX+TdR, TdR or AICAR alone. For comination
treatment, cells were pretread with PTX + TdR or TdR for 20 hr followed by VP16 treatment 6
hrs before harvesting the cells. For AICAR combination studies with PTX + TdR or TdR,
indicated drugs were added simulatnously for 26 hrs. Cells were harvested and immunoblotting
performed to analyze p53, p-H2A.X and p21. β-actin was used as loading control.
9/5/13
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3.4

DISCUSSION

The studies in this chapter were started with a fairly simple but important question of how p53
status affected PTX mediated effects on mTORC1? Very early in the studies we found that PTX
activated AMPK could still inhibit mTORC1 in cells which have lost p53 function, inspite of the
fact that the mTORC1 is hyper-activated in these cells. This led us to question why PTX effects
on mTORC1 are p53 independent. In order to understand that, PTX effects were compared with
those of AICAR, a moderately well studied AMPK activator. We found that the effects of PTX
and AICAR were the same on AMPK activation but different downstream to that.

PTX-

activated AMPK only phosphorylates Raptor and thereby blocks mTORC1 kinase activity,
whereas AICAR-activated AMPK phosphorylates both TSC2 and Raptor. Thus, AICAR
activated both controlling arms whereby AMPK inhibits mTORC1, whereas PTX could only
activate one of these arms.

Involvement of p53.

The difference in the effects of PTX and AICAR proved to be due to

differential transcriptional activity of p53; p53 stabilized by AICAR was transcriptionally active
and caused the transcription of TSC2 and sestrin2, two molecules involved in and required for
AMPK mediated phosphorylation and activation of TSC2, whereas PTX stabilized p53 is
transcriptionally inactive, unable to promote the transcription of the TSC2 and sestrin2 genes. In
the presence of low levels of these proteins, AMPK does not phosphorylate TSC2 and thus TSC2
GAP activity is not enhanced. This answered the question why PTX effects on mTORC1 are p53
independent; it does not activate p53 regulated TSC2 arm of pathway. Thus p53 function it does
not make a difference in the inhibition of mTORC1 by PTX. We further found that the effects
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of PTX on mTORC1 are indeed TSC2 and sestrin2 independent.

PTX-mediated AMPK signaling This raised the hypothesis that, if PTX does not exploit TSC2
GAP activity, then raptor phosphorylation has to be taking the whole burden of inhibition of
mTORC1. In order to test this hypothesis we transfected TSC2-/-p53-/- MEFs with WT and
double mutant Raptor (AA: S792A and S772A) that cannot be phosphorylated by AMPK. We
found that upon PTX treatment, cells which have WT raptor, show inhibition of mTORC1 but
not those with AA raptor. In the absence of TSC2, WT raptor when phosphorylated by AMPK
led to inhibition of mTORC1 in these cells suggested that AMPK mediated phosphorylation of
Raptor is dominant, necessary and sufficient for inhibition of mTORC1. This was reflected in
the cell growth assays that PTX mediated inhibition of cell growth was p53 and TSC2
independent while loss of p53 or TSC2 was diminishing the growth inhibitory effects of AICAR.
This is a critical and an important observation, as this property of PTX can be harnessed in the
cancers that have lost p53 or TSC2 function and have enhanced activity of mTORC1.

AICAR-mediated AMPK signaling.

Given that the effects of PTX-activated AMPK on

mTORC1 suppression was independent of TSC2 function, it was of interest to determine if
AICAR mediated suppression of mTORC1 requires TSC2 function or whether the
phosphorylation of Raptor by AICAR is sufficient. Treatment of MEFs null for TSC2 with
AICAR showed that AICAR could inhibited mTORC1 only in TSC2 competent MEFs and not in
MEFs null of TSC2. This suggested that at the dose of AICAR used in this experiment, is
dependent on both TSC2 and Raptor phosphorylation. Presumably, at higher doses of AICAR,
Raptor phosphorylation could also become sufficient to mTORC1 inhibition.
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P53 PTMs

PTX stabilized p53 was transcriptionally crippled and thus does not increase the

levels of TSC2 and Sestrin2. We set off to understand the reason for this phenomenon. We used
DNA damaging agent VP16 as a control, which is well studied and known to activate the
transcriptional activity of p53. We saw very interesting differences and similarities between
AICAR and VP16 or AICAR and PTX. Whereas AICAR and VP16 both stabilize and activate
p53 transcriptional activity, they had very clear and surprising differences in the posttranslational
modifications of p53. VP16 activated p53 was post transnationally modified at all the residues
analyzed in this study, but AICAR activated p53 was only phosphorylated at Ser15 and Ser392.
Interestingly, PTX stabilized p53 was only phosphorylated at Ser392, a residue thought to be
responsible for tetramer formation of p53.

Therefore the only difference at the level of

posttranslational modification evident between AICAR and PTX, was p-S15. This suggested that
absence of p-S15 of p53 might be the causative factor for transcriptional inactivity of p53 in PTX
treatment. We also analyzed the binding of p53 and occupancy of acetylated histone 4 at p21
promoter, and found that occurence of both the events were equivalent in AICAR and PTX
(+TdR) treatments, eliminating the possibility of these events to be a limiting factor for p53
transcriptional inactivity under PTX treatment. Phosphorylation of p53 at ser15 and ser20
stabilizes p53 by inhibiting its interaction with MDM2, an E3-ubiqitin protein ligase.

Signaling upstream of p53 As ATM and ATR are the kinases known to phosphorylate Chk2
and Chk1, respectively, upon DNA damage which then phosphorylate p53 at S15, we studied the
activation of these proteins and their target protein H2AX, as an indicator of DNA damage. We
found that Chk1 was phosphorylated only under VP16 treatment, known to cause DSBs, but not
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under AICAR treatment, in spite of the fact that AICAR also caused H2A.X phosphorylation.
While both AICAR and VP16 treated cells show p-S15 p53 and increased p21 levels, ATRmediated Chk1 phosphorylation was absent in AICAR as it was in PTX-treated cells. This
suggested that phosphorylation of Chk1 is not required for the transcriptional activation of p53.
Interestingly, unlike PTX (+TdR), both VP16 and AICAR treated cells showed increased levels
of ATM-mediated phosphorylation of Chk2. Therefore, the absence of phosphorylation of Chk2
and p53 at S15 were the only differences noted between AICAR and PTX. It was clear by the
time course studies that phosphorylation of; p53 at S15 and Chk2 at T68 was coinciding with the
induction of H2A.X, an indicator of DNA damage after VP16 or AICAR treatment. None of the
events; p-S345Chk1, p-T68Chk2, p-S15 p53 were present in PTX (+ TdR) nor was the DNA
damage indicator p-S139H2A.X. This suggested that in the absence of DNA damage, ATM
does not get activated, which, in turn, does not phosphorylate and activate Chk2, leaving ser15
p53 un-phosphorylated and p53 transcriptionally inactive .
We decided to check if DNA damage is required for the transcriptional activation of p53.
PTX in the absence of TdR inhibits thymidylate synthase and can cause genotoxic stress. We
decided to test if PTX in the absence of the thymidine can activate DNA damage followed by
transcriptional activation of p53.

When cells were treated with PTX alone, it caused a

remarkable increase in the levels of p53, p-S15 p53, p-S345Chk1 and p-S139 H2A.X with no
increase of p21 protein levels. This suggests that even after genotoxic stress, p53 stabilized by
PTX is not transcriptionally active. This showed that the genomic stress caused by PTXmediated inhibition of thymidylate synthase is not sufficient to activate p53 transcriptional
activity.

Interestingly, the genomic stress caused by PTX could cause activation of ATR

mediated activation of Chk1 without causing an increase in p21 levels. The only difference
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between the signaling after treatments stabilizing transcriptionally active p53 (VP16 and
AICAR) versus treatment stabilizing transcriptionally inactive p53 (PTX + TdR and PTX alone),
was pT68 Chk2. This suggested that in the absence of Chk2 activation, and therefore activation
of ATM, p53 is transcriptionally compromised.

PTX interfered with the DNA damage response. Interestingly, when we pretreated cells with
PTX (+ TdR), followed by exposure to VP16, we saw that the DNA damage induced by VP16
was blocked, concomitant with a failure to promote transcription of p21. Similar observations
were made with the co-treatment of PTX + thymidine and AICAR: PTX + TdR blocked the
AICAR-mediated DNA damage and hence, p53 could not transcribe p21.
We know by the data generated by Scott Rothbart, a former graduate student of our lab, that PTX
in the presence of thymidine blocks cells at the G1/S border and PTX without thymidine inhibits
thymidylate synthase and causes S phase cell-cycle block. From this information, we inferred
that the pretreatment of cells with PTX in the presence of thymidine blocks cells at G1 phase of
cell cycle and does not allow the induction of DNA damage by VP16 or AICAR. This was a
surprise, since topoisomerase poisons were thought to act at several parts of the cell cycle.
When cells are treated with PTX (-TdR), it causes a S phase cell cycle block and increases in pS139 H2A.X but it does not transactivate p53. Cells pretreated with PTX followed by VP16,
apparently had all signaling events caused by ATM activation (p-ser15 p53, p-ser345Chk1, pT68Chk2, p-ser139 H2A.X) induced but there was still no increase in the p21 levels. A possible
explanation could be that upon PTX treatment, due to thymidine insufficiency, DNA replication
is halted but it does not allow the double stranded DNA damage caused by VP16 and thus is not
capable of transactivation of p53. Similar effects were seen when cells were treated with PTX
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and AICAR together. In addition we found that PTX decreased the level of p-T68 Chk2
activated by AICAR in the cells pretreated with PTX. Perhaps the transcriptional inactivation of
p53 caused by PTX does not allow the production of a protein essential to the DNA damage
response, e.g. 53BP1.
This chapter raises many important questions and unleashes some very interesting phenomenon
taking place under unique pharmacological stimuli. This study clearly challeneges the corealtion
of signaling events like p-S15p53, p-S345Chk1, p-T68Chk2 and p-S139H2A.X and p53
transcriptional activity.
3.5

CONCLUSIONS

Studies in this chapter lead to the conclusion that PTX effects on the mTORC1 pathway are
independent of p53 and TSC2 function, which makes it a suitable drug for cancers with
hyperactive mTORC1 due to loss or mutation of these genes. We also uncovered the mechanism
of this independence by showing that p53 accumulated under PTX treatment, is transcriptionally
compromised and thus does not allow the activation of TSC2 transcription and its GAP activity
leaving the mTORC1 inhibition by PTX, TSC2 function independent. PTX mediated effects on
mTORC1 inhibition are due to robust phosphorylation of Raptor by AMPK and this effect is
necessary and sufficient to inhibit mTORC1, even in cells with enhanced mTORC1 activity.
Later we went on to address the reason of p53 transcriptional incompetence under PTX treatment
and we show some very interesting effects of this drug on the ATM/Chk2-ATR/Chk1-P53
pathway. We believe that, in the presence of thymidine, the G1 cell cycle arrest blocked the
DNA damaging effects of VP16 and AICAR and allow the accumulation of a transcriptionally
inactive p53. On the other hand, in the absence of thymidine PTX inhibits thymidylate synthesis
and arrest cells at S phase of cell cycle, which probably leads to a replication halt, which neither
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activates p21 transcription itself nor allows VP16 or AICAR mediated activation of p21
transcription.
3.6

SURPRISES FROM THIS STUDY

These surprises are discussed in more detail in the future directions section of this thesis
(Chapter 5).
Ø PTX (+ TdR) stabilizes p53 without causing phosphorylation of p53 at ser15.
Ø Chk1 activation has been reported to inhibit transcriptional activity of p53. In my studies,
etoposide activates Chk1 and AICAR does not, but both activate p53 transcriptional
activity.
Ø PTX (+TdR) can block the DNA damage mediated by VP16 or AICAR and blocks p21
transcription. This provides strong evidence that DNA damage is required for VP16 or
AICAR activation of p53.
Ø PTX-activated AMPK, does not cause DNA damage and does not activate p21
transcription. Hence, AMPK activation per se does not activate p53
Ø We found that although both AICAR and VP16 lead to transcriptional activation of p53,
AICAR treatment does not lead to increase in pS345Chk1 but levels of pS15p53 and
pT68Chk2 are increased. On the contrary, VP16 treatment led to increase in the
phosphorylation of all these three proteins; pS345Chk1, pS15p53 and pT68Chk2. This
challenges the correlation between activation of Chk1, Chk2, phosphorylation of p53 at
ser15 and trans-activation of p53.
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Chapter 4

4

Interference of PTX with transcriptional activity of mutant p53 may help
to explain its effects against lung cancers

4.1

ABSTRACT

The role of p53 as a tumor suppressor gene is very well studied and p53 has been established as
one of the most frequently mutated genes in human cancers. Until a decade or two ago, it was
believed that the mutation of p53 most often led to a nonfunctional protein.

However,

substantial evidence has accumulated that supports the concept that DNA binding domain
mutations of p53, can also confer properties that intensify its oncogenic activity. Such mutant
p53 proteins with neomorphic activities are referred to as Gain-of-Function (GOF) mutant p53s.
Different missense mutations confer different and unique activities and the literature on this field
is quite extensive.

This chapter addresses a very unique phenomenon observed under PTX

treatment that PTX not only prevents transcriptional activation by wild type p53, but also
interfers with GOF mutant p53 transcription. Most human lung cancers have GOF mutp53s that
often lead to transcriptional activation of growth and chemoresistance promoting genes not
induced by wt p53. The previous chapter of this dissertation determined that PTX increases the
levels of WT p53 but blocks its transcriptional activity. Therefore, we hypothesized that PTX
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might also block the transcriptional activity of mutp53s. This proved to be the case.

4.2

DISCOVERY OF MUTANT P53 AND ITS ROLE IN CANCER

The p53 protein was first identified in a complex with the simian virus 40 large T- antigen (Lane
& Crawford, 1979). It was demonstrated that many tumors expressed abundant levels of this
protein, and that the levels of the p53 protein positively correlated with the progression of cancer
(DeLeo et al., 1979); thus, p53 was initially though to be an oncogene. This concept was
reinforced when ectopic expression of the newly cloned p53 cDNA was shown to cooperate with
oncogenic Ras to transform primary cells in culture (Eliyahu, Raz, Gruss, Givol, & Oren, 1984).
Later, when several groups compared the sequence of their cloned p53 cDNAs, the striking
results was that each clone differed in sequence (Levine & Oren, 2009). It was later recognized
that these early experiments demonstrating that p53 overexpression could transform cells and
promote in vivo tumor growth were actually performed with mutant version of p53 that has been
isolated from tumor cells (Hinds, Finlay, & Levine, 1989; Levine & Oren, 2009). Thus, the
concept of gain-of-function of mutant p53 came to be recognized. Mutation in p53 gene can lead
to three possible outcomes (Fig.4-1).
A) Loss of function
B) Dominant Negative behavior
C) Gain of function
4.2.1 Loss of function of p53
More than 85% of mutations found in the p53 gene are single point mutations that result in
missense proteins. Mutations, which lead to complete loss of p53 tumor suppresser function,
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would severely compromise the ability of the cells to respond to genotoxic stress. Mutations of
p53 can occur by deletion, insertion, truncation or point mutation and tumors with a mutant p53
allele very frequently subsequently undergo loss of heterozygosity with loss of the wild type
allele of p53 resulting in complete loss of p53 or p53 function. Some of these point mutations
lead to formation of protein which is functionally inactive (Fig.4-1) (Hollstein et al., 1994).
4.2.2 Dominant Negative Behavior
Point mutation in one allele results in a missense protein with loss of function of one allele.
Some of these mutations, especially when expressed in higher amount, can exert a dominant
negative effect on protein coded by the remaining wild-type allele. This results in an abrogation
of the ability of wt p53 to inhibit cellular transformation (Fig. 4-1) (Brosh & Rotter, 2009; Oren
& Rotter, 2010). This dominant negative behavior is either due to formation of mutant/wild type
co-tetramers (Chan, Siu, Lau, & Poon, 2004) or the incorporation of wild type p53 into mutant
p53 super-tetrameric aggregates (Xu et al., 2011). This is rare in human cancers as the wild type
allele is usually lost by deletion or gene conversion.
4.2.3 Gain of function (GOF) mutants of p53
Unlike most of the tumor suppressor genes, which have one allele inactivated by mutations or
truncations followed by silencing of the second wild type allele (Weinberg, 1997), the vast
majority of cancer-associated mutations in p53 are missense mutation with substitution of one
base pair, which lead to translation of a different amino acid in that position and can give rise to
a protein with an unique functionality. The great majority of these mutations are clustered in the
central-most region of the p53 known as the DNA binding domain (Fig. 4-2). Of the several
mutations known and mentioned in the literature, some occur at higher frequency and are known
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as “hot spot” mutations (Harris & Hollstein, 1994). The wild type p53 is a very short-lived
protein expressed at low steady state levels in normal conditions, but is stabilizes during any kind
of genotoxic or cellular stress. However, missense mutations lead to expression of altered full
length proteins with a substantially increased half life (Fig. 4-3)(Strano et al., 2007). Each
mutation leads to a very different and unique protein and protein function, and generalizations
about p53 across mutations can be misleading. The selection of inactivating mutations in p53
during tumor progression might be preserving their activity as dominant negative inhibitors of
wild type p53, but the extensive prior literature on this point provides enough evidence to say
that some missense mutation give an additional survival advantage; these mutant p53s are known
as Gain of Function mutants (GOF) (Fig.4-1, 2,3).
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Figure 4-1 Schematic representing differnces in the mutant forms of p53 at the
level of their transcriptional specificity
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GOF mutants most commonly consist of DBD
mutations
WT p53

GOF p53
mutant

DBD
(102-292)

R267P R273P

R158L

7

Figure 4-2 Structure of wt and Gain-of-function mutant p53.
Top) WT p53, Bottom) GOF p53, where read lines in the DNA binding domain represent the
mutations present in the cells lines used in this study.
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Figure 4-3. Schematic representation of difference in half-life and effects on
downstream cell processes after DNA damage.
A. Wild type p53, B. Gain-of-function mutp53.
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One of the clearest pieces of evidence for GOF effects derives from experiments in which the
expression of tumor derived mutant p53s in non-transformed, otherwise p53 null cells are
inoculated into mice; such constructed cell lines greatly increased their tumor forming ability in
nude mice compared with cells transfected with wt p53. Wolf et al. showed that L12, an AbMuLV-transformed, p53 null cells, when transfected with a tumor derived p53 gene, gave rise to
a L12 derived cell with mutant p53 which efficiently transcribed p53 mRNA and synthesized the
p53 protein. When injected into syngeneic mice, L12 derived cells expressing this mutant p53
protein showed much more tumorogenicity than parental L12 cells. Tumors formed by parental
L12 later regressed but tumors formed by L12 derived clones with mutp53 made lethal tumors,
suggested an advantage of survival gained by mutant p53 over loss of p53 function (Wolf,
Harris, & Rotter, 1984). Dittmer et al. reported that the expression of human or murine mutant
p53 in p53 null cells exerted a new and additional phenotype to these cells. They showed that
expression of mutant p53 in p53 null cells increases their tumorigenic potential in nude mice or
enhances plating efficiency in agar cell culture. Introduction of mutant p53 in p53 null cells
increased the expression of the gene regulated by the multidrug resistant enhancer promoter
element suggesting that other then loss of function, mutations can also lead to “Gain of
function”(Dittmer et al., 1993) which is oncogenic.
These pioneering studies were done either in cell culture or by injecting cells in nude mice.
However, to understand and confirm this phenomenon, mouse models were required to
demonstrate that mutation of p53 is not equivalent to loss of p53 function. Almost a decade after
the p53 knock out mouse was generated, two “knock- in” mouse of Li-Fraumeni Syndrome
(LFS) were generated (Lang et al., 2004; Olive et al., 2004). In an attempt to better recapitulate
the human disease, these groups created tumor derived mutp53 expressing, genetically
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engineered mice, by inserting a tumor derived p53 cDNA into the endogenous TP53 locus, using
homologous recombination. Two hot spot mutations were used; structural mutant p53 R172H
and the contact mutant p53R270H, which are murine equivalent of human p53 codon 175 and
273, respectively. Also, p53R172H/- and p53R270H/- mice developed biologically different
tumors compared to p53-/- mice, including a variety of carcinomas and more frequent
endothelial tumors. They showed that p53R172H/+ and p53R270H/+ mice developed allelespecific tumor behavior, which is quite distinct from that of p53+/- mice. This suggested that
there was a difference in tumor behavior upon loss of one allele versus mutation in one allele.
These results clearly suggested that mutation in p53 generated a genetically altered tumor along
with a more metastatic capability, supporting the hypothesis of GOF mutant p53 (Lang et al.,
2004; Olive et al., 2004). Similarly, in an analysis of a LFS patient, a germ line missense
mutation in TP53 have been shown to be associated with an earlier age (approximately 9 yrs)
onset of tumor when compared to germ line deletion in TP53, suggesting a gain of function
effect of missense p53 mutants in human tumors (Bougeard et al., 2008). Also, several studies
have shown that the presence and level of expression of mutant p53 has a strong co-relation with
poor prognosis of several types of human tumors, including breast cancer (Elledge et al., 1993;
Olivier et al., 2006).
4.3

VARIOUS ASPECTS OF CELLULAR PROGRAMMING MODULATED BY
MUTANT P53:

In addition to knockout mice and human epidemiology data, cell based assays also have
implicated that mutant p53 affects different aspects of tumorigenesis by targeting different
modes of cellular programming. Some of them are discussed below (Fig.4-4):
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4.3.1 RNA synthesis and proliferation
Bossi et al showed that inhibition of mutant p53 by RNA interference reduces cell proliferation
in vitro, and in vivo it increases tumorigenicity and resistance to cancer drugs. Overall they
demonstrated that knock down of mutant p53 weakens the aggressiveness of human cancer cells
and provides evidence of the GOF hypothesis (Bossi et al., 2006). A mutant form of p53 protein
interacted with the NF-Y transcription factor and, after DNA damage, this interaction causes a
p53/NF-Y dependent increase in RNA synthesis. They showed that mutant p53 binds NF-Y
target promoters and, upon DNA damage, recruits p300, leading to histone acetylation. The
recruitment of mutant p53 to the CCAAT sites was severely impaired upon abrogation of NF-Y
expression. Endogenous NF-Y, mutant p53, and p300 proteins formed a triplex complex upon
DNA damage. This study suggested that aberrant transcriptional regulation might explain the
ability of mutant p53 proteins to act as an oncogenic factor (Di Agostino et al., 2006)
4.3.2 Cell Survival
Various experiments done for the purpose of differentiating loss of function of p53 and from the
effects of expression of a mutant p53 suggested that mutant p53 showed an advantage of survival
over loss of p53. Stambolsky et al. showed that mutant p53 can be recruited to the vitamin Dreceptor (VDR) regulated genes and modulates their expression. Mutant p53 can increase the
accumulation of VDR in the nucleus. It can augment the transactivation of some genes and
relieve the repression of others. Overall, mutant p53 can convert vitamin D into an anti-apoptotic
agent that promotes cell growth and survival of tumor cells (Stambolsky et al., 2010).
4.3.3 Chemoresistance
Several studies have compared the properties of the cells with and without p53 mutations within
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the same cell population. These experiments were usually done by introducing human tumor
derived mutant p53 species into p53-null H1299 cells. Clonogenic survival assays performed on
these cells suggested that cells overexpressing the His175 p53 mutant, but not the His273
mutant, recover preferentially from etoposide treatment. Moreover, etoposide-induced apoptosis
were substantially reduced in the presence of p53His175 or p53His179, whereas p53His273 and
p53Trp248 did not have much protective effect. In contrast, both p53His175 and p53His273
showed increased resistance against low concentrations of cisplatin, but resistance reduced with
higher concentration and showed no protection at all against high concentrations. This suggested
that particular p53 mutants might offer a selective survival advantage to tumor cells during
chemotherapy. These findings define a new type of mutant p53 selective gain of function which
may compromise the efficacy of cancer chemotherapy (Fig.4-3,4) (Blandino, Levine, & Oren,
2002).
4.3.4 Abnormal centrosome and spindle checkpoints
Fibroblasts from Li-Fraumeni syndrome heterozygotes expressing mutant p53s, when exposed to
a spindle depolymerizing agent, generates polyploid cells more frequently than p53 null
fibroblasts from LFS heterozygotes. This study also showed that, this class of dominant gain of
function mutants (p53-RSC (relaxed spindle checkpoint allele)) does not need any new
transcriptional activity of mutant p53 to exert this behavior. This suggested that one of the ways
by which mutant gain of function p53 can help tumor survival and progression can be a direct
promotion of genetic instability (Gualberto, Aldape, Kozakiewicz, & Tlsty, 1998).
4.3.5 Gene amplification
Albor et al. showed that mutant p53 proteins can interact and activate topoisomerase I, and that
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this could be a mechanism for induction of genomic instability by mutant p53 proteins (Albor,
Kaku, & Kulesz-Martin, 1988). Later, this group followed up with the study of the effects of
exogenous mutant p53 protein expression in genomic stability in human p53-/- Saos-2 cells.
They established the correlation between the presence of mutant p53 and an increased number of
PALA (N-(phosphoacetyl)-L-apartate)-resistant colonies, a phenotype caused by gene
amplification of the aspartate transcarbamylase gene. They showed by immunoprecipitation that
mutant p53 interacts with topoisomerase I and upon continuous expression of mutant p53 for
several generations, the number of PALA resistant colonies increases after subsequent exposure
of PALA. Furthermore, following exposure to camptothecin (which stabilizes topoisomerase I
cleavage complexes and mediates non homologous recombination) the number of PALA
resistant colonies increased. When combining the expression of mutant p53 with exposure to
camptothecin, an additive increase in the number of PALA resistant colonies was evident. These
studies suggested that mutant p53 mediated gene amplification processes independent of its
capability to inactivate wild type p53 protein but dependent on interaction of mutant p53 with
topoisomerase I (El-Hizawi, Lagowski, Kulesz-Martin, & Albor, 2002).
4.3.6 Somatic cell reprogramming and stem cell characteristics
A well-known hallmark of some of the most aggressive and deadly cancers is a poorly
differentiated phenotype thought to result from the presence of stem-like cancer cells. (BenPorath et al., 2008). The increased expression of a set of embryonic stem cell (ESC) genes and a
decreases expression of genes that are targets for polycomb identifies a poorly differentiated lung
adenocarcinoma. This gene expression signature was the marker of poor prognosis and worse
overall survival in lung adenocarcinomas but not all poorly differentiated non-small cell lung
cancers exhibit such a gene expression profile (Hassan, Chen, Kalemkerian, Wicha, & Beer,
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2009) Human cancers are known to consist of a heterogenous set of diseases which are
from one another by pathologic presentation and molecular signature.
Breast cancer in one of the best fitting example of this phenomenon and each breast cancer
subtype on the basis of pathological presentation is also heterogenous when viewed on a
molecular basis. Mizuno et al. studied if a p53 mutation could allow cells within a tumor to
acquire a stem cell-like state by coordinating expression of stem cell identified genes. Using
microarray and database studies, they demonstrated that breast and lung cancers with p53
mutations exhibit a stem cell-like transcriptional pattern. These data suggest the model that loss
of p53 function enables acquisition of stem cell properties, which are positively selected during
tumor progression (Mizuno, Spike, Wahl, & Levine, 2010).
4.3.7 Disruption of tissue architecture
Breast cancer is thought to arise from mammary epithelial cells found in acini, which
collectively form terminal ductal lobular units.

Each acinus consists of a single layer of

polarized luminal epithelial cells surrounding a hollow lumen (Bissell, Radisky, Rizki, Weaver,
& Petersen, 2002). Freed-Pastor et al. used 3D culture system to understand the involvement of
mutant p53 in the distortion of tissue architecture. They showed that depletion of mutant p53 is
sufficient to phenotypically revert breast cancer cells to more acinar-like morphology (FreedPastor et al., 2012)
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Figure 4-4 Schematic representation of mechanism of mutp53 mediated induction
of chemo-resistance in cancer cells
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4.3.8 Angiogenesis
Angiogenesis is one of the requirements for tumor growth and progression because unlimited
growth of cells demands high supply of nutrient and thus blood supply. There are some studies,
which suggest that mutant p53 transcriptional programming includes some genes like ID4, which
are directly involved in angiogenesis. ID4 (inhibitor of DNA binding 4) is a member of a family
of proteins that function as dominant-negative regulators of basic helix-loop-helix transcription
factors. The ID4 protein binds to and stabilizes mRNAs encoding pro-angiogenic factors IL8 and
GRO-alpha. This results in the increase of the angiogenic potential of cancer cells expressing
mutant p53 (Fontemaggi et al., 2009)
4.3.9 Migration, invasion and metastasis
One of the biggest challenges faced cancer therapeutics is migration, invasion and metastasis of
cancer cells. There is some evidence that suggests that mutant p53 might play a role of an
oncogene by helping and promoting cell migration, invasion, and metastasis. When immune
deficient SCID mice are transplanted with human T cell acute lymphoblastic leukemia (T-ALL),
only those cells which either possessed a mutant p53 gene or lacked the wild type allele
infiltrated and induced the lethal hematopoietic disease. The mutant p53 genes exert a distinct
pattern in vivo and in vitro: mutants which showed greatest cell proliferation of T-ALL lines in
vitro and colony formation in methylcellulose cultures, also showed greatest tissue invasiveness
of T-ALL cells in vivo (Hsiao et al., 1994). It was clear that mutant p53 gave an additional
advantage for survival and invasion in vivo and in vitro over lack of wild type p53 function.
Some specific hot spot mutants of p53 play a role in the generation of lymphohematopoietic
metastatic potential and tissue invasiveness as assayed in SCID mice, whereas the expression of
wild-type p53 is capable of keeping this metastatic potential in check (Hsiao et al., 1994).
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4.4

MOLECULAR MECHANISM OF TUMOR PROMOTING ACTIVITY OF GOF
MUTANT P53

All known mutants of p53 are either loss of function or gain of function proteins. A huge focus
of researchers in the p53 field is to understand and elucidate the underlying molecular
mechanism of the GOF behavior. A significant amount of research has been done to address this
question and there are several molecular mechanisms that have been proposed to explain the gain
of function of mutant p53. These are discussed below.

4.4.1 Interaction and Inhibition of the activity of other p53 family proteins
Mutant p53 has been suggested to interact, sequester and interfere with the activity of proteins
involved in the antitumor protective mechanisms of cells. The p63 and p73 proteins, which are
not targets of WT p53, have been shown to interact with gain-of-function mutant p53 (Fig.4-3)
(Di Como, Gaiddon, & Prives, 1999; Marin et al., 2000). The p63 and p73 genes each encode
several isoforms derived by combination of multiple transcription start sites and alternative
splicing. Some of those isoforms share or mimic WT p53 function. Upon expression or
accumulation of mutant p53, p63 and p73 bind to mutant p53 and thus cannot perform their
transcriptional activity, leading to deregulation of p63 and p73 target genes. p63 and p73 target
genes are mainly involved in apoptosis and cell proliferation regulation. Thus, the binding of
mutant p53 to p63 and p73 severely diminishes their transcriptional activity and diminishes
apoptosis (Irwin et al., 2003; Strano et al., 2000). The core domain of the mutant p53 is sufficient
for the binding to p63 and p73 (Gaiddon, Lokshin, Ahn, Zhang, & Prives, 2001; Strano et al.,
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2002; Strano & Blandino, 2003) Thus, this region of mut p53 might serve as a protein-protein
interaction module which contributes to gain of function activity. Keeping the complexity of the
proteins involved in the interaction network of the WT p53 in mind, it would not be unexpected
to find additional new interacting partners of GOF mutant p53 in the future.
4.4.2 Mutant p53 as a bona-fide transcription factor
Almost a decade of research has investigated this aspect of gain of function p53. Levin's group
reported that a p53 mutant with mutation at two critical residues at the N-terminus loses its gain
of function activity (Lin, FAU, & Levine, 1995). A genome-wide approach has shown that
mutant p53 modulates the levels of numerous transcripts. Most of these genes are found to be
involved in cell cycle, cell growth and cell proliferation, cell migration, angeiogenesis, and
chemoresistance suggesting that regulation of

these genes by GOF mutant p53 could be

pivotal in its function as a pro-oncogenic protein (S. Deb, Jackson, Subler, & Martin, 1992; M.
W. Frazier et al., 1998a; Iwanaga & Jeang, 2003; Y. I. Lee et al., 2000; Ludes-Meyers et al.,
1996; Margulies & Sehgal, 1993; Mizuarai, Yamanaka, & Kotani, 2006; Scian et al., 1203;
Subler, Martin, & Deb, 1994; Tsutsumi-Ishii, Tadokoro, Hanaoka, & Tsuchida, 1995).
Consequently, gain-of-function mutant p53 might trigger other pathways by modulating the
transcription of genes, which may represent the molecular basis of the broad-spectrum gain-offunction activity. Despite continuous efforts from the scientific community, the understanding of
molecular details of the transcription activity of mutant p53 is still very scarce mainly due to
different behavior of each mutant.

However, some of the possible mechanisms for this

regulation of transcription by mutant p53 are as follows;
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4.4.3 Interaction of gain-of-function mutant p53 with transcription factors leading to
differential regulation of WT p53 targets.
Wild type p53 has been shown to interact with a number of transcription factors (E2F1, SP1, NFY, YY1, TBP, TAFs), giving rise to protein-protein-DNA complexes.

Mostly, these

macromolecular complexes modulate the transcription of genes whose promoters lack wild type
p53 binding sites. Often these promoters are inhibited by wt p53 in specific phases of the cell
cycle after DNA damage (Farmer, Friedlander, Colgan, Manley, & Prives, 1996; Lu & Levine,
1995; Manni et al., 2001; mbriano et al., 2005; St Clair et al., 2004). Some studies have shown
interaction of wt p53 with NF-Y on CCAAT box-containing promoters, and upon DNA damage
this complex recruits histone deacetylases (HDACs) and releases histone acetyl transferase
(HATs), causing repression of the key cell cycle control genes like cyclin A, cyclin B1, cdk1,
cdc25c and cdk1-associated kinase activity (mbriano et al., 2005). Interestingly, Di Agostino
recently reported that mutant p53 interacts with NF-Y upon DNA damage and leads to response
opposite to that of wt p53. This interaction provoked the expression of cyclin A, cyclin B1,
cdk1, cdc25c and cdk1-associated kinase activity leading to mutp53/NF-Y complex-dependent
increase in DNA synthesis. Upon DNA damage, mutant p53 binds NF-Y target promoters and
recruits p300, leading to histone acetylation and promoting the initiation of transcription of those
genes. They further showed that even in normal conditions, NF-Y and mutant p53 are present on
NF-Y regulated gene promoters along with HDACs, independent of DNA damage.

This

suggests that binding of mutant p53 with NF-Y is dependent on the presence of NF-Y and on the
CCAAT box of the promoter; upon DNA damage this association increases. This leads to the
recruitment of the p300 HATs in a mutant p53-dependent manner. The switch between p300 and
HDACs is shifted towards increased acetylation and reduced methylation of neighboring
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histones leading to the promotion of initiation of transcription from these promoters. This
observation opened up several interesting questions. The foremost is: since both WT and mutant
p53 can interact with both p300 or HDACs in complex containing NF-Y, then how are p300 or
HDACs recruited in an opposed manner by Wt and mutant p53?

Second, as mutant p53 is

present in a complex with NF-Y/HDACs in unstressed condition, what is the role of this complex
under these conditions ? However, the overall conclusion of the study by Di Agostino et. al. was
that mutant p53 enhances transcription of proliferative targets of NF-Y.
In fact, mutp53 interacts with many other sequence specific transcription factors and shows
differential regulation from that by wt p53. One such factor is Sp-1 which regulates transcription
by binding to Sp-1-response elements (Sp-1-REs) and interacts with both mut p53 as well as wt
p53 (Chicas, Molina, & Bargonetti, 2000; Gualberto et al., 1998). Transcription regulation
outcomes by p53:Sp-1 interaction depends on the type of p53 protein. While wt p53 leads to
inhibition of Sp-1 dependent transcription activation, presumably by interfering with the DNA
binding of Sp-1 (Bargonetti, Chicas, White, & Prives, 1997), mutp53 elicits co-operative effects
on Sp-1 mediated transcription activation. Similarly, wt p53 interaction with the proto-oncogene
ETS-1 is inhibitory to its activity (E. Kim et al., 2003; Pastorcic & Das, 2000), whereas mutp53:
ETS-1 interaction promotes ETS-1 mediation transcription activation (Sampath et al., 2001).
This suggest that the macromolecular complex assemblies containing WT or mut p53 are
functionally distinct.
Interaction of gain-of-function mutant p53 with DNA.
The question of whether mutp53 transactivation may require its direct binding with DNA has
been a discussion of controversy for a long time. This is mainly due to a lack of evidence
suggesting that mutp53 can bind to DNA with specificity. This question has been approached
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mainly by analysis of the ability of mutp53 proteins to bind at wt p53 recognition sequences, and
the lack of binding was interpreted as an inability of mutp53 to bind DNA specifically.
However, most of the promoters activated by mutp53 do not contain wt p53 binding consensus
sequences nor show similarity to it, suggesting that mutp53 regulates these promoter by binding
at response elements different than wt p53-Res (Dittmer et al., 1993; M. W. Frazier et al., 1998b;
Gualberto et al., 1998; Tsutsumi-Ishii et al., 1995; Yang, Pater, & Tang, 1999). However, from
studies performed on mut p53-regulated promoters and not based on wt p53-REs , it was clear
that mutp53 binds with DNA (Bargonetti et al., 1997; Chicas et al., 2000; Y. I. Lee et al., 0907;
Zalcenstein et al., 2003). Chromatin immunoprecipitation studies reveled that mutp53 proteins
do physically bind with their responsive promoters in vivo, suggesting that mutp53 targets DNA
in a specific manner but independent of Wtp53 canonical binding sequence (Zalcenstein et al.,
2003). One of the biggest barriers in the determination of the putative binding site for mutp53 on
DNA is that most of the promoters activated by mutp53 do not show any sequence homology of
mut p53 binding site. However, Kim and Deppert's lab has proposed the idea that mutp53
binding with DNA is not sequence specific but it is largely determined by DNA structure. This
idea was originated after the observation that mutp53, but not wt p53, interacts with Matrix
Attachment Region (MAR) elements, which are regulatory DNA sequences shown to play a role
in high order chromatin organization, and chromatin modification (E. Kim & Deppert, 2004).
Weissker et al tested the interaction of the mutant p53 with DNA representing high complexity
with regard to sequence and secondary structure. They showed a specific binding of the mutp53
with lambda DNA and suggested the possibility that p53 might be able to interact with nuclear
MAR DNA sequences (Weissker, Muller, Homfeld, & Deppert, 1992).

There are several

studies which suggest that wt and mutp53 interact with promoters as macromolecular complexes
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that show distinct functionality. On the other hand, it is shown that regulation of the MDR1
promoter by wt p53 and mutp53 are from different promoter regions (Sampath et al., 2001).
There have been several studies focusing on defining the new targets of mutp53 which are now
categorized as neo-morphic genes.
4.5

POTENTIAL TRANSCRIPTION TARGET GENES OF MUTANT P53

The mechanism for oncogenicity of mutp53 which has been studied the most, is transcriptional
regulation of mutp53. Mutp53 have been reported to modulate the transcription of various genes
(Table 4.1) that are briefly discussed below. These genes are: MDR1, NfkB2, Axl, PCNA,
hTERT,, hsp70 and EGFR, all of which have been functionally implicated in increased
aggressive behavior of tumors. The characteristics of each of these neomorphic p53 targets are
briefly summarized, below.
4.5.1 Multidrug resistant gene 1 (MDR1)
Each cancer has different response towards cytotoxic drugs; some are relatively sensitive and
some are more refractory.

Multidrug resistance (MDR) describes the phenomenon of an

acquired simultaneous resistance to unrelated drugs. Multidrug resistance was first described in
1969 and than in 1970 when chinese hamster ovarian cancer cells were exposed to increasing
concentration of actinomycin D (Biedler & Riehm, 1970; Simard & Cassingena, 1969). Though
these cells were selected with one drug, they were later found to be resistant to a range of
clinically important natural products, including anthracyclines (doxorubicin and duanomycin),
the vinca alkaloids (vincristine, vinblastin and vindesine), etoposide and colchicine. Extensive
studies with cell lines and transplantable tumors have shown that MDR can develop rapidly. The
genes involved in MDR have been identified and their role in drug resistance has been confirmed
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by gene transfer. Mechanisms identified to date include reduced drug accumulation, involved the
P-glyco-protein (Pgp; mdr1 gene) (Childs & Ling, 1994) mainly, but also the MDR-associated
protein (mrp) gene (Cole et al., 1992). MDR cells overexpressing MDR1 show resistance to a
broad spectrum of drug structures and thus it has been thought that Pgp may be acting by altering
the intracellular pH or modifying membrane potential. Classic studies demonstrated that cells
exposed to increasing concentrations of any of the natural products (except bleomycin)
underwent amplification of the mdr gene, with the appearance of homogeneously staining
regions in CHO cells (Biedler & Riehm, 1970) and double minute chromosomes in mouse and
human cells (Biedler & Riehm, 1970). Studies done with purified MDR1 and functionally
reconstituting it into liposomes to investigate its properties show that Pgp alone is sufficient to
transport many drugs.
4.5.1.1 MDR1 and mutant p53
The most frequently expressed drug resistance genes, MDR1 and MRP1, occur in human tumors
with mutant p53 and their over expression is correlated with the presence and transcriptional
activity of mutant p53 (de Kant, Heide, Thiede, Herrmann, & Rochlitz, 1996; Fukushima et al.,
1999; Galimberti et al., 1998; Oka et al., 1997; Sampath et al., 1204). Sampath et al showed that
mutant p53 did not activate either the MRP1 promoter or the endogenous gene but strongly upregulated the MDR1 promoter and expression of the endogenous MDR1 gene. Transient
transfection of mutant p53 caused increased expression of endogenous MDR1 in comparison to
empty vector or transcriptionally inactive mutant p53 transfection. Oka et al studied some
surgically removed colorectal tumors using immuno-histochemistry and found that p53 and
MDR1 were co-expressed in a significant number of samples (P < 0.002). Although they did not
find any relationship between MDR1 or p53 protein accumulation with histologic grade or stage
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but their study clearly demonstrated that MDR1 expression is closely associated with p53 protein
accumulation in human colorectal cancers (Oka et al., 1997).
4.5.1.2 MDR1 and cancer
There are several studies, which suggest that levels of MDR1 are correlated with poor prognosis
of cancer chemotherapy. The most significant observations were made in leukemia and pediatric
cancers. For example, using an anti-MDR1 monoclonal antibody, Ma et al. were the first to
demonstrate that MDR1 may be overexpressed in acute myelogenous leukemia (AML) (Ma et
al., 1987). In two patients, leukemia cells were negative for MDR1 at diagnosis of AML, but
one patient became positive at first relapse and the other on recovering from second induction
chemotherapy.

Subsequently, two large studies correlated mdr1 mRNA expression with

response to treatment in acute leukemia and showed that the higher the expression of MDR1, the
worse was the response of the disease to chemotherapeutics. (Pirker et al., 1991; SSato et al.,
1990). Development of agents to overcome multidrug resistance (MDR) is important in cancer
chemotherapy.
4.5.2 Nuclear factor Kappa B 2 (NFkB2)
The Rel/NFkappaB family of transcription factors is involved in multiple cellular processes,
including inflammation, cell cycle regulation, apoptosis and oncogenesis. Constitutive activation
of NFkappaB has been described in a great number of solid tumors and this activation appears to
support cancer cell survival and to reduce the sensitivity against chemotherapeutic drugs (Scian
et al., 2005). Additionally, some of these drugs induce this transcription factor and, through this
mechanism, lower their cytotoxic potential (Bug & Dobbelstein, 2011). Nuclear factor-κB2/p100
has been reported to promote endometrial carcinoma (a common cancer in females) cell survival
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under hypoxia in a HIF-1α independent manner. Inhibition of NFkappaB has been shown to
enhance the sensitivity to antineoplastic- or radiation-induced apoptosis in vitro and in vivo
(Yeramian et al., 2011)

4.5.3 AXL
The Axl subfamily of mammalian receptor tyrosine kinases (RTKs), also known as the TAM
family, consists of Axl, Tyro3 (or Sky), and Mer. Axl was first isolated during a transfection
experiment using cDNA from a patient with myeloproliferative disorders (Crosier & Crosier,
1997; Neubauer et al., 1994). Axl is a 140 kDa protein has been found to be involved in the
transformation of various cell types and thus believed to have oncogenic potential (Janssen et al.,
1991; McCloskey, Pierce, Koski, Varnum, & Liu, 1994). Axl expression is observed
predominantly in fibroblasts, myeloid progenitor cells, macrophages, neural tissue, ovarian
follicles, cardiac and skeleton muscle but rarely present in normal epithelial cells (Crosier &
Crosier, 1997).
TAM receptor tyrosine kinases are known to play a role in cell adhesion as well as in
intracellular signaling. In fact, it was observed that Axl mediates adhesion of 32D myeloid cell
line (McCloskey et al., 1997), whereas Lee et al. (1999), demonstrated that increased expression
of the Axl receptor induces transformation of NIH 3T3 cells into highly tumorigenic cells in
nude mice (W. P. Lee et al., 1999).
4.5.3.1 Axl and cancers
Axl was described in CML patients and its overexpression in fibroblasts suggested Axl’s
transforming activity (Janssen et al., 1218; McCloskey et al., 1994; O'Bryan et al., 1991).
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Following its original identification, upregulation of Axl has been reported in a variety of
cancers including breast, gastric, prostate, ovarian and lung cancers (Berclaz et al., 2001; Jacob
et al., 1992; Shieh et al., 2005; W. Sun, Fujimoto, & Tamaya, 2004; Wimmel, Glitz, Kraus,
Roeder, & Schuermann, 2001b; Wu et al., 2002)
4.5.3.2 Metastatic potential of Axl
The expression of Axl was found to be higher in the metastatic prostate carcinoma cell line
DU145 than in the less aggressive prostate carcinoma cell line PC-3 or in normal prostate cells
(Jacob et al., 0805; Sainaghi et al., 2005). Moreover, Sainaghi et al. also showed that Axl/Gas6
interaction induces mitogenic activity in DU145 and PC-3 cell lines, which is not mediated by
inhibition of apoptosis and is proportional to Axl expression (Sainaghi et al., 2005).
4.5.3.3 The role of Axl in non-small cell lung cancer (NSCLC): A key player in resistance
against chemotherapy.
Overexpression of Axl has been related to increased resistance of cancer cells to
chemotherapeutic drugs in numerous types of cancer. Axl has been shown to be overexpressed
in NSCLC (Shieh et al., 0221; Wimmel, Glitz, Kraus, Roeder, & Schuermann, 2001a) and,
recently, two independent studies reinforced the idea that Axl is important for NSCLC and
demonstrated that Axl plays a key role in acquiring resistance to chemotherapy. One of these
reports by Zhang et al. (2012) demonstrated increased activation of Axl and evidence for
epithelial-to-mesenchymal transition (EMT) in the mutant epidermal growth factor receptor
(EGFR) lung cancer models with acquired resistance to erlotinib (a tyrosine kinase inhibitor used
in the treatment of lung cancer) in vitro and in vivo. Inhibition of Axl led to restoration of
sensitivity to erlotinib, indicating that Axl may represent a promising therapeutic target to
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prevent or overcome acquired resistance to drugs (Zhang et al., 2010).
4.5.3.4 The role of mutant p53 in Axl transcription regulation
The receptor protein tyrosine kinase Axl is upregulated at both RNA and protein levels in H1299
lung cancer cells expressing any of a few mutant p53s-R175H, -R273H, and -D281G. On the
other hand, knockdown of endogenous mutant p53 levels in human lung cancer cells H1048
(p53-R273C) and H1437 (p53-R267P) resulted in reduction in the level of Axl as well. Using
ChIP, they showed the direct nucleation of GOF p53 on the Axl promoter and facilitation of the
acetylation of the Axl promoter, suggesting that mutp53 regulates transcriptional activation of
the Axl gene. Furthermore, knockdown of Axl using siRNA led to decrease tumorogenicity and
migration of cancer cells, suggesting that increase in Axl levels by mutp53, help in cancer
progression and survival. (Vaughan et al., 2012).
4.5.4 Proliferating Cell Nuclear Antigen (PCNA)
PCNA is known to be involved in the DNA replication and thus molecular marker for cell
proliferation. PCNA was first identified in the sera of group of patients with systemic lupus
erythematosus,

as

an

antigen

to

an

autoimmune

antibody

(Mathews,

Bernstein,

Franza,BR,Jr,Garrels., & Garrels, 1984). Later studies showed that this antigen was actively
expressed in proliferating human cancer cells and showed a pattern of expression similar to a
‘cyclin’ protein with peak expression during the late G1 and S phase (Bravo R FAU - Fey,,S.J. et
al., 0222). Three identical PCNA molecules associate in a head-to-tail fashion to form a
homotrimeric ring that encircles the DNA double helix as a sliding clamp and make a critical
platform on replicating DNA for the coordinate recruitment and regulation of other proteins
essential for DNA replication.

PCNA-interacting proteins important for DNA metabolism
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include polymerases, ligases, topoisomerases, and proteins controlling replication initiation, cell
cycle control, chromatin and epigenetic regulation, gene transcription, cell survival, and
metabolism (Maga & Hubscher, 2003; Moldovan, Pfander, & Jentsch, 2007; Naryzhny & Lee,
2010; Ulrich & Takahashi, 2013; Warbrick, 2000).
4.5.4.1 PCNA and Cancer
PCNA engenders special interest among cancer researchers because of its role in cell
proliferation. Because cell growth is a requirement for cancer progression at both primary and
metastatic sites, and PCNA is an essential factor for DNA replication, inhibition of PCNA has
been exploited as an anticancer strategy. Due to its involvement in more than one cell survival
mechanisms, circumvention of its inhibition by cells (developing resistance) is less likely than
therapies targeting other signaling pathways (Stoimenov & Helleday, 2009). Small molecule
inhibitors and peptides against PCNA have been used to target it and study its mechanism and
function. PCNA has also been widely used as a tumor marker, but there are conflicting results
regarding the correlation between PCNA expression in tumor tissues and patient prognosis
(Grossi et al., 2003; Heimann, Ferguson, Recant, & Hellman, 1997; Wang et al., 2006).
4.5.4.2 The role of mutant p53 in transcription of PCNA
Shivkumar et.al have shown that low levels of wild-type p53 transcriptionally activate the human
PCNA promoter but higher levels of wild-type p53 inhibit promoter activation in vivo.
Interestingly, in contrast to what is seen with wt p53, expression of tumor derived mutant p53 at
low levels failed to activate the PCNA promoter but at higher levels significantly increased the
transcription of PCNA (Shivakumar, Brown, Deb, & Deb, 1995). This study indicated that mild
DNA damage which moderately elevates wt p53 levels increases the expression of PCNA,
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probably to assist DNA repair. As mutant p53 is always present at high levels in tumor cells,
they constitutively induce the expression of PCNA to avail the cell proliferation property of
PCNA. They also showed that where wild-type p53 binds to the human PCNA promoter in a
sequence specific manner, a tumor-derived p53 mutant does not require the wild-type p53
response element for transactivation of the human PCNA promoter (Shivakumar et al., 1995).
4.5.5 Human Telomerase Reverse Transcriptase (HTERT)
The ribonucleoprotein complex telomerase is continuously expressed in stem and germ cells and
repressed in most normal somatic cells. Almost 70–90% of cancer cells stably express this
enzyme (Shay & Bacchetti, 1997), which is reactivated during malignant transformation. This
reactivation grants unlimited proliferation capacity for the tumor cells by de novo synthesis of
telomeric (TTAGGG)n sequences, circumventing the ‘‘end-replication problem’’ of DNA
synthesis (Dahse, Fiedler, & Ernst, 1997; N. W. Kim et al., 1994; Mansfield et al., 2007;
Smogorzewska & de Lange, 2004). Inactivation of mammalian telomerase leads to telomere
attrition, eventually leading to uncapped telomeres, which elicit a DNA damage response and
cell cycle arrest or death.
4.5.5.1 hTERT and cancer
It has been shown that telomerase activity is strongly correlated with the state of malignancy and
metastatic potential of cancer cells. hTERT has been suggested to be a useful molecular marker
in cancer prognosis.

hTERT represents the catalytic subunit of telomerase with reverse

transcriptase activity (Albanell et al., 1997; Bryan, Sperger, Chapman, & Cech, 1998;
Smogorzewska & de Lange, 2004; Triginelli et al., 2006; Uen et al., 2007). Telomerase as an
enzyme consist of two subunits, an RNA template molecule known as hTERC and enzyme unit

245

hTERT. To render its enzymatic activity hTERT needs hTERC (Albanell et al., 1997; Bryan et
al., 1998; Dahse et al., 1997; N. W. Kim et al., 1994; Mansfield et al., 2007; Smogorzewska & de
Lange, 2004; Triginelli et al., 2006; Uen et al., 2007) and various telomerase associated proteins
(Smogorzewska & de Lange, 2004).
4.5.5.2 Transcription of hTERT by mutant p53 and other oncogenic factors.
Since transcription activity of mutant p53 has been correlated with transcription regulation of
various genes, Scian et al. in 2004, investigated and, indeed, showed that hTERT is a
transcriptional target of GOF mutp53 using microarray analysis, later confirmed by qPCR
analysis (Scian et al., 2004). Transient transcriptional assays, testing the ability of tumor derived
mutant p53 to mediate transactivation of hTERT promoter, suggested that mutp53 transactivates
the hTERT promoter. ChIP followed by qPCR analysis demonstrated that mutp53 was present
on the hTERT promoter suggesting its involvement in transactivation of the gene (Scian et al.,
2004).

4.5.6 Heat Shock protein 70 (hsp70)
One class of the heat shock proteins (Hsp70s) are 70 kDa, conserved, ubiquitously expressed and
consist of eight homologous chaperones. These proteins play a crucial role in protein folding
and their translocation from one compartment to the other of the cell.

Hsp70, a protein

unfolding machine, binds and releases stretches of hydrophobic amino acids in an ATP
dependent process (Morano, 2007; Tavaria, Gabriele, Kola, & Anderson, 1996). Hsp70 proteins
have a substrate-recognizing domain, which interacts with sequences of hydrophobic amino acid
residues in newly synthesized proteins as they emerge from the ribosomes. Hsp70 binds tightly
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to partially synthesized protein sequences and prevents them from aggregating and being
rendered nonfunctional.

When the protein is synthesized, a nucleotide exchange factor

stimulates the release of ADP and binding of fresh ATP, opening the binding pocket of Hsp70.
Then the client protein is free to fold on its own, or to be transferred to other chaperones for
further processing
4.5.6.1 Hsp70 and cancer and its transcriptional regulation by mutant p53
Hsp70 has been implicated in four crucial steps of tumorigenesis: (Ciocca, Arrigo, &
Calderwood, 2013) (1) stabilizing oncogenic proteins (Gray, Prince, Cheng, Stevenson, &
Calderwood, 2008; Khaleque et al., 2005) (2) inhibiting programmed cell death (Garrido et al.,
0212) and replicative senescence; (3) induction of tumor angiogenesis (J. Sun & Liao, 2004) (4)
activation of invasion and metastasis (Durech, Vojtesek, & Muller, 2012; J. Sun & Liao, 2004).
Most of the client proteins for the hsp70-hsp90 complex participate in functions that promote cell
growth, proliferation, and cell survival associated with carcinogenesis. The mechanisms of the
induction of HSP70/90 in cancer are not fully clear. Tsutsumi-Ishii et. al showed that mutant p53
transactivates HSP70 and analysis using in vitro mutagenesis of the heat shock response element
(HSE) suggests that a HSE with heat shock factor binding ability is required for transactivation
of the heat shock protein70 promoter by mutated p53 genes. (Tsutsumi-Ishii, Tadokoro,
Hanaoka, & Tsuchida, 0519)
4.5.7 Epidermal growth factor receptor (EGFR)
The ErbB transmembrane receptor family consist of various members including, EGFR (ErbB1),
ErbB2 (HER2/neu), ErbB3 (HER3), and ErbB4 (HER4). These receptors are structurally similar
and consist of three domains: an extracellular domain, a trans-membrane domain, and an
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intracellular domain. The extracellular domain has a ligand-binding region, and several ligands,
including Epidermal Growth Factor (EGF) bind to it. The ligand binding leads to receptor
homo- or hetero-dimerization between EGFR and other ErbB family members at the cell surface,
causing internalization of the dimerized receptor.

The receptor dimerization results in

autophosphorylation of the intracellular EGFR tyrosine kinase domain. The phosphorylated
tyrosine kinase stimulates an intracellular signal transduction cascade which leads to activation
of several downstream pathways (including the Ras-Raf-MEK-ERK, PI3K- AKT-mTOR, and
JAK-STAT3 pathways), leading to cell proliferation and growth (Scaltriti & Baselga, 2003;
Toyooka et al., 2011).
4.5.7.1 EGFR and Cancer
EGFR tyrosine kinase mutations are one of the most frequent mutations in human cancers, which
usually occur between exons 18 to 21 of the EGFR gene. These mutations leads to constitutively
activated ligand-independent EGFR protein production, leading to carcinogenesis (Lynch et al.,
2004; Paez et al., 2004). About 80-90% of EGFR mutations are either short in-frame deletions
in exon 19 or point mutations resulting in substitution of arginine for lysine at codon 858
(L858R) in exon 21(Mitsudomi & Yatabe, 2007). Cancer cells with constitutively active mutant
EGFR are highly dependent on the ligand-independent activity of this protein or its
overexpression, a phenomenon called “oncogene addiction” (Gazdar, Shigematsu, Herz, &
Minna, 2004). This constitutive expression or activity allows cancer cells to circumvent the
normal cell growth and proliferation regulation mechanism and, at the same time, the resulting
oncogenic addiction leads to a greater sensitivity of these cancers towards small molecule
inhibitors of these oncogenic proteins.

In first line treatment, EGFR inhibitors show

approximately 75% response rate in patients with typical EGFR mutations (Mok et al., 2009).
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4.5.7.2 Transcription regulation of EGFR by mutp53
wt and tumor derived mutp5, can both transactivate the EGFR promoter (S. P. Deb, Munoz,
Brown, Subler, & Deb, 1994). Transient transfection assays with a promoter-CAT construct
containing the entire EGFR promoter (pER-1.CAT) were performed to compare the
transactivation efficiency of wt and mut p53. This experiment suggested that, although wt p53
can transactivate the EGFR promoter, it is a very weak transactivation in comparison to that
caused by several mutants of tumor-derived p53. Although each p53 mutant had a different
efficiency toward transactivation of EGFR, p53-R281G was proven to be the strongest
transactivator of this promoter (Ludes-Meyers et al., 1216).
4.6

POST TRANSLATIONAL MODIFICATION OF MUTP53

The posttranslational modification of wt p53 has been studied extensively.

However, a

knowledge base of PTMs on mutp53 is not well established, although it has been demonstrated
that PTMs play some role in the activity of mutp53. One would think that, as PTMs are thought
to play a major role in the activity and function specificity of wt p53, mutation on these residues
would abolish the function of wt p53 and should be frequently observed in cancers. Interestingly
enough, whereas mutations have been indicated in all coding exons of p53, more than 95% of the
base substitution mutations are located in exons 4-9, which encode the DNA binding domain of
the protein. About 30% of mutations locate within six “hotspot” residues that are frequently
mutated in almost all cancer types (Hollstein et al., 1994) that is, Arg175, Gly245, Arg248,
Arg249, Arg273, and Arg282, none of which are known to be post-translationally modified. As
indicated previously, most frequent mutations are on residues not subject to post translational
modification. A probable explanation of this is that a mutation in a residue of p53 subject to a
controlling PTM have a survival disadvantage or that, the PTM is important for mutp53 function
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so is not selected in vivo. Whereas most of the PTM sites described in the DNA binding domain
(DBD), do not fall in a hotspot for tumor mutations, the codons for Lys132, Thr155, Ser215,
Glu258, Asp 259, and Cys277 have been suggested to have over 90 cancer-associated
mutations/codon. (Cross ref. (Nguyen, Menendez, Resnick, & Anderson, 2014))
4.6.1 Phosphorylation of Serines and Threonines in mut p53
Like wt p53, mutp53 can also be post-transnationally modified in response to various stress and
DNA damage signals. In 1993, one of the pioneering studies by Ullrich et al showed that, in the
absence of stress signals, the posttranslational modification pattern of mutp53 is different than
that of WT p53 (Ullrich et al., 1993). Later, it was shown that phosphorylation and acetylation of
p53 was substantially higher in tumor cells than in non-transformed cells. This pattern was true
irrespective of tumor types or the presence of mutp53. Out of 10 sites analyzed, phosphorylation
at residues 15, 81, and 392 were the most frequently observed modifications along with some
acetylation sites. (Minamoto et al., 0802). Conservation of PTM residues in tumor cells suggests
that mutp53 function may either needs these PTMs or atleast these PTMs do not affect mutp53
oncogenic activity negatively (M. Matsumoto, Furihata, & Ohtsuki, 1222; M. Matsumoto et al.,
2004). Perhaps the most studied PTM of WT and mutant p53 is Ser15. One of the major
limitations in the studies of mutp53 is that each mutant protein behaves very different in different
conditions and cell types, which may make the conclusions from one study contradictory or not
in accordance with the conclusions of the other studies. Indeed, different studies to understand
the importance of Ser15 modification in mutp53 show contradictory results (Nagata et al., 1999;
Ullrich et al., 1993). However, later studies that included many more cells lines and conditions
suggested that there is no conclusive correlation between ser15 modification and stability,
localization DNA binding, transcriptional activity of mutp53 under stressed and unstressed
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conditions (Liu et al., 2013; Minamoto et al., 0802; Ray, Murphy, & Gal, 2012).
4.7

FOCUS OF THIS CHAPTER

Mutation of p53 is one of the most common genetic alterations in human cancers and tumors that
express mutant p53 are usually more aggressive, resistant to chemotherapy, and show worse
prognosis then p53-null tumors. This tumor promoting activity has been correlated with the
transcription activity of mutant p53. One of the main foci of this dissertation was to understand
why PTX effects on mTORC1 regulation are independent of wt p53 (chapters 2 and 3). This
chapter is mainly focused to understand the effects of PTX on the transcription activity of tumorderived mutp53. As we found that PTX blocks transcriptional activation of WT p53 towards its
target genes, we hypothesized that PTX might block the transcription activation of GOF mutp53
as well. As discussed in the introduction of this chapter, novel transcription targets of this
neomorphic mutp53 are chemoresistance, cell growth and proliferation promoting genes.
Therefore, blockade of transcription of these genes by mutp53, under PTX treatment, might offer
a therapeutic advantage for cancers with mutp53 like lung cancer and breast cancer.
4.8

RESULTS

4.8.1 Sensitivity of mutant p53 cells lines to PTX
PTX has been approved by the US FDA for first line treatment for non-small cell lung cancer.
One of the most common genetic mutations in lung cancers is mutation of p53 and as PTX is the
only antifolate with activity against lung cancer, we sought to understand the mechanism of the
effects of PTX against lung cancer. We used H1437 NSCLC cells with a R267P mutation in p53
and H1048 NSCLC cells with R273P mutation in p53. These cells lines have been shown to have
gain- of-function mutp53 activity (Vaughan et al., 2012).

251

We tested the growth suppression of these NSCLC cells lines by PTX treatment in the presence
(Fig. 4-5A) or absence of thymidine (Fig. 4-5B). Cells were treated for 72 hrs followed by
electronic counting using a coulter counter (Fig 4-5). We found that the growth of both lung
cancer cell lines, H1437 (with a R267P mutation in p53) and H1048 (R273P) are suppressed by
PTX. This suggested that both lung cancer cell lines, with mutant p53, are sensitive to PTX.
4.8.2 PTX blocks mTORC1 pathways in mutp53 containing lung cancer cells
We showed in the previous chapter that cell lines expressing mutant p53 have higher mTORC1
activity than that with wt p53 (Chapter 2) and that PTX treatment mediates activation and
phosphorylation of AMPK at Thr172 leading to inhibition of mTORC1 (Chapter 3). This PTXactivated AMPK mediated inhibition of mTORC1 was p53 function independent. Therefore, we
hypothesized that PTX will inhibit the enhanced mTORC1 activity in cells with mutp53. Lung
cancer cell lines H1437 and H1048 were treated with either thymidine or PTX (1µM) with
thymidine (5.6µM) in order to determine the AMPK-mediated effects on mTORC1 in these cells.
Phosphorylation of AMPK at P-Thr172 was enhanced in both H1437 (Fig. 4-6A) and H1048
(Fig. 4-6B). This activation of AMPK leads to a decrease in the phosphorylation of pT70 4EBP1
suggesting that PTX inhibits mTORC1 via activating AMPK in cells with mutp53 (Fig. 4-6). It
is shown previously in this thesis (Chapter 2) that mTORC1 activity is remarkably higher in cells
with mutp53 have mTORC1 activity than in isogenic cells with WT p53. Now, this data
suggests that PTX can decrease the mTORC1 kinase activity in the cells with gain of function
mutp53.
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Figure 4-3. Growth suppression curve of H1437 and H1048 cells after PTX (+/-TdR)
treatment
Cells were treated for 72 hrs followed by counting by coulter counter. A. Cells were treated with
PTX (+/- TdR), B. Cells were treated only with PTX
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Figure 4-6 Effects of PTX on AMPK and mTORC1 pathway.
Cells were treated either with thymidine (Tdr) or PTX (1µM) + Tdr (5.6 µM) for 24 hrs followed
by immunoblotting to analyze the P-Thr172 AMPK, pT704EBP1, 4EBP1 and p53 in A) H1437
cells B) H1048 cells.
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4.8.3 PTX increases the levels of mutp53 without increasing the levels of its transcription
targets
We have shown in chapter 3 that treatment of p53+/+ HCT116 cells with VP16, AICAR, or PTX
leads to accumulation of WT p53. VP16 mediated activation of p53 leads to transactivation of
its target genes such as p21, Sestrin2, Bax and HDM2, whereas the p53 accumulated in PTX
treated cells is transcriptionally inactive. As a logical extension of that study we sought to
understand how PTX affects gain of function mutant p53. Bug et al. (2011) showed that
treatment with the anthracyclines, doxorubicin or duanorubicin induces the accumulation of
mutant p53 and this may augment any new oncogenic functions of mutp53 (Bug & Dobbelstein,
2011). We decided to compare the effects of PTX and DNA damaging agents on mutp53.
We first studied the effects of PTX on mutp53 levels and on its transcription target Axl.
Treatment of lung cancer cells, H1437 (Fig. 4-7A) and H1048 (Fig.4-7B) with PTX in the
presence of thymidine increases the protein levels of mutp53. Surprisingly, PTX was not only
inhibiting the increase in mutp53 transcription target Axl, it was causing a decrease in this
protein. (Fig. 4-7).

In chapter 3, we found that PTX accumulated p53 is transcriptionally

inactive; hence, we asked whether PTX treatment would augment the oncogenic transcriptional
activity of mutp53.
We treated H1048 (R273P) cells either with VP16 (20µM), Doxorubicin (2µM) or PTX (1µM)
with TdR (5.6µM) for given time periods, followed by immunoblotting to check the levels of
mutp53 and two of its transcription targets Axl and NFκB2 (Fig. 4-8A,B). Treatment with
doxorubicin and PTX both leads to increase in mutp53 levels (Fig. 4-6,7,8). Considering that the
basal levels of mutp53 in these cells are significantly higher than the basal levels of wt p53 in
cancer cells, it is an interesting effect exerted by PTX. As expected, doxorubicin (Fig. 4-8A) and
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VP16 (Fig. 4-8B) treatments activate mutp53 transcription activity towards its target genes Axl
and NFκB2 but PTX does not (Fig.4-8). Axl and NFκB2 are known to promote tumor
progression, providing a survival advantage to the cancer cells. This data suggests that whereas
mutp53 cells, upon treatment with either VP16 or doxorubicin, will have the survival advantage
provided by mutp53 transcription targets, PTX treated cells will not.
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Figure 4-7 Effects of PTX on mutp53 and its transcription target Axl.
Cells were treated either with thymidine (Tdr) or PTX (1um) + Tdr (5.6 um) for 24 hrs followed
by immunoblotting to analyze the levels of mutp53 and of Axl in A) H1437 cells B) H1048 cells.
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Figure 4-8 Effects of VP16, doxorubicin and PTX on mutp53 levels and its transcription
targets.
H1048 cells were treated either left untreated or treated with (A) doxorubicin (2um) for 3, and 6
hrs or PTX (1um) + Tdr (5.6 um) for 24 hrs (B) VP16 (20um) for 6,12,and 24 hrs or PTX (1um)
+ Tdr (5.6 um) for indicated time durations followed by immunoblotting to analyze the levels of
p53 and its transcription targets.
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4.8.4 Unlike etoposide and doxorubicin, PTX does not lead to an increase in the
transcription of mutp53 target genes
In these initial experiments, we saw that DNA damaging agents mediated an increase in the
abundance of two mutp53 transcriptional targets, Axl and NFkB2, but that the time dependency
of these increases could not be predicted and were different for the two transcriptional targets.
Hence, we tested if that regulation was at the levels of transcription, as would be expected by
analogy with the effects of wt p53. We first started with analyzing the levels of mutant p53 in
four NSCLC cell lines; H1437, H1048, H661 and H441 (Fig. 4-9). As expected, the levels of p53
in H1048, H661 and H441 cells were very high in comparision to HCT116 with wt p53.
Interestingly the level of mutant p53 was remarkably low in H1437 cells (Fig. 4-9). We treated
four NSCLC cell with VP16 for 3, 6, 12 and 24 hrs, doxorubicin for 3,6 and 12 hrs and PTX 6,
12 and 24 hrs followed by RNA extraction. In this analysis, we were looking for increases in the
abundance of mut53 transcriptional targets, and we considered that mRNA levels might show a
more consistent pattern.

A cDNA synthesis reaction was performed from these RNA

populations using random hexamer followed by RT-qPCR analysis to measure steady state levels
of mRNAs. Drug-treated H1048 (R273P) lung cancer cells were analyzed for steady state
mRNA levels of several mutp53 transcription targets: NFκB2, HSP70, Axl, PCNA, and hTERT.
The mRNA levels of NFκB2, HSP70 and PCNA were increased after treatment with either
etoposide or doxorubicin. The levels of Axl and hTERT mRNA levels were increased after
etoposide but not after doxorubicin (Fig. 4-10). These increments were time course dependent as
levels of mRNA of different genes are enhanced at different time points by the same drugs.
None of these mRNAs were increased after PTX treatment (without thymidine) at any time point
(Fig. 4-10).
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Upon observing no increase in the mRNA levels of these genes after PTX treatment, we further
tested if PTX in the presence of TdR would also have similar effects. Indeed, the effects of PTX
with or without thymidine were almost identical (Fig. 4-11) as none of mutp53 targets showed
any increase at the mRNA level after PTX or PTX + TdR treatment.
In order to understand if these effects of PTX on mut p53 were cell line dependent or more of
general effects in different cell lines, we performed similar experiments in H1437, which bear a
p53 gene with a mutation that confers a R to P change at codon 267. The levels of NFκB2, Axl,
EGFR, MDR1, HSP70, and PCNA were increased by both VP16 and doxorubicin, however
hTERT mRNA was increased only after etoposide treatment but not by doxorubicin (Fig 4-12).
Once again the effects of the two DNA-damaging drugs were different for different genes. As
expected, PTX did not increase the levels of mRNA of any of these neomorphic target genes.
Interestingly, we saw an increase in p21, a wt p53 transcription target upon VP16 and
doxorubicin but not after PTX treatment in this cell line that had no wt p53 allele (Fig. 4-12).
This suggests that this p53 mutant itself still had some remaining wt p53 activity. The level of
p53 in these cells also supports the similarity of behavior between the R267P mutant and wt p53,
in that the levels of the R267P mutant p53 were maintained at lower levels than the levels
expected for gain of function mutant p53s (Fig. 4-9).

H1437 cells were also analyzed for

differences in response after PTX and PTX + TdR. H1437 cells also showed almost identical
results when treated with PTX in the presence or absence of thymidine (Fig. 4-13).
Two other lung cancer cells H441 (R158L) and H661 (R158L) were also tested to investigate the
generality of the PTX mediated effects. H441 cells were treated in the same way as H1048 and
H1437 , and the data are shown in Fig 4-14. Levels of NFκB2, EGFR, HSP70, PCNA, and
hTERT increased after VP16 or doxorubicin treatment in a time-dependent manner in H441.
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The mRNA levels of hTERT were not affected by doxorubicin, there was an evident increase in
the levels of hTERT mRNA after VP16 treatment. The levels of Axl mRNA were increased by
VP16 but not by doxorubicin (Fig. 4-14). Again, none of the mRNAs levels for any of these mut
p53 neomorphic targets was increased after PTX treatment (Fig. 4-14), suggesting that it was a
generality that PTX does not increase mutp53-mediated GOF transcription of these oncogenic
genes.
When H661 cells were studied, which have a mutation in p53 at codon 158 (R158L) NFκB2, and
hTERT were increased after either VP16 or doxorubicin treatment. The mRNA levels of Axl,
HSP70 and PCNA were increased only after doxorubicin treatment with no evident increase after
VP16 treatment. As seen in the other three cells lines, none of these mRNAs were increased after
PTX treatment (Fig. 4-15).
Overall this data suggested that, whereas both DNA damaging agents, VP16 and doxorubicin,
lead to enhanced transcriptional activity of mutp53 in several lung cancer cell lines, PTX does
not cause transcriptional activation of mutp53 transcription targets in any.

These data is

summarized in table 4-1. Hence, mutp53 containing lung cancers can exploit the survival
advantage provided by the increased levels of oncogenic transcription targets of mutp53
followed by VP16 or doxorubicin, but not following PTX treatment.
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H1437- R267P
H1048- R273P
H661- R158L * mut p1
H441- R158L * mut KR

p53
β-actin
Figure 4-9. Protein levels of p53 in different cell lines
All the cells were cultured in the same conditions and harvested. Equal levesl of protein was
loaded to compare the p53 levels in these cells lines. β-actin is used a loading control.
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Figure 4-10. mRNA levels of various oncogenic genes in H1048 cells after DNA damaging
drugs increased but not after PTX.
H1048 cells treated with etoposide (20um) for 6,12 and 24hrs, Doxorubicin (2um) for 3,6,and 12
hrs and PTX (1um) for 6,12, and 24 hrs. Steady state mRNA levels were analyzed using RTqPCR. This experiment has been repeated twice.
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Figure 4-11. mRNA levels of various oncogenic genes in H1048 cells after DNA damaging
drugs increased but not after PTX.
H1048 cells treated with etoposide (20um) for 6,12 and 24hrs, Doxorubicin (2um) for 3,6,and 12
hrs and PTX (1um) +/- TdR (5.6um ) for 24 hrs. Steady state mRNA levels were analyzed using
RT-qPCR. This experiment ahs been repeated twice.
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Figure 4-12. mRNA levels of various oncogenic genes in H1437 cells after DNA damaging
drugs increased but not after PTX.
H1437 cells treated with etoposide (20um) for 6,12 and 24hrs, Doxorubicin (2um) for 3,6,and 12
hrs and PTX (1um) for 6,12, and 24 hrs. Steady state mRNA levels were analyzed using RTqPCR. This experiment has been repeated twice.
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Figure 4-13. mRNA levels of various oncogenic genes in H1437 cells after DNA damaging
drugs increased but not after PTX.
H1437 cells treated with etoposide (20um) for 6,12 and 24hrs, Doxorubicin (2um) for 3,6,and 12
hrs and PTX (1um) +/- TdR (5.6um ) for 24 hrs. Steady state mRNA levels were analyzed using
RT-qPCR. This experiment has been repeated twice.
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Figure 4-14. mRNA levels of various oncogenic genes in H441 cells after DNA damaging
drugs increased but not after PTX.
H441 treated with etoposide (20um) for 6,12 and 24hrs, Doxorubicin (2um) for 3,6,and 12 hrs ,
PTX (1um) for 6, 12 and 24 hrs. Steady state mRNA levels were analyzed using RT-qPCR. This
experiment has been repeated twice.
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Figure 4-15. mRNA levels of various oncogenic genes in H661 cells after DNA damaging
drugs increased but not after PTX.
(A) H661 cells treated with etoposide (20um) for 6,12 and 24hrs, Doxorubicin (2um) for 3,6,and
12 hrs and PTX (1um) for 6,12, and 24 hrs. Steady state mRNA levels were analyzed using RTqPCR. This experiment has been done once.
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Table 4-1 Summary: the highest increase in levels of mRNA in RT-qPCR analysis.
Cell$line$

Drug$

H1048$$
(R273C)$
$

VP16

10

3

4

4

----

----

2.5

Doxorubicin

5

3

1.7

0.7

----

----

2.7

$

PTX (+/TdR)

1

1

1.1

0.5

----

----

1.1

H1437$
(R267C)$
$

VP16

3

2

6

1

4.5

2.6

1.02

Doxorubicin

7.3

3.5

1.1

3

2.5

2.9

5.2

$

PTX (+/TdR)

0.8

0.6

1

1

1

1.1

1

H441$
(R158L)$

VP16

10

2

4

2.3

----

2.9

1.9

$

Doxorubicin

6

2.5

2

1.1

----

2

2.3

$

PTX (+/TdR)

1

1

1

1.2

----

1

0.8

H661$
(R158L)$

VP16

2

1.2

2

1.2

----

----

1

$

Doxorubicin

2.2

2.7

2.2

2

----

----

2

1

1.1

1.1

1

----

----

1

PTX (+/TdR)

NFkB2$

PCNA$

hTERT$

Axl$

MDR1$

EGFR$

Hsp70$

These numbers represent the highest fold increase in the mRNA levels upon indicated
treatments. Numbers represent the ratios of mRNA levels found in the treated cells devided by
that in untreated cells. Experiments done on H1437, H1048 and H441 cells were repeated twice
and pattern of change in mRNA levels is reproducible. Experiment on H661 cells was done once.
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4.8.5 PTX can block the VP16 mediated transcription activation of mutant p53
It has been previously reported that an increase in NFκB2, PCNA, MDR1, EGFR, Axl, Hsp70,
and hTERT caused by transcriptional activation by mutp53 may lead to survival advantage to
cancer cells and allow the development of chemo-resistance. We also had shown in Chapter 3
that PTX did not activate wt p53 and, in addition, could block the transcriptional activation of the
p21 gene by wt p53. Because PTX does not cause activation of mutp53 transcription activity,
we hypothesized that combining PTX with VP16 might block VP16 mediated the GOF
transcriptional activation of mutp53 and inhibit the enhancement of oncogenic targets of mutp53.
H1048 cells containing mutp53 (R273P) cells were either left untreated or treated with VP16
(20µM) for 6 hrs or PTX (1µM) in the presence or absence of TdR (5.6µM) for 24 hrs. For
combination treatment, H1048 cells were treated with PTX for 20hrs followed by VP16
treatment for 6 hrs. Cells were harvested in Trizol and RNA was extracted. RT-qPCR analysis
was performed to measure the steady state levels of mRNAs for the several genes discussed
above. We found that, after 6 hrs treatment with VP16 alone, the levels of mRNA from genes of
interest were increased significantly; NFκB2 increased 10-14 fold, PCNA increased 2.5-3 fold,
AXL increased 3-3.5 fold, Hsp70 2-2.5 fold, and hTERT 5-8 fold (Fig 4-16). However, when
cells were pretreated with PTX (+/- TdR) for 20 hrs followed by 6hr exposure to VP16, there
was a 50-60% blockade of VP16-mediated increase in NFκB2 mRNA levels, a remarkable effect
considering that NFκB2 is strongly transactivated by VP16 activated mutp53.

More

interestingly, we found a complete suppression of VP16 mediated increment in PCNA, AXL,
Hsp70 and hTERT mRNA levels when cells were pretreated with PTX in the presence or
absence of TdR (Fig. 4-16). This clearly suggests that pretreatment with PTX does not allow the
VP16 mediated transcriptional activation of mutp53. This led us to hypothesize that if PTX can
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block the transcription activation of mutp53 transcriptional targets induced by DNA-damaging
drags, then combination treatment of PTX will increase the cytotoxic effect of these drugs.
4.8.6 Combination drug treatment shifts the growth curve towards left
As we found that PTX can block the VP16 mediated enhancement of the transcriptional activity
of mutp53, we hypothesized that combination treatment of these two drugs might lead to better
cell growth suppression. H1048 and H1437 cells were either treated separately or co-treated
with various concentrations of PTX and VP16 for 72 hrs followed by measurement of cell
densities by coulter counter. We found that combination treatment of PTX and VP16 shows
better growth suppression of H1437 and H1048 cells in comparison to either of the two drugs
alone (Fig. 4-17), as evidenced by a shift of the dose-response curves for PTX to the left. It now
remains to be proven whether blockade of transcriptional activity of mutp53 might be playing
role in the cell growth suppression of the combination treatment.
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Figure 4-16. PTX can block the VP16 mediated transcription activation of mutant p53.
H1048 cells were either left untreated or treated withVP16 (20µM) or PTX (1µM) in the
presence or absence of TdR (5.6µM) for 24 hrs. For combination treatment H1048 cells were
treated with PTX for 20hrs followed by VP16 treatment for 6 hrs. Steady state mRNA levels
were analyzed by RT-qPCR. This experiment has been repeated twice and effects shown in this
experiment are reproducible.
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Fig.6$
B

A

C$

D$

Figure 4-17. Combination of PTX and etoposide increases the sensitivity of GOF mutant p53
containing lung cancer cells.
Combination of PTX and etoposide increases the sensitivity of GOF mutant p53 containing cells

(A,B) H1048 cells treated with increasing concentration of VP16 and PTX and cell densities
were measured by coulter counting after 72 hrs. C,D) H1437 cells treated with increasing
concentration of VP16 and PTX and cell densities were measured by coulter counter after
72 hrs. Data is plotted after normalizing with untreated cells, which is considered as 100%
growth.

273

4.9

DISCUSSION

We asked a fairly simple but important question of how PTX will affect the cells with gain of
function mutp53. We addressed this question using lung cancer cell lines with gain of function
mutp53, because the most frequent gene mutated in lung cancer is p53.
As, in the third chapter of this thesis, we showed that cells with mutp53 have equivalent
mTORC1 activity as isogenic p53 null cells, but much higher levels of p53. Hence, this study
becomes very important, because it suggests that PTX can block the effects of loss of p53 as well
as the effects of mutp53 on mTORC1.
We asked if PTX can inhibit transcriptional activity of mutp53 as it does the transcriptional
activity of wt p53. Indeed, PTX blocks the transcriptional activation of GOF mutp53. This is a
therapeutically very important phenomenon as it has been previously reported that treatment with
DNA damaging drugs leads to enrichment in chemoresistant cells in cell culture due to increase
levels of mutp53 (Blandino et al., 2002). It has been suggested that DNA damaging drug leads
to increase in mutp53 levels, increasing the expression of proteins responsible for or factors in
the development of chemo-resistance in these cancers and that, hence, provide growth advantage
in the faced of drug treatement by supporting tumor progession ((MDR1) (Y. Matsumoto,
Takano, & Fojo, 1997; Y. Matsumoto, Takano, Kunishio, Nagao, & Fojo, 2001; Y. Matsumoto,
Tamiya, & Nagao, 2005) (NFKb2) (Harte et al., 2014; Ludes-Meyers et al., 1216; Scian et al.,
1203; Scian et al., 2004; Shivakumar et al., 1995; Vaughan et al., 2012). This is the first time
that it has been shown that a chemotherapeutic drug can inhibit the activation of GOF
transcription from mutp53 and suggests that this effect may by involved in the therapy with PTX.
As PTX can block the transactivation of transcriptional target of mutp53 gene, it suggests that
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combination treatment of PTX with other drugs that usually stimulate mut p53 GOF transcription
can be therapeutically more effective than these drugs alone.
Interestingly we found H441 and H661 cells, both of which have the same mutation in p53
(R158L) show different transcriptional activation profiles after doxorubicin or etoposide
treatment. This suggested that mutation of other genes, perhaps KRAS in H441 and p63 in
H661, was affecting the mut p53 selectivity towards its transcriptional targets as well as the
intensity of transactivation. It is clear that each mutant p53 behaves differently and responds
differently towards different DNA damaging drugs, with an overall of similarity but quite
different details of the response. This complexity is rather daunting to explain.

There are

several questions left unanswered by my studies that beg experimental explanation. Some of
those are discussed below;

1. Why do PTX and DNA damaging drug treatments lead to increased protein levels of mutp53
? Our current understanding of mutp53 indicate that the untreated levels of mutp53 are much
higher than untreated levels of wt p53 due to an increased half life, most likely due to a lower
binding of mdm2 to the mutant forms of p53. Out of the several theories to explain this, he most
likely one is that mutp53 is constantly phosphorylated at ser15 and thus not allow the binding of
MDM2, avoiding degradation; the well studied mechanism of wt p53 stabilization after
genotoxic stress. This raises a question that if mutp53 is already phosphorylated at ser15 than by
what mechanism do these treatments increase mutp53 levels? However, we know by our studies
in chapter 3 that PTX (with thymidine) does not mediate phosphorylation of ser15 of WT p53,
but we don’t know what happens in the case of mutp53.

275

2. Why is the transcription activity of mutp53 compromised after PTX treatment: Studies in the
chapter 3 done on PTX mediated effects on transcriptional activity of wt p53 suggests that PTX
stabilizes a transcriptionally compromised p53 and we propose that this p53 is transcriptionally
inactive due to the inability of PTX to induce a DNA damage signal. As we see that PTX leads
to an increased levels of mutp53 without enhancing its transcriptional activity, it would be
interesting to analyze the status of H2A.X in cells treated with VP16 or PTX to see if PTX
effects on DNA damage are the same in cells with mutp53.

3.

What are the post-translational modifications of mutp53 under PTX vs VP16 and

doxorubicin. In Chapter 3, we examined the posttranslational modifications after PTX treatment
and after VP16 treatment, and found that the post-transcriptional modifications of p53 were a
reflection of the type of genotoxic stress induced by the drugs. Therefore, it will be interesting to
know the posttranslational profile of mutp53 after different treatment to predict the underlying
mechanism of action of these drugs.

4. What are the mechanism(s) of the PTX-mediated effects on transcriptional activation by wt
p53 and mut p53. Our current understanding suggests that transcriptional activity of mutp53 is
regulated very differently than that of wt p53. As PTX affects are similar towards transactivation
inhibition of both wt and mut p53, this suggests a common mechanism by PTX is at play which
interfers with ctranscription from both wt and mutp53. Thus a better understanding of the
mechanism by which PTX blocks transcriptional activity of wt and mut p53 might improve the
fundamental understanding of this field.
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Chapter 5

5

Overview and perspective

It has been shown previously that some of the very frequent mutations in lung cancers, like
EGFR mutations and amplifications, K-Ras mutations, and PI3K muations act upstream of
mTORC1 and feed into hyperactivity of mTORC1 in these cancers. However, the most frequent
mutations found in lung cancer is p53, but it is not known how loss or mutation of p53 affects
mTORC1 kinase activity.
My PhD. thesis work started by addressing the fairly simple but very important question of how
p53 regulates mTORC1 activity. Later, after understanding the affects of deletion or hot-spot
mutation of p53 on mTORC1 activity, we explored how this regulation may affect the
therapeutics of PTX on cancer. This dissertation has also discovered a very important mechanism
of the regulation of the mTORC1 pathway by mutp53 and how PTX affects the oncogenic
affects of GOF mutp53 in lung cancer cells.

The loss or hotspot mutation of p53 enhance mTORC1 activity.
Our very initial studies in this quest led to the discovery that p53 null cells have higher mTORC1
activity because p53 null cells had lower levels of TSC2 and sestrin2. The mTORC1 complexes
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in cells null for p53 had lower levels of TSC2 and PRAS40 bound with a increased levels of
mTOR suggesting that upon loss of p53 more mTOR is present as mTORC1 complex and
something fundamentally different was happening with the recruitment of components of the
complex. These finding were confirmed and strengthened by experiments by my colleague
Catherine M. Bell who performed subcellular fractionation and confocal microscopy studies to
analyze the distribution and co-localization of mTOR, TSC2 and Rheb in cells with or without
p53. The site of function of mTORC1 is currently thought to be the lysosomal membrane and
TSC2 has been reported to be localized at this site under serum starved condition. Accordingly
Ms Bell found that the levels of TSC2 are decreased in the lysosomal membrane of p53 null
cells, and the decreased levels of TSC2 were concomitant with an increased level of Rheb at
lysosomal membrane of p53 null cells. We also showed that cells with gain of function mutant
p53 also have enhanced mTORC1 activity and this is also due to decrease in TSC2 and Sestrin2
levels in absence of WT p53 and its transcription activity. This is first time anyone had showed
these effects. We concluded that deletion or hotspot mutation of p53 enhances mTORC1 activity
by decreasing TSC2 levels, its localization at lysosomal membrane and at least partially as result
of increased levels of Rheb at lysomal membrane.

Future perspective
We still don’t understand the reasons for the differences seen in the components of mTORC1
complexes from wt and null p53 cells.
1. More mTOR present as mTORC1 complex: mTOR can be present in the form of two
complexes, mTORC1 and mTORC2.

Using an anti-raptor antibody for

immunoprecipitations of mTORC1, more mTOR was pulled down in p53 -/- cells. As
the levels of mTOR and Raptor are the same in the lysates from both cell lines this

278

suggested that, in p53 null cells, more Raptor-bound mTOR is present i.e, more
mTORC1 complex is present. It seems as if the dynamic distribution of mTOR
between mTORC1 and mTORC2 complex might be of importance for the mechanism
of regulation of mTORC1 activity.
2. Lower levels of PRAS40 bound to the complex: PRAS40 is an inhibitor of mTORC1
kinase activity unless phosphorylated by AKT at T-246. In our immunoprecipitation
studies, we saw that the levels of PRAS40 bound to mTORC1 complex is decreased
in p53 null cells. We think that possibly PRAS40 interacts with mTORC1 complex
via TSC2 and that the lower levels of TSC2 in p53-/- cells led to decreased levels of
PRAS40 binding to mTORC1 in these cells, contributing to the higher mTORC1
activity. However, there is no direct experimental evidence for this hypothesis, and
studies to confirm or negate it will be very useful.
3. Higher levels of Rheb in lysosomal membranes of p53 null cells: Subcellular
fractionation and confocal microscopy studies done by Ms. Bell, indicated that the
levels of Rheb are increased at the lysosomal membrane of p53 null cells. Although
we don’t understand the mechanism of this difference yet as there was no difference
in the total Rheb protein levels and steady state mRNA levels in the cells. We think
that possibly Rheb-GTP has higher affinity for lysosomal membrane than Rheb-GDP
and this could explain the increased localization of Rheb in p53 null cells.
Immunoprecipitations using an anti-raptor antibody also suggested more Rheb present
in the mTORC1 complex from p53 null cells, an extremely controversial observation.
4. Colocalization of TSC2 and Rheb with mTOR in mutp53 cells: We showed that the
levels of TSC2 are decreased in cells with mutp53 in comparison to p53 competent
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cells and this phenomenon was consistent with the increased levels of mTORC1
activity. It would be of interest to see if the localization of TSC2 and Rheb in mutp53
cells are similar to that seen in p53 null cells.

Because p53 negatively regulates mTORC1, it was expected that loss of p53 would diminish
the therapeutic effects of PTX; it did not.

My initial experiments of this study showed that PTX can effectively down-regulate the
enhanced mTORC1 activity in p53 null cells. This result was more interesting than surprising.
We continued on this study and sought to understand the mechanism of the p53-independent
mechanism of PTX mediated inhibition of mTORC1. We found that, whereas AICAR-activated
AMPK phosphorylates both TSC2 and Raptor, PTX-activated AMPK only phosphorylates
Raptor but not TSC2.

We discovered that the levels of TSC2 are not increased in p53

competent cells after PTX treatment because of a failure to activate p53 transcription. Therefore,
we concluded that PTX-stabilized p53 does not increase levels of TSC2 and Setsrin2, so that, as
in p53 null cells, PTX treated cells cannot phosphorylate and activate TSC2. We proved this
postulate and showed that Raptor phosphorylation was sufficient for mTORC1 inhibition. We
tried to understand the transcriptional incompetence of the p53 stabilized by PTX.

It was not

due to the binding of p53 at the promoter of p21, nor the recruitment of HATS to regional
histones. We shifted our attention to the clues left by the pattern of PTMs in p53 after PTX.

We concludeded that PTX (±TdR) does not cause transcriptional activation because it does
not cause DNA damage of the nature caused by drugs such as VP16 or AICAR, which do
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activate transcription by p53.
Studies done to test this hypothesis brought several surprises to us. As expected, cells treated
with PTX in the absence of TdR led to increased levels of H2A.X pS139, indicating genotoxic
stress but we still did not observe any increase in the levels of p21.

Future perspectives
1. How does AMPK activation by PTX stabilize p53 ?.
PTX in the presence of thymidine stabilizes p53 without causing phosphorylation of p53 at
S15, a PTM thought to be required for the stabilization of p53 after DNA damage as it inhibit
the interaction of p53 with it E3 ubiquitin ligase and protects p53 from proteolysis. How p53
can be stabilized without phosphorylation of S15 is as yet unknown.
2. Why does PTX in the absence of TdR not induce p53 transcription ? PTX without
thymidine allows the effects of inhibition of thymidylate synthase to be expressed,
including the incorporation of dUMP into DNA and subsequent damage to DNA
following patch excision.

It is of great interest that how inhibition of thymidylate

synthase is not sufficient to activate p53 transcriptional activity.

It seems that

phosphorylation of p53 at S15 works as an enhancer of p53 stabilization but it is not a
mandatory event for p53 stabilization, as we see higher levels of p53 in treatments that
induce phosphorylation at S15 (VP16, AICAR and PTX (-TdR)), than in PTX+ TdR.

3.

Chk1 activation has been reported to inhibit transcriptional activity of p53. Studies

done by Beckerman and Prives suggested that HU-stabilized p53 is transcriptionally inactive due
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to activation of Chk1. Following inhibition of Chk1 activation by an ATR inhibitor or by
knocking down Chk1 using siRNA, p53 transcriptional activity can be regained. Interestingly, in
my studies VP16 activates Chk1 and AICAR does not, however they both stabilize
transcriptionally active p53, suggesting that the presence or absence of Chk1 activation is not
mandatory for p53 transactivation. This is of great interest to dissect the phenomenon of how the
activation of Chk1 can play as an inhibitor of p53 transactivation under one stimuli (HU), an
activator in other (VP16) or just remain a non-affecting factor in another (AICAR, PTX (+TdR)).

4. PTX (+TdR) can block the DNA damage by VP16 or AICAR and blocks p21
transcription.
We found that cells pretreated with PTX (+TdR) blocked the VP16 or AICAR mediated DNA
damage signal and increase of p21 levels. This is strong evidence that DNA damage is required
for VP16 or AICAR mediated transcriptional activation of p53. A former PhD. student of our
lab, Dr. Scott Rothbart showed that cells treated with PTX with thymidine are arrested at G1
stage of cell cycle, while cells treated with only PTX (- TdR) are arrested in S phase. This
suggested that blockade of cells at the G1/S border or in S-phase does not allow the DNA
damage to occur even after VP16 treatment, thus blocking DNA damage signaling, leaving p53
transcriptionally inactive.

However, PTX in the absence of TdR blocks cells at S phase,

probably due to a replication halt caused by thymidylate synthase inhibition. This replication halt
allows the increased levels of pS139 H2AX but does not induce DNA double strand break DNA
damage signal and thus does not allow p53-mediated induction of p21 levels. This also explains
the PTX (+/-TdR) mediated block of VP16 and AICAR effects on p53 as cells are already
arrested at G1 and S phase under PTX (+TdR) or PTX, respectively, without double strand
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break. Therefore addition of VP16 or AICAR is incapable to induce DNA damage and in the
absence of a certain type DNA damage (DSBs and SSBs), p53 is transcriptionally inactive.

5.

PTX-activated AMPK does not cause DNA damage and does not activate p21

transcription. Whereas AICAR-activated AMPK causes DNA damage and leads to induction of
p21 mRNA and protein levels, PTX-activated AMPK neither causes DNA damage nor induction
of p21 levels. This suggests that AMPK activation per se does not induce DNA damage and
AICAR induced DNA damage proceeds via an unknown mechanism.

6.

The relationship between activation of Chk1 and Chk2, phosphorylation of p53 at S15,

and p53 transactivation.
A great deal of research has been done in order to understand how DNA damage leads to
stabilization, post-translational modification and transactivation of p53. A general understanding
is that DNA damage leads to stabilization of p53 by multiple and specific posttranslational
modifications by the activity of several kinases: ATM/ATR/ Chk2/Chk1, leading to
transcriptional activation of p53.

My studies are suggesting that the correlation of S15

phosphorylation of p53 with p53 stabilization does not necessarily apply to conditions other than
DNA damage. Also, multiple phosphorylations at specific residues of p53 have been reported to
be necessary for p53 transactivation, which dos not seem to be a case, at least under the
condition of AICAR treatment. In addition, Chk1/Chk2 have been shown to be involved in the
S15 phosphorylation of p53, which is also not in accordance with our studies as AICAR shows
pS15 but no p-S345 Chk1 and PTX (-TdR) shows p-S15 but no pChk2. Therefore, dissection of
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the interdependence of these events would be a great contribution in the field of p53 signaling
pathways, especially after treatment with AMPK activators.

Transactivation of unique genes by GOF mutant p53 and PTX
We found that PTX does not activate transcriptional activity of wt p53 and it blocks VP16
mediated transactivation of mutp53.

In four lung cancer cell lines with different hot-spot

mutations I analyzed the transcriptional activity of mutp53 at 7 different genes after treatment
with the DNA damaging agents, VP16 and Doxorubicin or PTX (+/- TdR). All of these genes
have been described in prior literature as being transcriptional targets of GOF mutp53. The
overall pattern suggested that, whereas treatment with VP16 and doxorubicin leads to
transactivation of mutp53 and increases the levels of mRNA from these several genes (albeit to
different levels in different cell lines), PTX (+/-TdR) does not allow the transactivation of these
genes in any cell line. More interestingly, PTX can block the VP16 mediated transactivation of
GOF mutp53. This finding is very important as this suggests that where cancer cells with
mutp53 can have a survival advantage upon treatment with VP16 or doxorubicin due to
increased expression of the proliferative and cell survival genes, treatment with PTX will block
this effect.

Future perspectives
1. Mechanism of transactivation of mutp53: Not much is known about the transactivation
of mutp53. The fact that PTX can block the transactivation of both wt and GOF mutp53
suggests the use of some common mechanism of transactivation. Therefore, analysis of
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DNA damage signaling under PTX treatment in mutp53-carrying cells might be of
interest and may reveal the mechanism of these neomorphic properties.
2. Why do PTX or DNA damaging drugs lead to increased protein levels of mutp53: As
little is known about the stabilization of mutp53, these drugs can be used as a tool to
manipulate the pathway and understand the possible mechanism of mutp53 accumulation
in cancer cells.
3. Importance of post translational modification of mutp53 in its oncogenic activity:
Understanding the levels of various posttranslational modification of mutp53 after
different drug treatment or genotoxic stresses might help in understanding the mechanism
of transactivation of this protein.
4. Understanding the protein-protein interaction: mut p53 has been reported to interact
with p53 family proteins (p73 and p63) and inhibit their p53-like activity as one of its
several mechanisms by which mutp53 provides survival advantage to cancer cells.
Therefore, it will be interesting to understand if these different drugs lead to different
protein-protein interactions with p73 or p63, providing or avoiding a survival advantage.
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